activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
Not Active	1650855	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1650855	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554		Kd			CHEMBL4599	Homo sapiens	Kd		
	1650856	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	890.0	CHEMBL4599	Homo sapiens	Kd	uM	0.89
Not Active	1650857	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253		Kd			CHEMBL4599	Homo sapiens	Kd		
	1650858	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	2200.0	CHEMBL4599	Homo sapiens	Kd	uM	2.2
Not Active	1650859	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1650860	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1650861	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1650862	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1650863	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690		Kd			CHEMBL4599	Homo sapiens	Kd		
	1652193	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	17.0	CHEMBL4599	Homo sapiens	Kd	uM	0.017
Not Active	1652194	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652195	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652196	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652197	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652198	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652199	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652200	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652201	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652202	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828		Kd			CHEMBL4599	Homo sapiens	Kd		
Not Active	1652203	CHEMBL860662	Average Binding Constant for ACK1; NA=Not Active at 10 uM	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965		Kd			CHEMBL4599	Homo sapiens	Kd		
	1723085	CHEMBL860195	Inhibition of CDC42	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	nM	9500.0
	1723086	CHEMBL860195	Inhibition of CDC42	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	nM	9500.0
	1723087	CHEMBL860195	Inhibition of CDC42	B	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	nM	9500.0
	1723088	CHEMBL860195	Inhibition of CDC42	B	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	nM	9500.0
	1723089	CHEMBL860195	Inhibition of CDC42	B	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	nM	9500.0
	1723090	CHEMBL860195	Inhibition of CDC42	B	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	nM	9500.0
	1744509	CHEMBL867294	Inhibition of CDC42	B	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	>	Ki	nM	9500.0	CHEMBL4599	Homo sapiens	Ki	uM	9.5
	2000768	CHEMBL900478	Inhibition of ACK at 10 nM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCF)CC2)n1		CHEMBL240158	=	Inhibition	%	83.1	CHEMBL4599	Homo sapiens	Inhibition	%	83.1
	2000788	CHEMBL900478	Inhibition of ACK at 10 nM	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	96.4	CHEMBL4599	Homo sapiens	Inhibition	%	96.4
	2021944	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2oc3nccc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL240429	=	IC50	nM	110.0	CHEMBL4599	Homo sapiens	IC50	uM	0.11
	2021966	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCCC4)cc3)oc3nccc(NCCCn4ccnc4)c23)cc1		CHEMBL239591	=	IC50	nM	930.0	CHEMBL4599	Homo sapiens	IC50	uM	0.93
	2021967	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCCC4)cc3)oc3nccc(NCCc4cccnc4)c23)cc1		CHEMBL437754	=	IC50	nM	20.0	CHEMBL4599	Homo sapiens	IC50	uM	0.02
	2021968	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCCC4)cc3)oc3nccc(NCCc4ccncc4)c23)cc1		CHEMBL427687	=	IC50	nM	180.0	CHEMBL4599	Homo sapiens	IC50	uM	0.18
	2021969	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCCC4)cc3)oc3nccc(NCCN4CCNCC4)c23)cc1		CHEMBL393596	=	IC50	nM	120.0	CHEMBL4599	Homo sapiens	IC50	uM	0.12
	2021970	CHEMBL903616	Inhibition of Ack1	B	CC(C)N(CCOc1ccc(-c2oc3nccc(NCCN4CCNCC4)c3c2-c2ccccc2)cc1)C(C)C		CHEMBL239590	=	IC50	nM	180.0	CHEMBL4599	Homo sapiens	IC50	uM	0.18
	2021971	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCn4ccnc4)cc3)oc3nccc(NCCN4CCNCC4)c23)cc1		CHEMBL240432	=	IC50	nM	84.0	CHEMBL4599	Homo sapiens	IC50	uM	0.084
	2021972	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3nccc(NCCN4CCNCC4)c23)cc1		CHEMBL240431	=	IC50	nM	170.0	CHEMBL4599	Homo sapiens	IC50	uM	0.17
	2021973	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCOCC4)cc3)oc3nccc(NCCN4CCNCC4)c23)cc1		CHEMBL240430	=	IC50	nM	150.0	CHEMBL4599	Homo sapiens	IC50	uM	0.15
	2021974	CHEMBL903616	Inhibition of Ack1	B	c1ccc(-c2oc3nccc(NCCN4CCNCC4)c3c2-c2ccccc2)cc1		CHEMBL392990	=	IC50	nM	420.0	CHEMBL4599	Homo sapiens	IC50	uM	0.42
	2022127	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2oc3ncnc(NC[C@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247068	=	IC50	nM	523.0	CHEMBL4599	Homo sapiens	IC50	uM	0.523
	2022130	CHEMBL903634	Inhibition of Ack1	B	CC(C)Nc1ncnc2oc(-c3ccc(OCCN4CCCC4)cc3)c(-c3ccccc3)c12		CHEMBL247866	=	IC50	nM	78.0	CHEMBL4599	Homo sapiens	IC50	uM	0.078
	2022131	CHEMBL903634	Inhibition of Ack1	B	CC(C)(C)Nc1ncnc2oc(-c3ccc(OCCN4CCCC4)cc3)c(-c3ccccc3)c12		CHEMBL399008	=	IC50	nM	650.0	CHEMBL4599	Homo sapiens	IC50	uM	0.65
	2022132	CHEMBL903634	Inhibition of Ack1	B	c1ccc(CCNc2ncnc3oc(-c4ccc(OCCN5CCCC5)cc4)c(-c4ccccc4)c23)cc1		CHEMBL247667	=	IC50	nM	1.0	CHEMBL4599	Homo sapiens	IC50	uM	0.001
	2022133	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3ncnc(NCCC4CCNCC4)c23)cc1		CHEMBL247469	=	IC50	nM	332.0	CHEMBL4599	Homo sapiens	IC50	uM	0.332
	2022134	CHEMBL903634	Inhibition of Ack1	B	COc1cc(-c2oc3ncnc(NCCN4CCNCC4)c3c2-c2ccccc2)ccc1OCCN1CCCCC1		CHEMBL394490	=	IC50	nM	586.0	CHEMBL4599	Homo sapiens	IC50	uM	0.586
	2022135	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3ncnc(NCCN4CCNCC4)c23)cc1		CHEMBL247468	=	IC50	nM	98.0	CHEMBL4599	Homo sapiens	IC50	uM	0.098
	2022136	CHEMBL903634	Inhibition of Ack1	B	CN(C)CCOc1ccc(-c2oc3ncnc(NCCN4CCNCC4)c3c2-c2ccccc2)cc1		CHEMBL248286	=	IC50	nM	148.0	CHEMBL4599	Homo sapiens	IC50	uM	0.148
	2022137	CHEMBL903634	Inhibition of Ack1	B	O=C(c1ccc(-c2oc3ncnc(NCCN4CCNCC4)c3c2-c2ccccc2)cc1)N1CCCCC1		CHEMBL248081	=	IC50	nM	85.0	CHEMBL4599	Homo sapiens	IC50	uM	0.085
	2022138	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(CN4CCOCC4)cc3)oc3ncnc(NCCN4CCNCC4)c23)cc1		CHEMBL248080	=	IC50	nM	91.0	CHEMBL4599	Homo sapiens	IC50	uM	0.091
	2022139	CHEMBL903634	Inhibition of Ack1	B	CN1CCOc2cc(-c3oc4ncnc(NCCN5CCNCC5)c4c3-c3ccccc3)ccc21		CHEMBL248079	=	IC50	nM	97.0	CHEMBL4599	Homo sapiens	IC50	uM	0.097
	2022140	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(N4CCOCC4)cc3)oc3ncnc(NCCN4CCNCC4)c23)cc1		CHEMBL247880	=	IC50	nM	17.0	CHEMBL4599	Homo sapiens	IC50	uM	0.017
	2022141	CHEMBL903634	Inhibition of Ack1	B	CCN1CCN(C(=O)c2ccc(-c3oc4ncnc(NC[C@@H]5CCCO5)c4c3-c3ccccc3)cc2)CC1		CHEMBL247878	=	IC50	nM	13.0	CHEMBL4599	Homo sapiens	IC50	uM	0.013
	2022142	CHEMBL903634	Inhibition of Ack1	B	CN1CCN(Cc2ccc(-c3oc4ncnc(NC[C@@H]5CCCO5)c4c3-c3ccccc3)cc2)CC1		CHEMBL247677	=	IC50	nM	7.0	CHEMBL4599	Homo sapiens	IC50	uM	0.007
	2022143	CHEMBL903634	Inhibition of Ack1	B	COc1cc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)ccc1OCCN1CCCCC1		CHEMBL399212	=	IC50	nM	38.0	CHEMBL4599	Homo sapiens	IC50	uM	0.038
	2022144	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)oc3ncnc(NC[C@@H]4CCCO4)c23)cc1		CHEMBL247480	=	IC50	nM	16.0	CHEMBL4599	Homo sapiens	IC50	uM	0.016
	2022145	CHEMBL903634	Inhibition of Ack1	B	CN(C)CCOc1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247479	=	IC50	nM	11.0	CHEMBL4599	Homo sapiens	IC50	uM	0.011
	2022146	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2oc3ncnc(NCCN4CCNCC4)c3c2-c2ccccc2)cc1		CHEMBL247272	=	IC50	nM	181.0	CHEMBL4599	Homo sapiens	IC50	uM	0.181
	2022147	CHEMBL903634	Inhibition of Ack1	B	c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247070	=	IC50	nM	24.0	CHEMBL4599	Homo sapiens	IC50	uM	0.024
	2470417	CHEMBL981799	Inhibition of TNK2 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL4599	Homo sapiens	INH	%	10.0
	2585273	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CCOc1ccccc1Oc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(=O)Nc1c(C)cccc1C		CHEMBL459044	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585274	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc21		CHEMBL472392	=	Ki	nM	2.0	CHEMBL4599	Homo sapiens	Ki	uM	0.002
	2585275	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2ccccc2)c2cnc(Nc3ccccc3)nc21		CHEMBL472393	>	Ki	nM	4000.0	CHEMBL4599	Homo sapiens	Ki	uM	4.0
	2585276	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487242	=	Ki	nM	3.0	CHEMBL4599	Homo sapiens	Ki	uM	0.003
	2585277	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL487243	=	Ki	nM	7.0	CHEMBL4599	Homo sapiens	Ki	uM	0.007
	2585278	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(F)cc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL521379	=	Ki	nM	26.0	CHEMBL4599	Homo sapiens	Ki	uM	0.026
	2585279	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(C)cc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487048	>	Ki	nM	2500.0	CHEMBL4599	Homo sapiens	Ki	uM	2.5
	2585280	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc21		CHEMBL487896	=	Ki	nM	12.0	CHEMBL4599	Homo sapiens	Ki	uM	0.012
	2585281	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL487897	=	Ki	nM	2.0	CHEMBL4599	Homo sapiens	Ki	uM	0.002
	2585282	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)cc3)nc21		CHEMBL458333	=	Ki	nM	3.0	CHEMBL4599	Homo sapiens	Ki	uM	0.003
	2585283	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)c(F)c3)nc21		CHEMBL502156	=	Ki	nM	3.0	CHEMBL4599	Homo sapiens	Ki	uM	0.003
	2585284	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccc(OCCN4CCCC4)c(F)c3)nc21		CHEMBL504331	=	Ki	nM	2.0	CHEMBL4599	Homo sapiens	Ki	uM	0.002
	2585285	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCCN4CCCCC4)c(F)c3)nc21		CHEMBL450918	=	Ki	nM	3.0	CHEMBL4599	Homo sapiens	Ki	uM	0.003
	2585286	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2ccccc2)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL516660	=	Ki	nM	400.0	CHEMBL4599	Homo sapiens	Ki	uM	0.4
	2585287	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(F)cc2C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL514919	=	Ki	nM	18.0	CHEMBL4599	Homo sapiens	Ki	uM	0.018
	2585288	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(C)cc2C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL459220	=	Ki	nM	12.0	CHEMBL4599	Homo sapiens	Ki	uM	0.012
	2585289	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CN1CCN(CCn2nc(Nc3c(Cl)cccc3Cl)c3cnc(Nc4ccccc4)nc32)CC1		CHEMBL462189	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	2585290	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	ON1CCN(CCn2nc(Nc3c(Cl)cccc3Cl)c3cnc(Nc4ccccc4)nc32)CC1		CHEMBL462364	=	Ki	nM	50.0	CHEMBL4599	Homo sapiens	Ki	uM	0.05
	2585291	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	Cc1cccc(C)c1Nc1nn(CCN2CCOCC2)c2nc(Nc3ccccc3)ncc12		CHEMBL518822	=	Ki	nM	50.0	CHEMBL4599	Homo sapiens	Ki	uM	0.05
	2585292	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	OC[C@H]1CCCN1CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL520403	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585293	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CN(C)[C@@H]1CCN(CCn2nc(Nc3c(Cl)cccc3Cl)c3cnc(Nc4ccccc4)nc32)C1		CHEMBL488061	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	2585294	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CN(C)C(=O)Cn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL488062	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585295	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	O=C(Cn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21)N1CCOCC1		CHEMBL519916	=	Ki	nM	70.0	CHEMBL4599	Homo sapiens	Ki	uM	0.07
	2585296	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CN(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL487241	=	Ki	nM	5.0	CHEMBL4599	Homo sapiens	Ki	uM	0.005
	2585297	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CN(C)CCCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL487054	=	Ki	nM	5.0	CHEMBL4599	Homo sapiens	Ki	uM	0.005
	2585298	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	Cc1cccc(C)c1Nc1nn(CCCN(C)C)c2nc(Nc3ccccc3)ncc12		CHEMBL521381	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585299	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	CCN(CC)CCCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487055	=	Ki	nM	40.0	CHEMBL4599	Homo sapiens	Ki	uM	0.04
	2585300	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	Cc1cccc(C)c1Nc1nn(CCCN2CCCC2)c2nc(Nc3ccccc3)ncc12		CHEMBL461158	=	Ki	nM	100.0	CHEMBL4599	Homo sapiens	Ki	uM	0.1
	2585301	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	OC[C@H](O)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL461159	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	2585302	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	Cc1cccc(C)c1Nc1nn(CC[C@@H](O)CO)c2nc(Nc3ccccc3)ncc12		CHEMBL461337	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585303	CHEMBL1017265	Inhibition of histidine-tagged ACK1 (amino acids 117 to 489) expressed in SF9 cells	B	Cc1cccc(C)c1Nc1nn(CC[C@@H](O)CN(C)C)c2nc(Nc3ccccc3)ncc12		CHEMBL462365	=	Ki	nM	80.0	CHEMBL4599	Homo sapiens	Ki	uM	0.08
	2585304	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CCOc1ccccc1Oc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1C(=O)Nc1c(C)cccc1C		CHEMBL459044	=	Ki	nM	100.0	CHEMBL4599	Homo sapiens	Ki	uM	0.1
	2585305	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc21		CHEMBL472392	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
Not Determined	2585306	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2ccccc2)c2cnc(Nc3ccccc3)nc21		CHEMBL472393		Ki			CHEMBL4599	Homo sapiens	Ki		
	2585307	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487242	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585308	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL487243	=	Ki	nM	40.0	CHEMBL4599	Homo sapiens	Ki	uM	0.04
	2585309	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(F)cc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL521379	=	Ki	nM	5500.0	CHEMBL4599	Homo sapiens	Ki	uM	5.5
Not Determined	2585310	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(C)cc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487048		Ki			CHEMBL4599	Homo sapiens	Ki		
	2585311	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc21		CHEMBL487896	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	2585312	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL487897	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585313	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)cc3)nc21		CHEMBL458333	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585314	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)c(F)c3)nc21		CHEMBL502156	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585315	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccc(OCCN4CCCC4)c(F)c3)nc21		CHEMBL504331	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585316	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCCN4CCCCC4)c(F)c3)nc21		CHEMBL450918	=	Ki	nM	60.0	CHEMBL4599	Homo sapiens	Ki	uM	0.06
	2585317	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2ccccc2)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL516660	=	Ki	nM	2100.0	CHEMBL4599	Homo sapiens	Ki	uM	2.1
	2585318	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(F)cc2C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL514919	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585319	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	COC(C)(C)CCn1nc(Nc2c(C)cc(C)cc2C)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc21		CHEMBL459220	=	Ki	nM	50.0	CHEMBL4599	Homo sapiens	Ki	uM	0.05
	2585320	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CN1CCN(CCn2nc(Nc3c(Cl)cccc3Cl)c3cnc(Nc4ccccc4)nc32)CC1		CHEMBL462189	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585321	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	ON1CCN(CCn2nc(Nc3c(Cl)cccc3Cl)c3cnc(Nc4ccccc4)nc32)CC1		CHEMBL462364	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	2585322	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	Cc1cccc(C)c1Nc1nn(CCN2CCOCC2)c2nc(Nc3ccccc3)ncc12		CHEMBL518822	=	Ki	nM	70.0	CHEMBL4599	Homo sapiens	Ki	uM	0.07
	2585323	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	OC[C@H]1CCCN1CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL520403	=	Ki	nM	50.0	CHEMBL4599	Homo sapiens	Ki	uM	0.05
	2585324	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CN(C)[C@@H]1CCN(CCn2nc(Nc3c(Cl)cccc3Cl)c3cnc(Nc4ccccc4)nc32)C1		CHEMBL488061	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585325	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CN(C)C(=O)Cn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL488062	=	Ki	nM	90.0	CHEMBL4599	Homo sapiens	Ki	uM	0.09
	2585326	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	O=C(Cn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21)N1CCOCC1		CHEMBL519916	=	Ki	nM	140.0	CHEMBL4599	Homo sapiens	Ki	uM	0.14
	2585327	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CN(C)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL487241	=	Ki	nM	140.0	CHEMBL4599	Homo sapiens	Ki	uM	0.14
	2585328	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CN(C)CCCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL487054	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585329	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	Cc1cccc(C)c1Nc1nn(CCCN(C)C)c2nc(Nc3ccccc3)ncc12		CHEMBL521381	=	Ki	nM	40.0	CHEMBL4599	Homo sapiens	Ki	uM	0.04
	2585330	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	CCN(CC)CCCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487055	=	Ki	nM	140.0	CHEMBL4599	Homo sapiens	Ki	uM	0.14
	2585331	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	Cc1cccc(C)c1Nc1nn(CCCN2CCCC2)c2nc(Nc3ccccc3)ncc12		CHEMBL461158	=	Ki	nM	300.0	CHEMBL4599	Homo sapiens	Ki	uM	0.3
	2585332	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	OC[C@H](O)CCn1nc(Nc2c(Cl)cccc2Cl)c2cnc(Nc3ccccc3)nc21		CHEMBL461159	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	2585333	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	Cc1cccc(C)c1Nc1nn(CC[C@@H](O)CO)c2nc(Nc3ccccc3)ncc12		CHEMBL461337	=	Ki	nM	60.0	CHEMBL4599	Homo sapiens	Ki	uM	0.06
	2585334	CHEMBL1017266	Inhibition of flag-tagged ACK1 autophosphorylation expressed in human 293 cells	B	Cc1cccc(C)c1Nc1nn(CC[C@@H](O)CN(C)C)c2nc(Nc3ccccc3)ncc12		CHEMBL462365	=	Ki	nM	190.0	CHEMBL4599	Homo sapiens	Ki	uM	0.19
	2892653	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892654	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892655	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892656	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892657	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892658	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892659	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892660	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892661	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892662	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892663	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892664	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	5.6	CHEMBL4599	Homo sapiens	Kd	nM	5.6
	2892665	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	=	Kd	nM	5200.0	CHEMBL4599	Homo sapiens	Kd	nM	5200.0
	2892666	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892667	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892668	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892669	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892670	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892671	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892672	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892673	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892674	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892675	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892676	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892677	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892678	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	120.0	CHEMBL4599	Homo sapiens	Kd	nM	120.0
	2892679	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892680	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892681	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892682	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892683	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892684	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892685	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	16.0	CHEMBL4599	Homo sapiens	Kd	nM	16.0
	2892686	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	4900.0	CHEMBL4599	Homo sapiens	Kd	nM	4900.0
	2892687	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	8900.0	CHEMBL4599	Homo sapiens	Kd	nM	8900.0
	2892688	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	4400.0	CHEMBL4599	Homo sapiens	Kd	nM	4400.0
	2892689	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	2892690	CHEMBL1051355	Binding constant for TNK2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	uM	10.0
	3052519	CHEMBL1047770	Residual activity of ACK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	90.0	CHEMBL4599	Homo sapiens	Residual activity	%	90.0
	3052771	CHEMBL1046504	Residual activity of ACK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	40.0	CHEMBL4599	Homo sapiens	Residual activity	%	40.0
	3054080	CHEMBL1066598	Residual activity of ACK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	96.0	CHEMBL4599	Homo sapiens	Residual activity	%	96.0
	3055367	CHEMBL1047770	Residual activity of ACK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	76.0	CHEMBL4599	Homo sapiens	Residual activity	%	76.0
	3055619	CHEMBL1046504	Residual activity of ACK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	35.0	CHEMBL4599	Homo sapiens	Residual activity	%	35.0
	3056924	CHEMBL1066598	Residual activity of ACK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	105.0	CHEMBL4599	Homo sapiens	Residual activity	%	105.0
	3058244	CHEMBL1047770	Residual activity of ACK1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	106.0	CHEMBL4599	Homo sapiens	Residual activity	%	106.0
	3058496	CHEMBL1046504	Residual activity of ACK1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	31.0	CHEMBL4599	Homo sapiens	Residual activity	%	31.0
	3072842	CHEMBL1066598	Residual activity of ACK1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	87.0	CHEMBL4599	Homo sapiens	Residual activity	%	87.0
	3117912	CHEMBL1072188	Inhibition of ACK1	B	CC(=O)N1CCC(Nc2ncc3c(n2)-c2c(c(C(N)=O)nn2C)CC3)CC1		CHEMBL599224	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	3117965	CHEMBL1072188	Inhibition of ACK1	B	Cn1nc(C(N)=O)c2c1-c1nc(NC3CCN(C(=O)c4ccccc4)CC3)ncc1CC2		CHEMBL599428	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	3118018	CHEMBL1072188	Inhibition of ACK1	B	CNC(=O)c1nn(C)c2c1CCc1cnc(NC3CCN(C(=O)C4CCN(S(C)(=O)=O)CC4)CC3)nc1-2		CHEMBL597754	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	3333195	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	=	Inhibition	%	79.05	CHEMBL4599	Homo sapiens	INH	%	79.05
	3334600	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Inhibition	%	98.0	CHEMBL4599	Homo sapiens	INH	%	98.0
	3336020	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	=	Inhibition	%	88.0	CHEMBL4599	Homo sapiens	INH	%	88.0
	3336422	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	=	Inhibition	%	85.0	CHEMBL4599	Homo sapiens	INH	%	85.0
	3337666	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	=	Inhibition	%	97.4	CHEMBL4599	Homo sapiens	INH	%	97.4
	3338997	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	=	Inhibition	%	93.2	CHEMBL4599	Homo sapiens	INH	%	93.2
	3339253	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	=	Inhibition	%	97.2	CHEMBL4599	Homo sapiens	INH	%	97.2
	3340558	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	=	Inhibition	%	99.8	CHEMBL4599	Homo sapiens	INH	%	99.8
	3341964	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	=	Inhibition	%	99.0	CHEMBL4599	Homo sapiens	INH	%	99.0
	3343411	CHEMBL1168134	Inhibition of TNK2 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	=	Inhibition	%	99.0	CHEMBL4599	Homo sapiens	INH	%	99.0
	3351788	CHEMBL1175102	Inhibition of TNK2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	INH	%	0.6
	3358840	CHEMBL1175102	Inhibition of TNK2 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	11.0	CHEMBL4599	Homo sapiens	INH	%	11.0
	3446191	CHEMBL1244331	Inhibition of TNK2	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	IC50	nM	2.7	CHEMBL4599	Homo sapiens	IC50	nM	2.7
	5120344	CHEMBL1648169	Inhibition of human ACK1 at 10 uM after 60 mins by TR-FRET assay	B	S=c1[nH]nc(-c2ccncc2)n1-c1ccc2ccccc2c1		CHEMBL1644616	=	Inhibition	%	103.0	CHEMBL4599	Homo sapiens	INH	%	103.0
	5223295	CHEMBL1679286	Binding affinity to TNK2 at 10 uM by immobilized ligand displacement assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL1672987	>	Inhibition	%	90.0	CHEMBL4599	Homo sapiens	INH	%	90.0
	5223296	CHEMBL1679286	Binding affinity to TNK2 at 10 uM by immobilized ligand displacement assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C		CHEMBL1673039	>	Inhibition	%	90.0	CHEMBL4599	Homo sapiens	INH	%	90.0
	5223310	CHEMBL1679300	Binding affinity to TNK2 by immobilized ligand displacement assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C		CHEMBL1673039	=	Kd	nM	440.0	CHEMBL4599	Homo sapiens	Kd	nM	440.0
	6198100	CHEMBL1776511	Inhibition of ACK1 assessed as [33P]gamma-ATP incorporation into substrate after 60 mins by gamma counting	B	CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1		CHEMBL1738758	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	6340908	CHEMBL1826932	Activity of TNK2 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	89.0	CHEMBL4599	Homo sapiens	Activity	%	89.0
	7567201	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7567660	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7568131	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7568599	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7569174	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7569634	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	=	Kd	nM	760.0	CHEMBL4599	Homo sapiens	Kd	nM	760.0
	7570106	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	2600.0	CHEMBL4599	Homo sapiens	Kd	nM	2600.0
	7570554	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	8900.0	CHEMBL4599	Homo sapiens	Kd	nM	8900.0
	7571150	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7571607	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	5.6	CHEMBL4599	Homo sapiens	Kd	nM	5.6
	7572104	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7572520	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Kd	nM	2.0	CHEMBL4599	Homo sapiens	Kd	nM	2.0
	7573131	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	1600.0	CHEMBL4599	Homo sapiens	Kd	nM	1600.0
	7573588	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7573622	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	=	Kd	nM	870.0	CHEMBL4599	Homo sapiens	Kd	nM	870.0
	7574091	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	120.0	CHEMBL4599	Homo sapiens	Kd	nM	120.0
	7574499	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7575109	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7575599	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	=	Kd	nM	250.0	CHEMBL4599	Homo sapiens	Kd	nM	250.0
	7576064	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	=	Kd	nM	1100.0	CHEMBL4599	Homo sapiens	Kd	nM	1100.0
	7576472	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	64.0	CHEMBL4599	Homo sapiens	Kd	nM	64.0
	7577100	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	=	Kd	nM	200.0	CHEMBL4599	Homo sapiens	Kd	nM	200.0
	7577578	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	1600.0	CHEMBL4599	Homo sapiens	Kd	nM	1600.0
	7578048	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	9600.0	CHEMBL4599	Homo sapiens	Kd	nM	9600.0
	7578453	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7578649	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7579023	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7579473	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7579947	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7580416	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7580819	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	4400.0	CHEMBL4599	Homo sapiens	Kd	nM	4400.0
	7581007	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7581392	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7581837	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7582308	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7582772	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	70.0	CHEMBL4599	Homo sapiens	Kd	nM	70.0
	7583172	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7583353	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7583750	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7584195	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7584666	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7585683	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7586091	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7586537	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7587008	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7587020	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7587644	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	=	Kd	nM	6000.0	CHEMBL4599	Homo sapiens	Kd	nM	6000.0
	7588063	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	6.6	CHEMBL4599	Homo sapiens	Kd	nM	6.6
	7588516	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7588996	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7589609	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7590033	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7590532	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7590983	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7591582	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7592004	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7592034	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7592507	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7592960	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	29.0	CHEMBL4599	Homo sapiens	Kd	nM	29.0
	7593549	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7594014	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7594487	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7594939	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7595519	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7595993	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7596464	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7596911	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	16.0	CHEMBL4599	Homo sapiens	Kd	nM	16.0
	7597047	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7597500	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL4599	Homo sapiens	Kd	nM	10000.0
	7597973	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	=	Kd	nM	680.0	CHEMBL4599	Homo sapiens	Kd	nM	680.0
	7598443	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	=	Kd	nM	27.0	CHEMBL4599	Homo sapiens	Kd	nM	27.0
	7598885	CHEMBL1908504	Binding constant for TNK2 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	4900.0	CHEMBL4599	Homo sapiens	Kd	nM	4900.0
	8046137	CHEMBL1958810	Inhibition of ACK1 at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	8061380	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-1.7	CHEMBL4599	Homo sapiens	Inhibition	%	-1.7
	8061604	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	0.03	CHEMBL4599	Homo sapiens	Inhibition	%	0.03
	8061711	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	0.74	CHEMBL4599	Homo sapiens	Inhibition	%	0.74
	8062126	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	0.71	CHEMBL4599	Homo sapiens	Inhibition	%	0.71
	8062242	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.68	CHEMBL4599	Homo sapiens	Inhibition	%	1.68
	8062466	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.75	CHEMBL4599	Homo sapiens	Inhibition	%	0.75
	8062628	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	1.76	CHEMBL4599	Homo sapiens	Inhibition	%	1.76
	8062950	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-2.72	CHEMBL4599	Homo sapiens	Inhibition	%	-2.72
	8063082	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.36	CHEMBL4599	Homo sapiens	Inhibition	%	-0.36
	8063473	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	0.86	CHEMBL4599	Homo sapiens	Inhibition	%	0.86
	8063581	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	2.45	CHEMBL4599	Homo sapiens	Inhibition	%	2.45
	8063805	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	0.29	CHEMBL4599	Homo sapiens	Inhibition	%	0.29
	8063987	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.72	CHEMBL4599	Homo sapiens	Inhibition	%	1.72
	8064326	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	0.19	CHEMBL4599	Homo sapiens	Inhibition	%	0.19
	8064536	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.35	CHEMBL4599	Homo sapiens	Inhibition	%	-0.35
	8064674	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	-0.9	CHEMBL4599	Homo sapiens	Inhibition	%	-0.9
	8064898	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	-0.28	CHEMBL4599	Homo sapiens	Inhibition	%	-0.28
	8065064	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	1.6	CHEMBL4599	Homo sapiens	Inhibition	%	1.6
	8065404	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	1.03	CHEMBL4599	Homo sapiens	Inhibition	%	1.03
	8065579	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.31	CHEMBL4599	Homo sapiens	Inhibition	%	0.31
	8065918	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.85	CHEMBL4599	Homo sapiens	Inhibition	%	0.85
	8066128	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-0.22	CHEMBL4599	Homo sapiens	Inhibition	%	-0.22
	8066488	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	2.05	CHEMBL4599	Homo sapiens	Inhibition	%	2.05
	8066654	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	0.32	CHEMBL4599	Homo sapiens	Inhibition	%	0.32
	8067002	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.29	CHEMBL4599	Homo sapiens	Inhibition	%	0.29
	8067177	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.47	CHEMBL4599	Homo sapiens	Inhibition	%	0.47
	8067401	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.69	CHEMBL4599	Homo sapiens	Inhibition	%	0.69
	8067522	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.38	CHEMBL4599	Homo sapiens	Inhibition	%	0.38
	8067732	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-0.52	CHEMBL4599	Homo sapiens	Inhibition	%	-0.52
	8067956	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-0.83	CHEMBL4599	Homo sapiens	Inhibition	%	-0.83
	8068091	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	3.06	CHEMBL4599	Homo sapiens	Inhibition	%	3.06
	8068255	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	1.42	CHEMBL4599	Homo sapiens	Inhibition	%	1.42
	8068479	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.46	CHEMBL4599	Homo sapiens	Inhibition	%	0.46
	8068604	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	0.1	CHEMBL4599	Homo sapiens	Inhibition	%	0.1
	8069002	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	Inhibition	%	0.6
	8069127	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.16	CHEMBL4599	Homo sapiens	Inhibition	%	0.16
	8069422	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	35.6	CHEMBL4599	Homo sapiens	Inhibition	%	35.6
	8069807	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	0.86	CHEMBL4599	Homo sapiens	Inhibition	%	0.86
	8069933	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.23	CHEMBL4599	Homo sapiens	Inhibition	%	0.23
	8070157	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.89	CHEMBL4599	Homo sapiens	Inhibition	%	0.89
	8070329	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.59	CHEMBL4599	Homo sapiens	Inhibition	%	0.59
	8070454	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.87	CHEMBL4599	Homo sapiens	Inhibition	%	0.87
	8070678	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.23	CHEMBL4599	Homo sapiens	Inhibition	%	0.23
	8070752	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	0.29	CHEMBL4599	Homo sapiens	Inhibition	%	0.29
	8070976	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	9.11	CHEMBL4599	Homo sapiens	Inhibition	%	9.11
	8071133	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	0.54	CHEMBL4599	Homo sapiens	Inhibition	%	0.54
	8071483	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	-0.11	CHEMBL4599	Homo sapiens	Inhibition	%	-0.11
	8071656	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.47	CHEMBL4599	Homo sapiens	Inhibition	%	0.47
	8072005	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.19	CHEMBL4599	Homo sapiens	Inhibition	%	0.19
	8072319	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.5	CHEMBL4599	Homo sapiens	Inhibition	%	-0.5
	8072476	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	1.92	CHEMBL4599	Homo sapiens	Inhibition	%	1.92
	8072825	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	0.91	CHEMBL4599	Homo sapiens	Inhibition	%	0.91
	8072992	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.93	CHEMBL4599	Homo sapiens	Inhibition	%	0.93
	8073341	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	0.46	CHEMBL4599	Homo sapiens	Inhibition	%	0.46
	8073684	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.48	CHEMBL4599	Homo sapiens	Inhibition	%	-0.48
	8073917	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-1.08	CHEMBL4599	Homo sapiens	Inhibition	%	-1.08
	8074069	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	0.69	CHEMBL4599	Homo sapiens	Inhibition	%	0.69
	8074293	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.18	CHEMBL4599	Homo sapiens	Inhibition	%	1.18
	8074423	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	0.68	CHEMBL4599	Homo sapiens	Inhibition	%	0.68
	8074580	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	0.24	CHEMBL4599	Homo sapiens	Inhibition	%	0.24
	8074804	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.43	CHEMBL4599	Homo sapiens	Inhibition	%	1.43
	8074931	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.35	CHEMBL4599	Homo sapiens	Inhibition	%	1.35
	8075266	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-0.62	CHEMBL4599	Homo sapiens	Inhibition	%	-0.62
	8075503	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-0.98	CHEMBL4599	Homo sapiens	Inhibition	%	-0.98
	8075868	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.78	CHEMBL4599	Homo sapiens	Inhibition	%	0.78
	8076010	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	7.7	CHEMBL4599	Homo sapiens	Inhibition	%	7.7
	8076382	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	2.74	CHEMBL4599	Homo sapiens	Inhibition	%	2.74
	8076516	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.12	CHEMBL4599	Homo sapiens	Inhibition	%	1.12
	8076740	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	13.23	CHEMBL4599	Homo sapiens	Inhibition	%	13.23
	8076842	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-0.82	CHEMBL4599	Homo sapiens	Inhibition	%	-0.82
	8077089	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-1.32	CHEMBL4599	Homo sapiens	Inhibition	%	-1.32
	8077441	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	0.5	CHEMBL4599	Homo sapiens	Inhibition	%	0.5
	8077592	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	0.19	CHEMBL4599	Homo sapiens	Inhibition	%	0.19
	8077816	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	2.86	CHEMBL4599	Homo sapiens	Inhibition	%	2.86
	8077959	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	0.78	CHEMBL4599	Homo sapiens	Inhibition	%	0.78
	8078322	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.31	CHEMBL4599	Homo sapiens	Inhibition	%	-1.31
	8078424	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-1.72	CHEMBL4599	Homo sapiens	Inhibition	%	-1.72
	8078648	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-0.93	CHEMBL4599	Homo sapiens	Inhibition	%	-0.93
	8078674	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	-0.88	CHEMBL4599	Homo sapiens	Inhibition	%	-0.88
	8078898	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	-1.74	CHEMBL4599	Homo sapiens	Inhibition	%	-1.74
	8079014	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	0.82	CHEMBL4599	Homo sapiens	Inhibition	%	0.82
	8079396	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	-0.26	CHEMBL4599	Homo sapiens	Inhibition	%	-0.26
	8079538	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	2.21	CHEMBL4599	Homo sapiens	Inhibition	%	2.21
	8079901	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	-1.02	CHEMBL4599	Homo sapiens	Inhibition	%	-1.02
	8080230	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-2.5	CHEMBL4599	Homo sapiens	Inhibition	%	-2.5
	8080482	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	-0.91	CHEMBL4599	Homo sapiens	Inhibition	%	-0.91
	8080597	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	2.0	CHEMBL4599	Homo sapiens	Inhibition	%	2.0
	8080821	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	0.68	CHEMBL4599	Homo sapiens	Inhibition	%	0.68
	8080985	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	2.04	CHEMBL4599	Homo sapiens	Inhibition	%	2.04
	8081120	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.67	CHEMBL4599	Homo sapiens	Inhibition	%	0.67
	8081344	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	0.38	CHEMBL4599	Homo sapiens	Inhibition	%	0.38
	8081488	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	5.57	CHEMBL4599	Homo sapiens	Inhibition	%	5.57
	8081815	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-0.75	CHEMBL4599	Homo sapiens	Inhibition	%	-0.75
	8082067	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	0.01	CHEMBL4599	Homo sapiens	Inhibition	%	0.01
	8082404	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	1.66	CHEMBL4599	Homo sapiens	Inhibition	%	1.66
	8082577	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-1.87	CHEMBL4599	Homo sapiens	Inhibition	%	-1.87
	8082924	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.04	CHEMBL4599	Homo sapiens	Inhibition	%	1.04
	8083080	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	44.27	CHEMBL4599	Homo sapiens	Inhibition	%	44.27
	8083403	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-0.58	CHEMBL4599	Homo sapiens	Inhibition	%	-0.58
	8083657	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-1.67	CHEMBL4599	Homo sapiens	Inhibition	%	-1.67
	8083991	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	0.57	CHEMBL4599	Homo sapiens	Inhibition	%	0.57
	8084176	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	-2.1	CHEMBL4599	Homo sapiens	Inhibition	%	-2.1
	8084518	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	1.08	CHEMBL4599	Homo sapiens	Inhibition	%	1.08
	8084679	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	0.41	CHEMBL4599	Homo sapiens	Inhibition	%	0.41
	8084903	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	3.98	CHEMBL4599	Homo sapiens	Inhibition	%	3.98
	8085001	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-0.85	CHEMBL4599	Homo sapiens	Inhibition	%	-0.85
	8085257	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-1.55	CHEMBL4599	Homo sapiens	Inhibition	%	-1.55
	8085589	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	1.23	CHEMBL4599	Homo sapiens	Inhibition	%	1.23
	8085778	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	1.85	CHEMBL4599	Homo sapiens	Inhibition	%	1.85
	8086002	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	8.38	CHEMBL4599	Homo sapiens	Inhibition	%	8.38
	8086117	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	0.72	CHEMBL4599	Homo sapiens	Inhibition	%	0.72
	8086503	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	0.92	CHEMBL4599	Homo sapiens	Inhibition	%	0.92
	8086602	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-2.06	CHEMBL4599	Homo sapiens	Inhibition	%	-2.06
	8086826	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-0.95	CHEMBL4599	Homo sapiens	Inhibition	%	-0.95
	8087037	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	0.26	CHEMBL4599	Homo sapiens	Inhibition	%	0.26
	8087195	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	0.93	CHEMBL4599	Homo sapiens	Inhibition	%	0.93
	8087533	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	22.79	CHEMBL4599	Homo sapiens	Inhibition	%	22.79
	8087895	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.33	CHEMBL4599	Homo sapiens	Inhibition	%	2.33
	8088037	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	1.51	CHEMBL4599	Homo sapiens	Inhibition	%	1.51
	8088409	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-0.09	CHEMBL4599	Homo sapiens	Inhibition	%	-0.09
	8088537	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	2.15	CHEMBL4599	Homo sapiens	Inhibition	%	2.15
	8088761	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	3.06	CHEMBL4599	Homo sapiens	Inhibition	%	3.06
	8088854	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	1.12	CHEMBL4599	Homo sapiens	Inhibition	%	1.12
	8089206	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	-0.19	CHEMBL4599	Homo sapiens	Inhibition	%	-0.19
	8089354	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	0.21	CHEMBL4599	Homo sapiens	Inhibition	%	0.21
	8089578	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	0.01	CHEMBL4599	Homo sapiens	Inhibition	%	0.01
	8089698	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	1.01	CHEMBL4599	Homo sapiens	Inhibition	%	1.01
	8089878	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	-0.73	CHEMBL4599	Homo sapiens	Inhibition	%	-0.73
	8090102	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	Inhibition	%	0.6
	8090267	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	1.09	CHEMBL4599	Homo sapiens	Inhibition	%	1.09
	8090434	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	2.89	CHEMBL4599	Homo sapiens	Inhibition	%	2.89
	8090658	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	0.58	CHEMBL4599	Homo sapiens	Inhibition	%	0.58
	8090797	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.5	CHEMBL4599	Homo sapiens	Inhibition	%	0.5
	8091002	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.85	CHEMBL4599	Homo sapiens	Inhibition	%	0.85
	8091226	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	1.73	CHEMBL4599	Homo sapiens	Inhibition	%	1.73
	8091363	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	10.97	CHEMBL4599	Homo sapiens	Inhibition	%	10.97
	8091518	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	0.66	CHEMBL4599	Homo sapiens	Inhibition	%	0.66
	8091742	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	1.34	CHEMBL4599	Homo sapiens	Inhibition	%	1.34
	8091858	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	0.63	CHEMBL4599	Homo sapiens	Inhibition	%	0.63
	8092219	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	-0.4	CHEMBL4599	Homo sapiens	Inhibition	%	-0.4
	8092370	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	1.52	CHEMBL4599	Homo sapiens	Inhibition	%	1.52
	8092594	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	1.66	CHEMBL4599	Homo sapiens	Inhibition	%	1.66
	8092742	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	-0.33	CHEMBL4599	Homo sapiens	Inhibition	%	-0.33
	8093095	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	6.07	CHEMBL4599	Homo sapiens	Inhibition	%	6.07
	8093183	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	2.47	CHEMBL4599	Homo sapiens	Inhibition	%	2.47
	8093407	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	0.22	CHEMBL4599	Homo sapiens	Inhibition	%	0.22
	8093547	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	2.16	CHEMBL4599	Homo sapiens	Inhibition	%	2.16
	8093910	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	2.76	CHEMBL4599	Homo sapiens	Inhibition	%	2.76
	8094030	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	1.07	CHEMBL4599	Homo sapiens	Inhibition	%	1.07
	8094434	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	0.58	CHEMBL4599	Homo sapiens	Inhibition	%	0.58
	8094609	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	5.91	CHEMBL4599	Homo sapiens	Inhibition	%	5.91
	8094989	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	1.15	CHEMBL4599	Homo sapiens	Inhibition	%	1.15
	8095129	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	0.67	CHEMBL4599	Homo sapiens	Inhibition	%	0.67
	8095556	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	2.69	CHEMBL4599	Homo sapiens	Inhibition	%	2.69
	8095697	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	1.0	CHEMBL4599	Homo sapiens	Inhibition	%	1.0
	8096069	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	0.51	CHEMBL4599	Homo sapiens	Inhibition	%	0.51
	8096186	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	3.33	CHEMBL4599	Homo sapiens	Inhibition	%	3.33
	8096410	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	1.79	CHEMBL4599	Homo sapiens	Inhibition	%	1.79
	8096549	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	0.06	CHEMBL4599	Homo sapiens	Inhibition	%	0.06
	8096929	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	5.79	CHEMBL4599	Homo sapiens	Inhibition	%	5.79
	8097076	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.19	CHEMBL4599	Homo sapiens	Inhibition	%	-0.19
	8097387	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	1.16	CHEMBL4599	Homo sapiens	Inhibition	%	1.16
	8097607	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.57	CHEMBL4599	Homo sapiens	Inhibition	%	1.57
	8097757	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.28	CHEMBL4599	Homo sapiens	Inhibition	%	0.28
	8098114	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	-0.08	CHEMBL4599	Homo sapiens	Inhibition	%	-0.08
	8098234	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	3.27	CHEMBL4599	Homo sapiens	Inhibition	%	3.27
	8098458	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.46	CHEMBL4599	Homo sapiens	Inhibition	%	-0.46
	8098638	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	3.5	CHEMBL4599	Homo sapiens	Inhibition	%	3.5
	8098823	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	10.8	CHEMBL4599	Homo sapiens	Inhibition	%	10.8
	8099191	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.22	CHEMBL4599	Homo sapiens	Inhibition	%	1.22
	8099333	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	4.69	CHEMBL4599	Homo sapiens	Inhibition	%	4.69
	8099557	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	1.52	CHEMBL4599	Homo sapiens	Inhibition	%	1.52
	8099751	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	0.77	CHEMBL4599	Homo sapiens	Inhibition	%	0.77
	8099898	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	12.69	CHEMBL4599	Homo sapiens	Inhibition	%	12.69
	8100122	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	0.47	CHEMBL4599	Homo sapiens	Inhibition	%	0.47
	8100268	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	4.91	CHEMBL4599	Homo sapiens	Inhibition	%	4.91
	8100608	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	1.64	CHEMBL4599	Homo sapiens	Inhibition	%	1.64
	8100748	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	0.09	CHEMBL4599	Homo sapiens	Inhibition	%	0.09
	8101132	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	1.17	CHEMBL4599	Homo sapiens	Inhibition	%	1.17
	8101274	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.13	CHEMBL4599	Homo sapiens	Inhibition	%	1.13
	8101498	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	Inhibition	%	0.0
	8101683	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	0.31	CHEMBL4599	Homo sapiens	Inhibition	%	0.31
	8101936	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	1.63	CHEMBL4599	Homo sapiens	Inhibition	%	1.63
	8102091	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	5.21	CHEMBL4599	Homo sapiens	Inhibition	%	5.21
	8102315	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	5.44	CHEMBL4599	Homo sapiens	Inhibition	%	5.44
	8102446	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	Inhibition	%	0.6
	8102790	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	0.57	CHEMBL4599	Homo sapiens	Inhibition	%	0.57
	8102968	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	-0.27	CHEMBL4599	Homo sapiens	Inhibition	%	-0.27
	8103164	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	61.66	CHEMBL4599	Homo sapiens	Inhibition	%	61.66
	8103388	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	0.7	CHEMBL4599	Homo sapiens	Inhibition	%	0.7
	8103526	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	2.21	CHEMBL4599	Homo sapiens	Inhibition	%	2.21
	8103900	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	3.29	CHEMBL4599	Homo sapiens	Inhibition	%	3.29
	8104085	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.6	CHEMBL4599	Homo sapiens	Inhibition	%	1.6
	8104457	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	5.39	CHEMBL4599	Homo sapiens	Inhibition	%	5.39
	8104603	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	-0.82	CHEMBL4599	Homo sapiens	Inhibition	%	-0.82
	8104941	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	0.82	CHEMBL4599	Homo sapiens	Inhibition	%	0.82
	8105081	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	-0.42	CHEMBL4599	Homo sapiens	Inhibition	%	-0.42
	8105305	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.23	CHEMBL4599	Homo sapiens	Inhibition	%	0.23
	8105471	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	2.39	CHEMBL4599	Homo sapiens	Inhibition	%	2.39
	8105833	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.48	CHEMBL4599	Homo sapiens	Inhibition	%	0.48
	8106113	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	1.8	CHEMBL4599	Homo sapiens	Inhibition	%	1.8
	8106278	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	15.3	CHEMBL4599	Homo sapiens	Inhibition	%	15.3
	8106658	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	47.82	CHEMBL4599	Homo sapiens	Inhibition	%	47.82
	8106787	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	-0.01	CHEMBL4599	Homo sapiens	Inhibition	%	-0.01
	8107132	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-0.68	CHEMBL4599	Homo sapiens	Inhibition	%	-0.68
	8107304	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	0.03	CHEMBL4599	Homo sapiens	Inhibition	%	0.03
	8107528	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	0.49	CHEMBL4599	Homo sapiens	Inhibition	%	0.49
	8107729	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	3.88	CHEMBL4599	Homo sapiens	Inhibition	%	3.88
	8107864	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	2.29	CHEMBL4599	Homo sapiens	Inhibition	%	2.29
	8108088	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	22.22	CHEMBL4599	Homo sapiens	Inhibition	%	22.22
	8108246	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.43	CHEMBL4599	Homo sapiens	Inhibition	%	1.43
	8108421	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	0.12	CHEMBL4599	Homo sapiens	Inhibition	%	0.12
	8108792	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	3.05	CHEMBL4599	Homo sapiens	Inhibition	%	3.05
	8108934	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	0.92	CHEMBL4599	Homo sapiens	Inhibition	%	0.92
	8109158	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.03	CHEMBL4599	Homo sapiens	Inhibition	%	-0.03
	8109272	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	2.05	CHEMBL4599	Homo sapiens	Inhibition	%	2.05
	8109626	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.56	CHEMBL4599	Homo sapiens	Inhibition	%	0.56
	8109797	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	-0.17	CHEMBL4599	Homo sapiens	Inhibition	%	-0.17
	8110153	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	1.44	CHEMBL4599	Homo sapiens	Inhibition	%	1.44
	8110432	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	5.63	CHEMBL4599	Homo sapiens	Inhibition	%	5.63
	8110598	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	0.85	CHEMBL4599	Homo sapiens	Inhibition	%	0.85
	8110822	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.33	CHEMBL4599	Homo sapiens	Inhibition	%	1.33
	8110980	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-0.12	CHEMBL4599	Homo sapiens	Inhibition	%	-0.12
	8111103	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	1.62	CHEMBL4599	Homo sapiens	Inhibition	%	1.62
	8111327	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	-0.42	CHEMBL4599	Homo sapiens	Inhibition	%	-0.42
	8111454	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	2.63	CHEMBL4599	Homo sapiens	Inhibition	%	2.63
	8111844	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	1.45	CHEMBL4599	Homo sapiens	Inhibition	%	1.45
	8112049	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	1.1	CHEMBL4599	Homo sapiens	Inhibition	%	1.1
	8112410	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	-0.22	CHEMBL4599	Homo sapiens	Inhibition	%	-0.22
	8112578	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	4.41	CHEMBL4599	Homo sapiens	Inhibition	%	4.41
	8112750	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	-0.32	CHEMBL4599	Homo sapiens	Inhibition	%	-0.32
	8112974	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.06	CHEMBL4599	Homo sapiens	Inhibition	%	0.06
	8113126	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	19.81	CHEMBL4599	Homo sapiens	Inhibition	%	19.81
	8113486	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	-0.95	CHEMBL4599	Homo sapiens	Inhibition	%	-0.95
	8113610	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	0.55	CHEMBL4599	Homo sapiens	Inhibition	%	0.55
	8113950	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	0.03	CHEMBL4599	Homo sapiens	Inhibition	%	0.03
	8114126	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	1.13	CHEMBL4599	Homo sapiens	Inhibition	%	1.13
	8114350	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.49	CHEMBL4599	Homo sapiens	Inhibition	%	0.49
	8114482	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.07	CHEMBL4599	Homo sapiens	Inhibition	%	3.07
	8114758	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	2.3	CHEMBL4599	Homo sapiens	Inhibition	%	2.3
	8115148	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	1.25	CHEMBL4599	Homo sapiens	Inhibition	%	1.25
	8115313	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	0.81	CHEMBL4599	Homo sapiens	Inhibition	%	0.81
	8115657	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.35	CHEMBL4599	Homo sapiens	Inhibition	%	1.35
	8115790	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	-0.73	CHEMBL4599	Homo sapiens	Inhibition	%	-0.73
	8116014	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	-0.46	CHEMBL4599	Homo sapiens	Inhibition	%	-0.46
	8116173	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	-0.56	CHEMBL4599	Homo sapiens	Inhibition	%	-0.56
	8116376	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.4	CHEMBL4599	Homo sapiens	Inhibition	%	3.4
	8116734	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	0.84	CHEMBL4599	Homo sapiens	Inhibition	%	0.84
	8116906	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	5.03	CHEMBL4599	Homo sapiens	Inhibition	%	5.03
	8117301	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	Inhibition	%	0.6
	8117459	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	0.83	CHEMBL4599	Homo sapiens	Inhibition	%	0.83
	8117813	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-0.1	CHEMBL4599	Homo sapiens	Inhibition	%	-0.1
	8117951	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	1.36	CHEMBL4599	Homo sapiens	Inhibition	%	1.36
	8118175	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-0.47	CHEMBL4599	Homo sapiens	Inhibition	%	-0.47
	8118291	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.73	CHEMBL4599	Homo sapiens	Inhibition	%	-0.73
	8118687	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	0.96	CHEMBL4599	Homo sapiens	Inhibition	%	0.96
	8118823	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.13	CHEMBL4599	Homo sapiens	Inhibition	%	1.13
	8119094	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	4.5	CHEMBL4599	Homo sapiens	Inhibition	%	4.5
	8119477	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	2.06	CHEMBL4599	Homo sapiens	Inhibition	%	2.06
	8119644	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	-0.48	CHEMBL4599	Homo sapiens	Inhibition	%	-0.48
	8119987	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	0.19	CHEMBL4599	Homo sapiens	Inhibition	%	0.19
	8120350	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	-0.07	CHEMBL4599	Homo sapiens	Inhibition	%	-0.07
	8120510	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	0.03	CHEMBL4599	Homo sapiens	Inhibition	%	0.03
	8120711	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	0.61	CHEMBL4599	Homo sapiens	Inhibition	%	0.61
	8120935	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	1.17	CHEMBL4599	Homo sapiens	Inhibition	%	1.17
	8121063	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.13	CHEMBL4599	Homo sapiens	Inhibition	%	0.13
	8121235	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	36.6	CHEMBL4599	Homo sapiens	Inhibition	%	36.6
	8121459	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.74	CHEMBL4599	Homo sapiens	Inhibition	%	0.74
	8121626	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	0.97	CHEMBL4599	Homo sapiens	Inhibition	%	0.97
	8121789	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	1.43	CHEMBL4599	Homo sapiens	Inhibition	%	1.43
	8122013	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	0.68	CHEMBL4599	Homo sapiens	Inhibition	%	0.68
	8122134	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	0.61	CHEMBL4599	Homo sapiens	Inhibition	%	0.61
	8122496	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	-0.07	CHEMBL4599	Homo sapiens	Inhibition	%	-0.07
	8122616	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.22	CHEMBL4599	Homo sapiens	Inhibition	%	1.22
	8122840	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.03	CHEMBL4599	Homo sapiens	Inhibition	%	3.03
	8123007	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	1.1	CHEMBL4599	Homo sapiens	Inhibition	%	1.1
	8123149	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	1.93	CHEMBL4599	Homo sapiens	Inhibition	%	1.93
	8123373	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	0.63	CHEMBL4599	Homo sapiens	Inhibition	%	0.63
	8123427	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	1.18	CHEMBL4599	Homo sapiens	Inhibition	%	1.18
	8123651	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	13.96	CHEMBL4599	Homo sapiens	Inhibition	%	13.96
	8123801	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	1.06	CHEMBL4599	Homo sapiens	Inhibition	%	1.06
	8123968	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	2.35	CHEMBL4599	Homo sapiens	Inhibition	%	2.35
	8124192	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.06	CHEMBL4599	Homo sapiens	Inhibition	%	0.06
	8124311	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	2.87	CHEMBL4599	Homo sapiens	Inhibition	%	2.87
	8124674	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	Inhibition	%	0.6
	8124839	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-0.92	CHEMBL4599	Homo sapiens	Inhibition	%	-0.92
	8125264	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	1.41	CHEMBL4599	Homo sapiens	Inhibition	%	1.41
	8125394	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	4.69	CHEMBL4599	Homo sapiens	Inhibition	%	4.69
	8125786	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	0.96	CHEMBL4599	Homo sapiens	Inhibition	%	0.96
	8125950	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	1.34	CHEMBL4599	Homo sapiens	Inhibition	%	1.34
	8126338	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	1.87	CHEMBL4599	Homo sapiens	Inhibition	%	1.87
	8126453	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-0.32	CHEMBL4599	Homo sapiens	Inhibition	%	-0.32
	8126677	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-0.97	CHEMBL4599	Homo sapiens	Inhibition	%	-0.97
	8126813	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	0.75	CHEMBL4599	Homo sapiens	Inhibition	%	0.75
	8127159	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	0.73	CHEMBL4599	Homo sapiens	Inhibition	%	0.73
	8127326	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	2.89	CHEMBL4599	Homo sapiens	Inhibition	%	2.89
	8127692	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	6.53	CHEMBL4599	Homo sapiens	Inhibition	%	6.53
	8127980	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.46	CHEMBL4599	Homo sapiens	Inhibition	%	0.46
	8128132	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	5.3	CHEMBL4599	Homo sapiens	Inhibition	%	5.3
	8128523	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	3.07	CHEMBL4599	Homo sapiens	Inhibition	%	3.07
	8128642	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	1.79	CHEMBL4599	Homo sapiens	Inhibition	%	1.79
	8128866	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	21.7	CHEMBL4599	Homo sapiens	Inhibition	%	21.7
	8129003	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-0.27	CHEMBL4599	Homo sapiens	Inhibition	%	-0.27
	8129174	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-1.03	CHEMBL4599	Homo sapiens	Inhibition	%	-1.03
	8129398	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-1.03	CHEMBL4599	Homo sapiens	Inhibition	%	-1.03
	8129587	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	2.2	CHEMBL4599	Homo sapiens	Inhibition	%	2.2
	8129726	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	0.32	CHEMBL4599	Homo sapiens	Inhibition	%	0.32
	8129950	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	1.68	CHEMBL4599	Homo sapiens	Inhibition	%	1.68
	8130111	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	0.71	CHEMBL4599	Homo sapiens	Inhibition	%	0.71
	8130283	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.13	CHEMBL4599	Homo sapiens	Inhibition	%	-0.13
	8130507	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	0.07	CHEMBL4599	Homo sapiens	Inhibition	%	0.07
	8130667	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	-0.16	CHEMBL4599	Homo sapiens	Inhibition	%	-0.16
	8131007	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.09	CHEMBL4599	Homo sapiens	Inhibition	%	1.09
	8131146	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	1.83	CHEMBL4599	Homo sapiens	Inhibition	%	1.83
	8131490	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	1.8	CHEMBL4599	Homo sapiens	Inhibition	%	1.8
	8131657	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	2.97	CHEMBL4599	Homo sapiens	Inhibition	%	2.97
	8131881	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	13.23	CHEMBL4599	Homo sapiens	Inhibition	%	13.23
	8132022	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	0.8	CHEMBL4599	Homo sapiens	Inhibition	%	0.8
	8132308	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	1.9	CHEMBL4599	Homo sapiens	Inhibition	%	1.9
	8132455	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	1.45	CHEMBL4599	Homo sapiens	Inhibition	%	1.45
	8132679	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	2.24	CHEMBL4599	Homo sapiens	Inhibition	%	2.24
	8132847	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.2	CHEMBL4599	Homo sapiens	Inhibition	%	0.2
	8133192	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	0.35	CHEMBL4599	Homo sapiens	Inhibition	%	0.35
	8133330	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-0.08	CHEMBL4599	Homo sapiens	Inhibition	%	-0.08
	8133726	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.17	CHEMBL4599	Homo sapiens	Inhibition	%	0.17
	8133906	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	8.52	CHEMBL4599	Homo sapiens	Inhibition	%	8.52
	8134278	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	-0.17	CHEMBL4599	Homo sapiens	Inhibition	%	-0.17
	8134438	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	-0.17	CHEMBL4599	Homo sapiens	Inhibition	%	-0.17
	8134846	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	-0.49	CHEMBL4599	Homo sapiens	Inhibition	%	-0.49
	8135006	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	3.2	CHEMBL4599	Homo sapiens	Inhibition	%	3.2
	8135345	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.75	CHEMBL4599	Homo sapiens	Inhibition	%	1.75
	8135486	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	0.69	CHEMBL4599	Homo sapiens	Inhibition	%	0.69
	8135710	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	1.57	CHEMBL4599	Homo sapiens	Inhibition	%	1.57
	8135831	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	-0.14	CHEMBL4599	Homo sapiens	Inhibition	%	-0.14
	8136223	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	1.06	CHEMBL4599	Homo sapiens	Inhibition	%	1.06
	8136367	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	1.54	CHEMBL4599	Homo sapiens	Inhibition	%	1.54
	8136657	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.62	CHEMBL4599	Homo sapiens	Inhibition	%	0.62
	8137016	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	0.3	CHEMBL4599	Homo sapiens	Inhibition	%	0.3
	8137179	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	5.7	CHEMBL4599	Homo sapiens	Inhibition	%	5.7
	8137523	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	3.23	CHEMBL4599	Homo sapiens	Inhibition	%	3.23
	8137671	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	0.46	CHEMBL4599	Homo sapiens	Inhibition	%	0.46
	8137895	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	1.64	CHEMBL4599	Homo sapiens	Inhibition	%	1.64
	8138061	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	-0.05	CHEMBL4599	Homo sapiens	Inhibition	%	-0.05
	8138240	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	61.03	CHEMBL4599	Homo sapiens	Inhibition	%	61.03
	8138612	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	1.96	CHEMBL4599	Homo sapiens	Inhibition	%	1.96
	8138770	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.62	CHEMBL4599	Homo sapiens	Inhibition	%	0.62
	8138994	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	0.64	CHEMBL4599	Homo sapiens	Inhibition	%	0.64
	8139179	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	1.32	CHEMBL4599	Homo sapiens	Inhibition	%	1.32
	8139338	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	0.32	CHEMBL4599	Homo sapiens	Inhibition	%	0.32
	8139562	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	2.33	CHEMBL4599	Homo sapiens	Inhibition	%	2.33
	8139676	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	0.97	CHEMBL4599	Homo sapiens	Inhibition	%	0.97
	8140041	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	1.61	CHEMBL4599	Homo sapiens	Inhibition	%	1.61
	8140164	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	0.27	CHEMBL4599	Homo sapiens	Inhibition	%	0.27
	8140388	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	0.73	CHEMBL4599	Homo sapiens	Inhibition	%	0.73
	8140547	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.32	CHEMBL4599	Homo sapiens	Inhibition	%	3.32
	8140690	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	1.16	CHEMBL4599	Homo sapiens	Inhibition	%	1.16
	8140914	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	1.77	CHEMBL4599	Homo sapiens	Inhibition	%	1.77
	8140992	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.64	CHEMBL4599	Homo sapiens	Inhibition	%	0.64
	8141346	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	1.41	CHEMBL4599	Homo sapiens	Inhibition	%	1.41
	8141506	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	0.38	CHEMBL4599	Homo sapiens	Inhibition	%	0.38
	8141730	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	3.51	CHEMBL4599	Homo sapiens	Inhibition	%	3.51
	8141849	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	0.76	CHEMBL4599	Homo sapiens	Inhibition	%	0.76
	8142234	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	-0.12	CHEMBL4599	Homo sapiens	Inhibition	%	-0.12
	8142402	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	3.0	CHEMBL4599	Homo sapiens	Inhibition	%	3.0
	8142578	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	0.72	CHEMBL4599	Homo sapiens	Inhibition	%	0.72
	8142802	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	3.3	CHEMBL4599	Homo sapiens	Inhibition	%	3.3
	8142951	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	-0.81	CHEMBL4599	Homo sapiens	Inhibition	%	-0.81
	8143330	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.62	CHEMBL4599	Homo sapiens	Inhibition	%	1.62
	8143517	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	0.67	CHEMBL4599	Homo sapiens	Inhibition	%	0.67
	8143900	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	0.98	CHEMBL4599	Homo sapiens	Inhibition	%	0.98
	8144014	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	1.65	CHEMBL4599	Homo sapiens	Inhibition	%	1.65
	8144377	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	1.32	CHEMBL4599	Homo sapiens	Inhibition	%	1.32
	8144731	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	0.31	CHEMBL4599	Homo sapiens	Inhibition	%	0.31
	8144884	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	0.47	CHEMBL4599	Homo sapiens	Inhibition	%	0.47
	8145245	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	2.38	CHEMBL4599	Homo sapiens	Inhibition	%	2.38
	8145334	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.63	CHEMBL4599	Homo sapiens	Inhibition	%	0.63
	8145558	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	1.93	CHEMBL4599	Homo sapiens	Inhibition	%	1.93
	8145682	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.07	CHEMBL4599	Homo sapiens	Inhibition	%	-0.07
	8146067	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	1.13	CHEMBL4599	Homo sapiens	Inhibition	%	1.13
	8146187	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	9.44	CHEMBL4599	Homo sapiens	Inhibition	%	9.44
	8146411	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	0.06	CHEMBL4599	Homo sapiens	Inhibition	%	0.06
	8146571	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	3.47	CHEMBL4599	Homo sapiens	Inhibition	%	3.47
	8146738	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	5.42	CHEMBL4599	Homo sapiens	Inhibition	%	5.42
	8147131	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.24	CHEMBL4599	Homo sapiens	Inhibition	%	0.24
	8147273	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.35	CHEMBL4599	Homo sapiens	Inhibition	%	0.35
	8147497	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	0.76	CHEMBL4599	Homo sapiens	Inhibition	%	0.76
	8147650	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	1.81	CHEMBL4599	Homo sapiens	Inhibition	%	1.81
	8147837	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	3.22	CHEMBL4599	Homo sapiens	Inhibition	%	3.22
	8148219	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	2.35	CHEMBL4599	Homo sapiens	Inhibition	%	2.35
	8148333	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	-0.17	CHEMBL4599	Homo sapiens	Inhibition	%	-0.17
	8148557	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	1.61	CHEMBL4599	Homo sapiens	Inhibition	%	1.61
	8148696	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.3	CHEMBL4599	Homo sapiens	Inhibition	%	1.3
	8149058	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	0.55	CHEMBL4599	Homo sapiens	Inhibition	%	0.55
	8149217	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	1.54	CHEMBL4599	Homo sapiens	Inhibition	%	1.54
	8149575	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	1.4	CHEMBL4599	Homo sapiens	Inhibition	%	1.4
	8149897	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.99	CHEMBL4599	Homo sapiens	Inhibition	%	0.99
	8150022	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.93	CHEMBL4599	Homo sapiens	Inhibition	%	0.93
	8150246	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.17	CHEMBL4599	Homo sapiens	Inhibition	%	0.17
	8150406	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	4.21	CHEMBL4599	Homo sapiens	Inhibition	%	4.21
	8150750	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	1.64	CHEMBL4599	Homo sapiens	Inhibition	%	1.64
	8150915	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	0.24	CHEMBL4599	Homo sapiens	Inhibition	%	0.24
	8151078	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	46.15	CHEMBL4599	Homo sapiens	Inhibition	%	46.15
	8151302	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-0.76	CHEMBL4599	Homo sapiens	Inhibition	%	-0.76
	8151479	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	1.56	CHEMBL4599	Homo sapiens	Inhibition	%	1.56
	8151841	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	1.15	CHEMBL4599	Homo sapiens	Inhibition	%	1.15
	8151995	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	0.73	CHEMBL4599	Homo sapiens	Inhibition	%	0.73
	8152183	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	0.88	CHEMBL4599	Homo sapiens	Inhibition	%	0.88
	8152407	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	8.96	CHEMBL4599	Homo sapiens	Inhibition	%	8.96
	8152565	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	1.38	CHEMBL4599	Homo sapiens	Inhibition	%	1.38
	8152903	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	2.32	CHEMBL4599	Homo sapiens	Inhibition	%	2.32
	8153042	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	1.57	CHEMBL4599	Homo sapiens	Inhibition	%	1.57
	8153266	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	1.15	CHEMBL4599	Homo sapiens	Inhibition	%	1.15
	8153403	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	1.67	CHEMBL4599	Homo sapiens	Inhibition	%	1.67
	8153560	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	-0.59	CHEMBL4599	Homo sapiens	Inhibition	%	-0.59
	8153784	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	0.01	CHEMBL4599	Homo sapiens	Inhibition	%	0.01
	8153917	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	2.67	CHEMBL4599	Homo sapiens	Inhibition	%	2.67
	8154238	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	6.77	CHEMBL4599	Homo sapiens	Inhibition	%	6.77
	8154588	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.5	CHEMBL4599	Homo sapiens	Inhibition	%	0.5
	8154747	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	-0.6	CHEMBL4599	Homo sapiens	Inhibition	%	-0.6
	8155091	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	-0.05	CHEMBL4599	Homo sapiens	Inhibition	%	-0.05
	8155267	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	13.19	CHEMBL4599	Homo sapiens	Inhibition	%	13.19
	8155652	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	2.48	CHEMBL4599	Homo sapiens	Inhibition	%	2.48
	8155830	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	1.22	CHEMBL4599	Homo sapiens	Inhibition	%	1.22
	8156192	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	0.55	CHEMBL4599	Homo sapiens	Inhibition	%	0.55
	8156404	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	3.21	CHEMBL4599	Homo sapiens	Inhibition	%	3.21
	8156778	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	6.5	CHEMBL4599	Homo sapiens	Inhibition	%	6.5
	8156921	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	1.26	CHEMBL4599	Homo sapiens	Inhibition	%	1.26
	8157265	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	3.49	CHEMBL4599	Homo sapiens	Inhibition	%	3.49
	8157406	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	9.81	CHEMBL4599	Homo sapiens	Inhibition	%	9.81
	8157630	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	0.75	CHEMBL4599	Homo sapiens	Inhibition	%	0.75
	8157760	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	4.59	CHEMBL4599	Homo sapiens	Inhibition	%	4.59
	8158145	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	3.64	CHEMBL4599	Homo sapiens	Inhibition	%	3.64
	8158395	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.77	CHEMBL4599	Homo sapiens	Inhibition	%	3.77
	8158553	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	1.07	CHEMBL4599	Homo sapiens	Inhibition	%	1.07
	8158946	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-0.01	CHEMBL4599	Homo sapiens	Inhibition	%	-0.01
	8159081	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	2.46	CHEMBL4599	Homo sapiens	Inhibition	%	2.46
	8159305	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.09	CHEMBL4599	Homo sapiens	Inhibition	%	2.09
	8159425	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	2.37	CHEMBL4599	Homo sapiens	Inhibition	%	2.37
	8159780	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	2.01	CHEMBL4599	Homo sapiens	Inhibition	%	2.01
	8159921	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.05	CHEMBL4599	Homo sapiens	Inhibition	%	0.05
	8160282	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	1.58	CHEMBL4599	Homo sapiens	Inhibition	%	1.58
	8160432	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	1.2	CHEMBL4599	Homo sapiens	Inhibition	%	1.2
	8160656	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-0.32	CHEMBL4599	Homo sapiens	Inhibition	%	-0.32
	8160726	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	1.58	CHEMBL4599	Homo sapiens	Inhibition	%	1.58
	8161100	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	1.35	CHEMBL4599	Homo sapiens	Inhibition	%	1.35
	8161243	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	3.09	CHEMBL4599	Homo sapiens	Inhibition	%	3.09
	8161467	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	3.29	CHEMBL4599	Homo sapiens	Inhibition	%	3.29
	8161592	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	27.35	CHEMBL4599	Homo sapiens	Inhibition	%	27.35
	8161954	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	3.69	CHEMBL4599	Homo sapiens	Inhibition	%	3.69
	8162084	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	1.03	CHEMBL4599	Homo sapiens	Inhibition	%	1.03
	8162308	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	3.97	CHEMBL4599	Homo sapiens	Inhibition	%	3.97
	8162468	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	2.56	CHEMBL4599	Homo sapiens	Inhibition	%	2.56
	8162721	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	1.08	CHEMBL4599	Homo sapiens	Inhibition	%	1.08
	8162869	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	1.27	CHEMBL4599	Homo sapiens	Inhibition	%	1.27
	8163093	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	1.41	CHEMBL4599	Homo sapiens	Inhibition	%	1.41
	8163262	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	-0.8	CHEMBL4599	Homo sapiens	Inhibition	%	-0.8
	8163620	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	2.88	CHEMBL4599	Homo sapiens	Inhibition	%	2.88
	8163743	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	0.57	CHEMBL4599	Homo sapiens	Inhibition	%	0.57
	8163967	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	1.01	CHEMBL4599	Homo sapiens	Inhibition	%	1.01
	8164101	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	5.79	CHEMBL4599	Homo sapiens	Inhibition	%	5.79
	8164241	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.93	CHEMBL4599	Homo sapiens	Inhibition	%	0.93
	8164465	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	-0.24	CHEMBL4599	Homo sapiens	Inhibition	%	-0.24
	8164620	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	3.21	CHEMBL4599	Homo sapiens	Inhibition	%	3.21
	8164988	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	0.4	CHEMBL4599	Homo sapiens	Inhibition	%	0.4
	8165058	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	4.37	CHEMBL4599	Homo sapiens	Inhibition	%	4.37
	8165282	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	2.4	CHEMBL4599	Homo sapiens	Inhibition	%	2.4
	8165423	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	8.46	CHEMBL4599	Homo sapiens	Inhibition	%	8.46
	8165790	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	21.67	CHEMBL4599	Homo sapiens	Inhibition	%	21.67
	8165916	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	1.29	CHEMBL4599	Homo sapiens	Inhibition	%	1.29
	8166140	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	3.26	CHEMBL4599	Homo sapiens	Inhibition	%	3.26
	8166278	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	0.5	CHEMBL4599	Homo sapiens	Inhibition	%	0.5
	8166632	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	1.47	CHEMBL4599	Homo sapiens	Inhibition	%	1.47
	8166733	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	10.05	CHEMBL4599	Homo sapiens	Inhibition	%	10.05
	8166957	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	52.89	CHEMBL4599	Homo sapiens	Inhibition	%	52.89
	8167045	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	1.01	CHEMBL4599	Homo sapiens	Inhibition	%	1.01
	8167410	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	9.93	CHEMBL4599	Homo sapiens	Inhibition	%	9.93
	8167574	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.12	CHEMBL4599	Homo sapiens	Inhibition	%	0.12
	8167931	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	1.53	CHEMBL4599	Homo sapiens	Inhibition	%	1.53
	8168279	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.84	CHEMBL4599	Homo sapiens	Inhibition	%	0.84
	8168420	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	41.13	CHEMBL4599	Homo sapiens	Inhibition	%	41.13
	8168780	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	0.43	CHEMBL4599	Homo sapiens	Inhibition	%	0.43
	8168944	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	2.35	CHEMBL4599	Homo sapiens	Inhibition	%	2.35
	8169310	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	1.26	CHEMBL4599	Homo sapiens	Inhibition	%	1.26
	8169614	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	10.79	CHEMBL4599	Homo sapiens	Inhibition	%	10.79
	8169748	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	1.56	CHEMBL4599	Homo sapiens	Inhibition	%	1.56
	8169972	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	2.62	CHEMBL4599	Homo sapiens	Inhibition	%	2.62
	8170117	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	1.04	CHEMBL4599	Homo sapiens	Inhibition	%	1.04
	8170466	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.06	CHEMBL4599	Homo sapiens	Inhibition	%	1.06
	8170606	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	2.57	CHEMBL4599	Homo sapiens	Inhibition	%	2.57
	8170965	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	2.85	CHEMBL4599	Homo sapiens	Inhibition	%	2.85
	8171162	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	5.75	CHEMBL4599	Homo sapiens	Inhibition	%	5.75
	8171379	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	-0.31	CHEMBL4599	Homo sapiens	Inhibition	%	-0.31
	8171603	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	-0.19	CHEMBL4599	Homo sapiens	Inhibition	%	-0.19
	8171744	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	6.79	CHEMBL4599	Homo sapiens	Inhibition	%	6.79
	8171897	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	0.56	CHEMBL4599	Homo sapiens	Inhibition	%	0.56
	8172121	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	0.24	CHEMBL4599	Homo sapiens	Inhibition	%	0.24
	8172253	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	3.08	CHEMBL4599	Homo sapiens	Inhibition	%	3.08
	8172605	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	3.68	CHEMBL4599	Homo sapiens	Inhibition	%	3.68
	8172747	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	0.88	CHEMBL4599	Homo sapiens	Inhibition	%	0.88
	8172971	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	5.0	CHEMBL4599	Homo sapiens	Inhibition	%	5.0
	8173107	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.31	CHEMBL4599	Homo sapiens	Inhibition	%	-0.31
	8173272	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	11.74	CHEMBL4599	Homo sapiens	Inhibition	%	11.74
	8173496	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	2.06	CHEMBL4599	Homo sapiens	Inhibition	%	2.06
	8173637	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	3.12	CHEMBL4599	Homo sapiens	Inhibition	%	3.12
	8173948	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	1.35	CHEMBL4599	Homo sapiens	Inhibition	%	1.35
	8174304	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	1.2	CHEMBL4599	Homo sapiens	Inhibition	%	1.2
	8174452	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	1.13	CHEMBL4599	Homo sapiens	Inhibition	%	1.13
	8174798	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	1.59	CHEMBL4599	Homo sapiens	Inhibition	%	1.59
	8174941	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	0.81	CHEMBL4599	Homo sapiens	Inhibition	%	0.81
	8175165	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	1.2	CHEMBL4599	Homo sapiens	Inhibition	%	1.2
	8175301	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	0.39	CHEMBL4599	Homo sapiens	Inhibition	%	0.39
	8175557	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	0.63	CHEMBL4599	Homo sapiens	Inhibition	%	0.63
	8175944	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	0.86	CHEMBL4599	Homo sapiens	Inhibition	%	0.86
	8176097	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	43.45	CHEMBL4599	Homo sapiens	Inhibition	%	43.45
	8176470	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	0.25	CHEMBL4599	Homo sapiens	Inhibition	%	0.25
	8176602	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	1.41	CHEMBL4599	Homo sapiens	Inhibition	%	1.41
	8176826	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	4.86	CHEMBL4599	Homo sapiens	Inhibition	%	4.86
	8176956	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	-0.42	CHEMBL4599	Homo sapiens	Inhibition	%	-0.42
	8177322	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	1.68	CHEMBL4599	Homo sapiens	Inhibition	%	1.68
	8177460	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.27	CHEMBL4599	Homo sapiens	Inhibition	%	0.27
	8177848	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	9.3	CHEMBL4599	Homo sapiens	Inhibition	%	9.3
	8177988	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	1.09	CHEMBL4599	Homo sapiens	Inhibition	%	1.09
	8178212	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	3.05	CHEMBL4599	Homo sapiens	Inhibition	%	3.05
	8178300	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	2.72	CHEMBL4599	Homo sapiens	Inhibition	%	2.72
	8178651	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	5.39	CHEMBL4599	Homo sapiens	Inhibition	%	5.39
	8178800	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.86	CHEMBL4599	Homo sapiens	Inhibition	%	0.86
	8179024	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	1.39	CHEMBL4599	Homo sapiens	Inhibition	%	1.39
	8179147	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.33	CHEMBL4599	Homo sapiens	Inhibition	%	1.33
	8179515	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	0.57	CHEMBL4599	Homo sapiens	Inhibition	%	0.57
	8179652	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	2.14	CHEMBL4599	Homo sapiens	Inhibition	%	2.14
	8179909	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	2.83	CHEMBL4599	Homo sapiens	Inhibition	%	2.83
	8180287	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	10.17	CHEMBL4599	Homo sapiens	Inhibition	%	10.17
	8180443	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	1.93	CHEMBL4599	Homo sapiens	Inhibition	%	1.93
	8180667	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	5.77	CHEMBL4599	Homo sapiens	Inhibition	%	5.77
	8180815	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	0.14	CHEMBL4599	Homo sapiens	Inhibition	%	0.14
	8181172	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	9.97	CHEMBL4599	Homo sapiens	Inhibition	%	9.97
	8181303	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	0.83	CHEMBL4599	Homo sapiens	Inhibition	%	0.83
	8181667	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	22.01	CHEMBL4599	Homo sapiens	Inhibition	%	22.01
	8181806	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	5.57	CHEMBL4599	Homo sapiens	Inhibition	%	5.57
	8182030	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	15.99	CHEMBL4599	Homo sapiens	Inhibition	%	15.99
	8182193	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	1.85	CHEMBL4599	Homo sapiens	Inhibition	%	1.85
	8182557	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.2	CHEMBL4599	Homo sapiens	Inhibition	%	1.2
	8182649	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.42	CHEMBL4599	Homo sapiens	Inhibition	%	1.42
	8182873	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	1.79	CHEMBL4599	Homo sapiens	Inhibition	%	1.79
	8182995	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	1.52	CHEMBL4599	Homo sapiens	Inhibition	%	1.52
	8183368	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	2.52	CHEMBL4599	Homo sapiens	Inhibition	%	2.52
	8183497	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	1.05	CHEMBL4599	Homo sapiens	Inhibition	%	1.05
	8183863	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	2.58	CHEMBL4599	Homo sapiens	Inhibition	%	2.58
	8183999	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	0.32	CHEMBL4599	Homo sapiens	Inhibition	%	0.32
	8184223	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	1.4	CHEMBL4599	Homo sapiens	Inhibition	%	1.4
	8184265	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.4	CHEMBL4599	Homo sapiens	Inhibition	%	1.4
	8184489	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	1.85	CHEMBL4599	Homo sapiens	Inhibition	%	1.85
	8184636	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.28	CHEMBL4599	Homo sapiens	Inhibition	%	0.28
	8185017	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	1.35	CHEMBL4599	Homo sapiens	Inhibition	%	1.35
	8185166	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	1.79	CHEMBL4599	Homo sapiens	Inhibition	%	1.79
	8185521	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	54.8	CHEMBL4599	Homo sapiens	Inhibition	%	54.8
	8185652	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-1.14	CHEMBL4599	Homo sapiens	Inhibition	%	-1.14
	8185876	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	0.65	CHEMBL4599	Homo sapiens	Inhibition	%	0.65
	8186015	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	0.74	CHEMBL4599	Homo sapiens	Inhibition	%	0.74
	8186380	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	1.57	CHEMBL4599	Homo sapiens	Inhibition	%	1.57
	8186544	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	3.57	CHEMBL4599	Homo sapiens	Inhibition	%	3.57
	8186907	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	0.83	CHEMBL4599	Homo sapiens	Inhibition	%	0.83
	8187229	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.58	CHEMBL4599	Homo sapiens	Inhibition	%	1.58
	8187353	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	3.5	CHEMBL4599	Homo sapiens	Inhibition	%	3.5
	8187725	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	15.3	CHEMBL4599	Homo sapiens	Inhibition	%	15.3
	8187854	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	6.74	CHEMBL4599	Homo sapiens	Inhibition	%	6.74
	8188078	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	8.14	CHEMBL4599	Homo sapiens	Inhibition	%	8.14
	8188221	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	0.4	CHEMBL4599	Homo sapiens	Inhibition	%	0.4
	8188580	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.34	CHEMBL4599	Homo sapiens	Inhibition	%	1.34
	8188854	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	2.06	CHEMBL4599	Homo sapiens	Inhibition	%	2.06
	8189002	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	0.88	CHEMBL4599	Homo sapiens	Inhibition	%	0.88
	8189382	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	13.04	CHEMBL4599	Homo sapiens	Inhibition	%	13.04
	8189531	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.45	CHEMBL4599	Homo sapiens	Inhibition	%	-0.45
	8189755	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.03	CHEMBL4599	Homo sapiens	Inhibition	%	-0.03
	8189887	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	2.03	CHEMBL4599	Homo sapiens	Inhibition	%	2.03
	8190243	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	1.04	CHEMBL4599	Homo sapiens	Inhibition	%	1.04
	8190383	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	3.97	CHEMBL4599	Homo sapiens	Inhibition	%	3.97
	8190744	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	4.87	CHEMBL4599	Homo sapiens	Inhibition	%	4.87
	8190908	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	1.51	CHEMBL4599	Homo sapiens	Inhibition	%	1.51
	8191132	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	2.14	CHEMBL4599	Homo sapiens	Inhibition	%	2.14
	8191270	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	1.49	CHEMBL4599	Homo sapiens	Inhibition	%	1.49
	8191590	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	6.06	CHEMBL4599	Homo sapiens	Inhibition	%	6.06
	8191712	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	1.32	CHEMBL4599	Homo sapiens	Inhibition	%	1.32
	8191936	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	3.83	CHEMBL4599	Homo sapiens	Inhibition	%	3.83
	8192085	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	1.3	CHEMBL4599	Homo sapiens	Inhibition	%	1.3
	8192438	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	3.84	CHEMBL4599	Homo sapiens	Inhibition	%	3.84
	8192582	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	3.7	CHEMBL4599	Homo sapiens	Inhibition	%	3.7
	8192806	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	1.54	CHEMBL4599	Homo sapiens	Inhibition	%	1.54
	8192942	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	1.96	CHEMBL4599	Homo sapiens	Inhibition	%	1.96
	8193214	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.5	CHEMBL4599	Homo sapiens	Inhibition	%	3.5
	8193359	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	0.51	CHEMBL4599	Homo sapiens	Inhibition	%	0.51
	8193583	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	5.5	CHEMBL4599	Homo sapiens	Inhibition	%	5.5
	8193740	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	0.36	CHEMBL4599	Homo sapiens	Inhibition	%	0.36
	8194113	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.78	CHEMBL4599	Homo sapiens	Inhibition	%	-0.78
	8194244	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	7.01	CHEMBL4599	Homo sapiens	Inhibition	%	7.01
	8194599	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	0.66	CHEMBL4599	Homo sapiens	Inhibition	%	0.66
	8194742	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	1.25	CHEMBL4599	Homo sapiens	Inhibition	%	1.25
	8194966	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	7.25	CHEMBL4599	Homo sapiens	Inhibition	%	7.25
	8195099	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	1.7	CHEMBL4599	Homo sapiens	Inhibition	%	1.7
	8195487	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	1.92	CHEMBL4599	Homo sapiens	Inhibition	%	1.92
	8195626	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	4.15	CHEMBL4599	Homo sapiens	Inhibition	%	4.15
	8195948	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.17	CHEMBL4599	Homo sapiens	Inhibition	%	1.17
	8196289	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	1.45	CHEMBL4599	Homo sapiens	Inhibition	%	1.45
	8196439	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	2.37	CHEMBL4599	Homo sapiens	Inhibition	%	2.37
	8196791	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	6.0	CHEMBL4599	Homo sapiens	Inhibition	%	6.0
	8197156	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	8.09	CHEMBL4599	Homo sapiens	Inhibition	%	8.09
	8197293	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	0.16	CHEMBL4599	Homo sapiens	Inhibition	%	0.16
	8197568	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	0.31	CHEMBL4599	Homo sapiens	Inhibition	%	0.31
	8197932	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	0.35	CHEMBL4599	Homo sapiens	Inhibition	%	0.35
	8198089	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	1.26	CHEMBL4599	Homo sapiens	Inhibition	%	1.26
	8198451	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.6	CHEMBL4599	Homo sapiens	Inhibition	%	-0.6
	8198581	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	1.4	CHEMBL4599	Homo sapiens	Inhibition	%	1.4
	8198805	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	5.7	CHEMBL4599	Homo sapiens	Inhibition	%	5.7
	8198936	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	3.17	CHEMBL4599	Homo sapiens	Inhibition	%	3.17
	8199308	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	1.01	CHEMBL4599	Homo sapiens	Inhibition	%	1.01
	8199442	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	2.83	CHEMBL4599	Homo sapiens	Inhibition	%	2.83
	8199666	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	1.84	CHEMBL4599	Homo sapiens	Inhibition	%	1.84
	8199829	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	6.27	CHEMBL4599	Homo sapiens	Inhibition	%	6.27
	8199967	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	1.72	CHEMBL4599	Homo sapiens	Inhibition	%	1.72
	8200191	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.78	CHEMBL4599	Homo sapiens	Inhibition	%	2.78
	8200295	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	1.16	CHEMBL4599	Homo sapiens	Inhibition	%	1.16
	8200634	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	3.26	CHEMBL4599	Homo sapiens	Inhibition	%	3.26
	8200784	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.74	CHEMBL4599	Homo sapiens	Inhibition	%	1.74
	8201008	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	7.9	CHEMBL4599	Homo sapiens	Inhibition	%	7.9
	8201138	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	3.84	CHEMBL4599	Homo sapiens	Inhibition	%	3.84
	8201497	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	0.6	CHEMBL4599	Homo sapiens	Inhibition	%	0.6
	8201630	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	1.19	CHEMBL4599	Homo sapiens	Inhibition	%	1.19
	8201854	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	-0.21	CHEMBL4599	Homo sapiens	Inhibition	%	-0.21
	8201909	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	-0.36	CHEMBL4599	Homo sapiens	Inhibition	%	-0.36
	8202133	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	0.57	CHEMBL4599	Homo sapiens	Inhibition	%	0.57
	8202273	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	7.05	CHEMBL4599	Homo sapiens	Inhibition	%	7.05
	8202440	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	0.78	CHEMBL4599	Homo sapiens	Inhibition	%	0.78
	8202664	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	0.1	CHEMBL4599	Homo sapiens	Inhibition	%	0.1
	8202789	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	2.51	CHEMBL4599	Homo sapiens	Inhibition	%	2.51
	8203143	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	1.47	CHEMBL4599	Homo sapiens	Inhibition	%	1.47
	8203274	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.5	CHEMBL4599	Homo sapiens	Inhibition	%	1.5
	8203498	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	1.67	CHEMBL4599	Homo sapiens	Inhibition	%	1.67
	8203644	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	4.65	CHEMBL4599	Homo sapiens	Inhibition	%	4.65
	8204002	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	3.24	CHEMBL4599	Homo sapiens	Inhibition	%	3.24
	8204168	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	1.33	CHEMBL4599	Homo sapiens	Inhibition	%	1.33
	8204529	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	2.64	CHEMBL4599	Homo sapiens	Inhibition	%	2.64
	8204634	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	0.77	CHEMBL4599	Homo sapiens	Inhibition	%	0.77
	8204858	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	4.09	CHEMBL4599	Homo sapiens	Inhibition	%	4.09
	8204973	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	1.76	CHEMBL4599	Homo sapiens	Inhibition	%	1.76
	8205346	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.19	CHEMBL4599	Homo sapiens	Inhibition	%	1.19
	8205482	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	9.04	CHEMBL4599	Homo sapiens	Inhibition	%	9.04
	8205706	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	3.04	CHEMBL4599	Homo sapiens	Inhibition	%	3.04
	8205845	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	2.21	CHEMBL4599	Homo sapiens	Inhibition	%	2.21
	8206201	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	0.9	CHEMBL4599	Homo sapiens	Inhibition	%	0.9
	8206477	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	1.13	CHEMBL4599	Homo sapiens	Inhibition	%	1.13
	8206620	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-1.13	CHEMBL4599	Homo sapiens	Inhibition	%	-1.13
	8207024	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	0.54	CHEMBL4599	Homo sapiens	Inhibition	%	0.54
	8207150	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	1.26	CHEMBL4599	Homo sapiens	Inhibition	%	1.26
	8207374	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	3.52	CHEMBL4599	Homo sapiens	Inhibition	%	3.52
	8207504	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	3.13	CHEMBL4599	Homo sapiens	Inhibition	%	3.13
	8207860	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	4.21	CHEMBL4599	Homo sapiens	Inhibition	%	4.21
	8208005	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	0.23	CHEMBL4599	Homo sapiens	Inhibition	%	0.23
	8208361	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	1.58	CHEMBL4599	Homo sapiens	Inhibition	%	1.58
	8208527	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	4.9	CHEMBL4599	Homo sapiens	Inhibition	%	4.9
	8208751	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	2.91	CHEMBL4599	Homo sapiens	Inhibition	%	2.91
	8208884	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	18.01	CHEMBL4599	Homo sapiens	Inhibition	%	18.01
	8209213	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.02	CHEMBL4599	Homo sapiens	Inhibition	%	1.02
	8209329	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	8.52	CHEMBL4599	Homo sapiens	Inhibition	%	8.52
	8209553	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.33	CHEMBL4599	Homo sapiens	Inhibition	%	2.33
	8209703	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	0.94	CHEMBL4599	Homo sapiens	Inhibition	%	0.94
	8210063	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	7.54	CHEMBL4599	Homo sapiens	Inhibition	%	7.54
	8210204	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	0.82	CHEMBL4599	Homo sapiens	Inhibition	%	0.82
	8210564	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-0.98	CHEMBL4599	Homo sapiens	Inhibition	%	-0.98
	8210823	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	0.65	CHEMBL4599	Homo sapiens	Inhibition	%	0.65
	8210967	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	-0.19	CHEMBL4599	Homo sapiens	Inhibition	%	-0.19
	8211191	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.92	CHEMBL4599	Homo sapiens	Inhibition	%	0.92
	8211361	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	0.77	CHEMBL4599	Homo sapiens	Inhibition	%	0.77
	8211708	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	2.83	CHEMBL4599	Homo sapiens	Inhibition	%	2.83
	8211837	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	1.69	CHEMBL4599	Homo sapiens	Inhibition	%	1.69
	8212193	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	0.71	CHEMBL4599	Homo sapiens	Inhibition	%	0.71
	8212334	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	-0.49	CHEMBL4599	Homo sapiens	Inhibition	%	-0.49
	8212558	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	0.53	CHEMBL4599	Homo sapiens	Inhibition	%	0.53
	8212691	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	3.35	CHEMBL4599	Homo sapiens	Inhibition	%	3.35
	8213085	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	20.27	CHEMBL4599	Homo sapiens	Inhibition	%	20.27
	8213214	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.76	CHEMBL4599	Homo sapiens	Inhibition	%	1.76
	8213542	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	7.85	CHEMBL4599	Homo sapiens	Inhibition	%	7.85
	8213879	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.94	CHEMBL4599	Homo sapiens	Inhibition	%	2.94
	8214026	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.28	CHEMBL4599	Homo sapiens	Inhibition	%	1.28
	8214387	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	6.31	CHEMBL4599	Homo sapiens	Inhibition	%	6.31
	8214521	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	3.94	CHEMBL4599	Homo sapiens	Inhibition	%	3.94
	8214745	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	3.73	CHEMBL4599	Homo sapiens	Inhibition	%	3.73
	8214897	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	-0.2	CHEMBL4599	Homo sapiens	Inhibition	%	-0.2
	8215148	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	0.3	CHEMBL4599	Homo sapiens	Inhibition	%	0.3
	8215525	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	5.56	CHEMBL4599	Homo sapiens	Inhibition	%	5.56
	8215689	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.66	CHEMBL4599	Homo sapiens	Inhibition	%	0.66
	8216032	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	3.26	CHEMBL4599	Homo sapiens	Inhibition	%	3.26
	8216151	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	3.9	CHEMBL4599	Homo sapiens	Inhibition	%	3.9
	8216375	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.36	CHEMBL4599	Homo sapiens	Inhibition	%	0.36
	8216511	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	1.65	CHEMBL4599	Homo sapiens	Inhibition	%	1.65
	8216873	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	1.19	CHEMBL4599	Homo sapiens	Inhibition	%	1.19
	8217007	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	1.67	CHEMBL4599	Homo sapiens	Inhibition	%	1.67
	8217405	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	0.99	CHEMBL4599	Homo sapiens	Inhibition	%	0.99
	8217536	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	3.72	CHEMBL4599	Homo sapiens	Inhibition	%	3.72
	8217760	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	6.02	CHEMBL4599	Homo sapiens	Inhibition	%	6.02
	8217861	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.36	CHEMBL4599	Homo sapiens	Inhibition	%	-0.36
	8218200	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	1.21	CHEMBL4599	Homo sapiens	Inhibition	%	1.21
	8218327	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.95	CHEMBL4599	Homo sapiens	Inhibition	%	1.95
	8218551	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	2.34	CHEMBL4599	Homo sapiens	Inhibition	%	2.34
	8218694	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	28.22	CHEMBL4599	Homo sapiens	Inhibition	%	28.22
	8219049	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	28.82	CHEMBL4599	Homo sapiens	Inhibition	%	28.82
	8219209	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	5.48	CHEMBL4599	Homo sapiens	Inhibition	%	5.48
	8219459	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	0.21	CHEMBL4599	Homo sapiens	Inhibition	%	0.21
	8219683	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	1.33	CHEMBL4599	Homo sapiens	Inhibition	%	1.33
	8219844	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	0.34	CHEMBL4599	Homo sapiens	Inhibition	%	0.34
	8220013	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.98	CHEMBL4599	Homo sapiens	Inhibition	%	0.98
	8220237	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.33	CHEMBL4599	Homo sapiens	Inhibition	%	1.33
	8220366	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	9.35	CHEMBL4599	Homo sapiens	Inhibition	%	9.35
	8220704	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	0.65	CHEMBL4599	Homo sapiens	Inhibition	%	0.65
	8220842	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	0.75	CHEMBL4599	Homo sapiens	Inhibition	%	0.75
	8221202	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	0.5	CHEMBL4599	Homo sapiens	Inhibition	%	0.5
	8221335	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	2.25	CHEMBL4599	Homo sapiens	Inhibition	%	2.25
	8221559	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	1.91	CHEMBL4599	Homo sapiens	Inhibition	%	1.91
	8221724	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	2.91	CHEMBL4599	Homo sapiens	Inhibition	%	2.91
	8222079	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	38.02	CHEMBL4599	Homo sapiens	Inhibition	%	38.02
	8222177	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.48	CHEMBL4599	Homo sapiens	Inhibition	%	-0.48
	8222401	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	1.65	CHEMBL4599	Homo sapiens	Inhibition	%	1.65
	8222535	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	2.51	CHEMBL4599	Homo sapiens	Inhibition	%	2.51
	8222877	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	13.15	CHEMBL4599	Homo sapiens	Inhibition	%	13.15
	8223021	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	4.09	CHEMBL4599	Homo sapiens	Inhibition	%	4.09
	8223374	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	0.59	CHEMBL4599	Homo sapiens	Inhibition	%	0.59
	8223535	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	5.14	CHEMBL4599	Homo sapiens	Inhibition	%	5.14
	8223759	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	2.24	CHEMBL4599	Homo sapiens	Inhibition	%	2.24
	8224009	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	0.74	CHEMBL4599	Homo sapiens	Inhibition	%	0.74
	8224171	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	1.05	CHEMBL4599	Homo sapiens	Inhibition	%	1.05
	8224565	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	1.6	CHEMBL4599	Homo sapiens	Inhibition	%	1.6
	8224700	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	3.99	CHEMBL4599	Homo sapiens	Inhibition	%	3.99
	8225038	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	0.65	CHEMBL4599	Homo sapiens	Inhibition	%	0.65
	8225172	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	1.9	CHEMBL4599	Homo sapiens	Inhibition	%	1.9
	8225396	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	1.36	CHEMBL4599	Homo sapiens	Inhibition	%	1.36
	8225534	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	0.02	CHEMBL4599	Homo sapiens	Inhibition	%	0.02
	8225893	CHEMBL1962183	GSK_PKIS: TNK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	5.95	CHEMBL4599	Homo sapiens	Inhibition	%	5.95
	8226051	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.84	CHEMBL4599	Homo sapiens	Inhibition	%	0.84
	8226400	CHEMBL1962182	GSK_PKIS: TNK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.73	CHEMBL4599	Homo sapiens	Inhibition	%	1.73
inactive	9584166	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCOCCO)c2)n1		CHEMBL1978271	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584167	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc(OCCCn4cccc4)c4[nH]nc(N)c34)cc2)c1		CHEMBL2007266	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584168	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2c(Nc3ccc(NC(=O)c4ccccc4)cc3)ncnc2cc1OCCCN1CCOCC1		CHEMBL202721	=	Ki	nM	125.89	CHEMBL4599	Homo sapiens	pKi		6.9
inactive	9584169	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584170	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(CCC(=O)Nc1cc(C(F)(F)F)ccc1Cl)NN=Cc1c[nH]c2ccccc12		CHEMBL1994308	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584171	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584172	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1nc(=O)[nH]c2sccc12		CHEMBL2007097	=	Ki	nM	100000.0	CHEMBL4599	Homo sapiens	pKi		4.0
inactive	9584173	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584174	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	1258.93	CHEMBL4599	Homo sapiens	pKi		5.9
active	9584175	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	398.11	CHEMBL4599	Homo sapiens	pKi		6.4
active	9584176	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	794.33	CHEMBL4599	Homo sapiens	pKi		6.1
active	9584177	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Ki	nM	0.7943	CHEMBL4599	Homo sapiens	pKi		9.1
active	9584178	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccc[nH]2)C(=O)N3)c1)Cc1ccccc1		CHEMBL1980407	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9584179	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)CCCN(C)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1964948	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584180	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cnc(Nc2nc(NC(C)C)ncc2Br)s1		CHEMBL1973013	=	Ki	nM	794.33	CHEMBL4599	Homo sapiens	pKi		6.1
inactive	9584181	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584182	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1987430	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584183	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1ccccc1		CHEMBL1993413	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584184	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584185	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc(-n2ccc3cnc(Nc4cc(OC)c(OC)c(OC)c4)nc32)cc1		CHEMBL1975927	=	Ki	nM	398.11	CHEMBL4599	Homo sapiens	pKi		6.4
active	9584186	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
active	9584187	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(Nc1cncc(-n2cnc3ccc(C#N)cc32)n1)c1ccccc1F		CHEMBL1977138	=	Ki	nM	100.0	CHEMBL4599	Homo sapiens	pKi		7.0
inactive	9584188	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584189	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1Nc2cc(-c3ccc(O)cc3)ccc2C1=Cc1ccc[nH]1		CHEMBL1980329	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584190	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	c1nc(-c2ccc3c(c2)OCO3)c2cc[nH]c2n1		CHEMBL2004515	=	Ki	nM	6309.57	CHEMBL4599	Homo sapiens	pKi		5.2
inactive	9584191	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C2Nc3ccc4ccccc4c3C3C=CCC32)c1)c1ccc(F)cc1		CHEMBL1992042	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584192	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2Cl)C1		CHEMBL1986265	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584193	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1c2ccc(N)cc2C(c2ccccc2)c2cc(N)ccc21		CHEMBL1991734	=	Ki	nM	630.96	CHEMBL4599	Homo sapiens	pKi		6.2
active	9584194	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Ki	nM	125.89	CHEMBL4599	Homo sapiens	pKi		6.9
inactive	9584195	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)s2)c1		CHEMBL1994724	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584196	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(-c2csc3c(C=CC(=O)NCCN(C)C)cnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1989267	=	Ki	nM	158.49	CHEMBL4599	Homo sapiens	pKi		6.8
inactive	9584197	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584198	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1NCc2c1cccc2-c1cccs1		CHEMBL1991782	<	Ki	nM	79432.82	CHEMBL4599	Homo sapiens	pKi		4.1
active	9584199	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1n[nH]c2ncc(Br)cc12		CHEMBL2002105	=	Ki	nM	39810.72	CHEMBL4599	Homo sapiens	pKi		4.4
inactive	9584200	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584201	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCCN(CCC#N)C(=O)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1983348	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584202	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ccc2c(C(=O)O)n(-c3ccccc3)nc2c1		CHEMBL1974574	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584203	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CC)CCNC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1970290	=	Ki	nM	1258.93	CHEMBL4599	Homo sapiens	pKi		5.9
active	9584204	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	=	Ki	nM	501.19	CHEMBL4599	Homo sapiens	pKi		6.3
active	9584205	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Ki	nM	2.512	CHEMBL4599	Homo sapiens	pKi		8.6
active	9584206	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	C#Cc1cn(C2CCCC2)c2ncnc(N)c12		CHEMBL1993877	=	Ki	nM	1995.26	CHEMBL4599	Homo sapiens	pKi		5.7
inactive	9584207	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2000934	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584208	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584209	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncnc2c1C(=O)Nc1ccccc1N2		CHEMBL1980671	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
active	9584210	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(NC(=O)N2CCC(c3nc4c(C(N)=O)cccc4[nH]3)CC2)c1		CHEMBL1973363	=	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9584211	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(Cl)c1)Nc1nc(CCNc2ncnc3ccsc23)cs1		CHEMBL1986177	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584212	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	=	Ki	nM	31.62	CHEMBL4599	Homo sapiens	pKi		7.5
active	9584213	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	=	Ki	nM	316.23	CHEMBL4599	Homo sapiens	pKi		6.5
inactive	9584214	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)c1ccc(N)c2ccccc12		CHEMBL1998253	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584215	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(Cl)ccc12		CHEMBL1981744	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584216	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccnc(Nc2cc(C)nc(-c3ccccc3)n2)c1		CHEMBL1985367	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584217	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584218	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1nc(N2CCNCC2)nc2ccccc12		CHEMBL1996510	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584219	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccccc1-c1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL2000029	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584220	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584221	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1cc(-c2cccc(NC(=O)c3ccc(C(C)(C)C)cc3)c2CO)cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c1=O		CHEMBL2001584	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584222	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	=	Ki	nM	2511.89	CHEMBL4599	Homo sapiens	pKi		5.6
active	9584223	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1967998	=	Ki	nM	63.1	CHEMBL4599	Homo sapiens	pKi		7.2
inactive	9584224	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(C#N)ccc21		CHEMBL1978562	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584225	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCO)c2)n1		CHEMBL1994977	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584226	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Oc1ccc2nc(-c3ccc(Sc4ccc(-c5nc6ccc(O)cc6[nH]5)cc4)cc3)[nH]c2c1		CHEMBL2001149	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584227	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(O)c1csc2c1NCCNC2=O		CHEMBL1974875	=	Ki	nM	100000.0	CHEMBL4599	Homo sapiens	pKi		4.0
inactive	9584228	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc2c(c1)c(-c1cc3nc(Br)cnc3[nH]1)cn2C		CHEMBL2005478	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584229	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(OC)c1CNc1nc(NC2CCCCC2)nc2ccc(Cl)cc12		CHEMBL1996646	=	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9584230	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1979773	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584231	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccnc2[nH]c3cc(C(C)C)ccc3c(=O)c12		CHEMBL1989471	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584232	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	79.43	CHEMBL4599	Homo sapiens	pKi		7.1
active	9584233	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCCN(C)C)cc2NC3=O)ccc1O		CHEMBL1996702	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9584234	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584235	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1ccc(-c2ccc(=O)[nH]n2)cc1)Nc1cccc(C(F)(F)F)c1		CHEMBL2007124	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584236	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1cc2c(-c3ccc(Br)cc3)cncc2s1		CHEMBL1978195	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584237	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584238	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584239	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1ccc2c(c1)C(c1ccc3c(n1)CCCC3O)C(=O)N2		CHEMBL1985681	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584240	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	125.89	CHEMBL4599	Homo sapiens	pKi		6.9
active	9584241	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL2002099	=	Ki	nM	199.53	CHEMBL4599	Homo sapiens	pKi		6.7
inactive	9584242	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584243	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584244	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncnc2c1N=C(c1ccccc1)CCN2		CHEMBL262623	=	Ki	nM	39810.72	CHEMBL4599	Homo sapiens	pKi		4.4
inactive	9584245	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584246	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL2004118	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584247	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN1CCN(c2ccc(Nc3ncc(C#N)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1973516	=	Ki	nM	100.0	CHEMBL4599	Homo sapiens	pKi		7.0
inactive	9584248	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1ccc2nc(N)n(-c3nc4c(s3)CCCC4)c2c1		CHEMBL1996345	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584249	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COCOc1cccc(OCOC)c1-c1ccc(NS(C)(=O)=O)cc1C(=O)OC		CHEMBL2004025	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584250	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	=	Ki	nM	794.33	CHEMBL4599	Homo sapiens	pKi		6.1
inactive	9584251	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584252	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1995211	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584253	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)cc1		CHEMBL1965033	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584254	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	=	Ki	nM	1995.26	CHEMBL4599	Homo sapiens	pKi		5.7
inactive	9584255	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584256	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1ccc(NC2CCCCC2N)nc1Nc1cccc(Cl)c1		CHEMBL1982753	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584257	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(CNC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2006299	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584258	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Oc1cc(O)cc(C=Cc2ccc(O)c(O)c2)c1		CHEMBL1972346	=	Ki	nM	630.96	CHEMBL4599	Homo sapiens	pKi		6.2
active	9584259	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1n[nH]c2cccc(-c3ccc(F)cc3)c12		CHEMBL1971519	=	Ki	nM	15848.93	CHEMBL4599	Homo sapiens	pKi		4.8
active	9584260	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc(C2=NNc3cccc4c(OC)ccc2c34)cc1OC		CHEMBL1997335	=	Ki	nM	1258.93	CHEMBL4599	Homo sapiens	pKi		5.9
inactive	9584261	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(-c2cc3nc(Br)cnc3[nH]2)cc1		CHEMBL1965169	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584262	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Ki	nM	398.11	CHEMBL4599	Homo sapiens	pKi		6.4
inactive	9584263	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(O)C1CN(Cc2ccc(OCc3cccc(C(F)(F)F)c3)cc2)C1		CHEMBL1971132	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584264	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(O)CO)c5)cnc(N)c34)cc2)cc1		CHEMBL1965170	=	Ki	nM	12.59	CHEMBL4599	Homo sapiens	pKi		7.9
inactive	9584265	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584266	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1n[nH]c2nc(Cl)sc12		CHEMBL1991867	=	Ki	nM	79432.82	CHEMBL4599	Homo sapiens	pKi		4.1
inactive	9584267	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Clc1ccc2c(c1)nnc1nnnn12		CHEMBL1986503	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584268	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1c(-c2nc3ccccc3[nH]2)c(O)cc2oc(C)cc(=O)c12		CHEMBL1972355	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584269	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(=O)[nH]nc1-c1ccc(NC(=O)Nc2cc(C(F)(F)F)ccc2F)c(Cl)c1		CHEMBL1997892	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584270	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(-c2cc(-c3cc(Br)ccc3O)[nH]c(=O)c2C#N)s1		CHEMBL1997193	=	Ki	nM	2511.89	CHEMBL4599	Homo sapiens	pKi		5.6
inactive	9584271	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)O)c2)n1		CHEMBL1964902	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584272	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Oc1cnc2ccc(-c3ccncc3)cc2c1		CHEMBL1973868	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584273	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCCC#Cc1ccc(CN2CC(C(=O)O)C2)cc1		CHEMBL1972462	=	Ki	nM	316.23	CHEMBL4599	Homo sapiens	pKi		6.5
inactive	9584274	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9584275	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584276	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	=	Ki	nM	398.11	CHEMBL4599	Homo sapiens	pKi		6.4
active	9584277	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3)n2)s1		CHEMBL1983715	=	Ki	nM	251.19	CHEMBL4599	Homo sapiens	pKi		6.6
inactive	9584278	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1NCc2c(Br)cccc21		CHEMBL1984500	<	Ki	nM	79432.82	CHEMBL4599	Homo sapiens	pKi		4.1
active	9584279	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	=	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9584280	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584281	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCCNC(=O)c1cn(C(CC)CC)c(=O)c2cc(OC)c(OC)cc12		CHEMBL1982700	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584282	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584283	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)Cc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2[nH]ccc12		CHEMBL1980763	=	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584284	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(N)=O)cc2)n1		CHEMBL1977634	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584285	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1nccc2nc(-c3ccccc3)cn12		CHEMBL2004887	=	Ki	nM	15848.93	CHEMBL4599	Homo sapiens	pKi		4.8
inactive	9584286	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584287	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCCNc1nc(N)c(C(=O)c2ccccc2)s1		CHEMBL2007479	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584288	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	c1ccc(-c2c[nH]c3ncnc(N4CCCCC4)c23)cc1		CHEMBL1998953	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584289	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2)c1		CHEMBL1971606	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584290	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)C(CO)NC(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1971223	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584291	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584292	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)c1cc(=O)[nH]c2[nH][nH]c(=O)c12		CHEMBL1999120	=	Ki	nM	25118.86	CHEMBL4599	Homo sapiens	pKi		4.6
active	9584293	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4ccc(OC(F)F)cc4)cc3)c12		CHEMBL1972220	=	Ki	nM	15.85	CHEMBL4599	Homo sapiens	pKi		7.8
inactive	9584294	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(OC(F)F)ccc12		CHEMBL1981215	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584295	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Fc1cccc(CNc2ncnc3[nH]cnc23)c1		CHEMBL2003785	=	Ki	nM	25118.86	CHEMBL4599	Homo sapiens	pKi		4.6
active	9584296	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1995.26	CHEMBL4599	Homo sapiens	pKi		5.7
inactive	9584297	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584298	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1999414	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9584299	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cc(F)cc12		CHEMBL1967336	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584300	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	=	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584301	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2003514	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584302	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584303	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	=	Ki	nM	25118.86	CHEMBL4599	Homo sapiens	pKi		4.6
inactive	9584304	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1ccc(-c2ccncc2)cc1NCc1ccccc1		CHEMBL1967992	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584305	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584306	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4c(Cl)cccc4Cl)s3)cc2)CC1		CHEMBL1989043	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584307	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584308	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCOC(=O)Cc1nc2c(N)cccc2[nH]1		CHEMBL1981671	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584309	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL2006450	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584310	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)ccc(F)c12		CHEMBL2001987	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584311	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCc1c(-c2ccc(C(C)=O)cc2)[nH]c2nccnc12		CHEMBL1994555	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584312	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1CN2C(=NN1)COc1ccccc12		CHEMBL1968515	=	Ki	nM	25118.86	CHEMBL4599	Homo sapiens	pKi		4.6
active	9584313	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	=	Ki	nM	25.12	CHEMBL4599	Homo sapiens	pKi		7.6
inactive	9584314	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584315	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584316	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3coc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1983640	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584317	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCOC(=O)c1nc2c(=O)[nH]c3cc([N+](=O)[O-])c(NC(C)=O)cc3n2c1C		CHEMBL1997611	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584318	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584319	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(=O)Nc1ccc(-n2nc3ccc(N)nc3n2)cc1		CHEMBL2002723	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	pKi		6.0
active	9584320	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1973720	=	Ki	nM	1995.26	CHEMBL4599	Homo sapiens	pKi		5.7
inactive	9584321	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Brc1ccc2cnc(Nc3ccncn3)cc2c1		CHEMBL1984686	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584322	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=S(=O)(Nc1ccc2c(c1)C(=NO)c1ccccc1-2)c1cccc(Br)c1		CHEMBL1973793	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584323	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584324	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	=	Ki	nM	25.12	CHEMBL4599	Homo sapiens	pKi		7.6
active	9584325	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCC1CC(NS(=O)(=O)C2CC2)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1992073	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9584326	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584327	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(NC(CCO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1986143	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584328	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncnc2sccc12		CHEMBL1972934	=	Ki	nM	50118.72	CHEMBL4599	Homo sapiens	pKi		4.3
inactive	9584329	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3sccc3n2)cc1		CHEMBL2007559	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584330	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Cc1ccc(-c2cccnc2)cc1)Nc1ccc(SC(F)F)cc1		CHEMBL1992581	=	Ki	nM	501.19	CHEMBL4599	Homo sapiens	pKi		6.3
active	9584331	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	=	Ki	nM	125.89	CHEMBL4599	Homo sapiens	pKi		6.9
active	9584332	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=c1[nH]c2cc(Br)cnc2[nH]1		CHEMBL1975921	=	Ki	nM	50118.72	CHEMBL4599	Homo sapiens	pKi		4.3
active	9584333	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=c1[nH]n2ccccc2c1Br		CHEMBL2004033	=	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584334	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(CCC(=O)O)(c1ccc(O)c(N)c1)c1ccc(O)c(N)c1		CHEMBL1975923	<	Ki	nM	1995.26	CHEMBL4599	Homo sapiens	pKi		5.7
active	9584335	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(Nc2nc(Cl)cc(NCc3ccccc3)n2)n[nH]1		CHEMBL2005449	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	pKi		6.0
inactive	9584336	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Cc1ccc(OC(F)(F)F)cc1)N1CCC2(CC1)NCCc1c2[nH]c2ccccc12		CHEMBL1996576	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584337	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584338	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(O)C1CN(Cc2ccc(OCc3ccccc3)cc2Cl)C1		CHEMBL1987998	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584339	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584340	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc([N+](=O)[O-])cc2)n1		CHEMBL242865	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9584341	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584342	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2ncc3c(N)nc4c(C)c(N)ccc4c3c2cc1OC		CHEMBL235157	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584343	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584344	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(CNC(=O)c2cnc(-c3ccncc3)nc2)c1		CHEMBL2004159	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584345	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#CC1=C(c2ccccc2)CC(c2ccc(Cl)cc2)C(C(=O)c2ccccc2)C1=O		CHEMBL1978371	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584346	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584347	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	[2H]C([2H])([2H])Oc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1998110	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584348	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(OCc2cccc(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1966501	=	Ki	nM	501.19	CHEMBL4599	Homo sapiens	pKi		6.3
active	9584349	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	316.23	CHEMBL4599	Homo sapiens	pKi		6.5
inactive	9584350	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584351	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584352	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	1258.93	CHEMBL4599	Homo sapiens	pKi		5.9
active	9584353	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(Nc2ncnc(N3CCCc4cc(C)ccc43)n2)cc(OC)c1OC		CHEMBL1992125	=	Ki	nM	2511.89	CHEMBL4599	Homo sapiens	pKi		5.6
inactive	9584354	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC1CCN(C(=O)CC#N)CC1c1ncc2cnc3[nH]ccc3n12		CHEMBL1966175	<	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9584355	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC#Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL2007375	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584356	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1[nH]c3ccc(O)cc3c21		CHEMBL379975	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9584357	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CS(=O)(=O)c1cccc(C(=O)Nc2nc3ccccc3n2CCCO)c1		CHEMBL1973016	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584358	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1n[nH]c2c(OCCCn3cccc3)ccc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL1965387	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9584359	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	1.585	CHEMBL4599	Homo sapiens	pKi		8.8
active	9584360	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(-c2ncnc3[nH]ccc23)ccc1F		CHEMBL1997041	=	Ki	nM	15848.93	CHEMBL4599	Homo sapiens	pKi		4.8
inactive	9584361	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(-c2ccc3c(c2)Nc2c(O)cccc2NC3=O)ccc1O		CHEMBL550418	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584362	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584363	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584364	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCOc1ccc(C=C2SC(=N)NC2=O)c(O)c1		CHEMBL1971289	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584365	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584366	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(F)cc12		CHEMBL2007603	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584367	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Cc1cccs1)Nc1nc2ccccc2s1		CHEMBL1421720	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9584368	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc2c(c1)c(-c1cc3nccnc3[nH]1)cn2C		CHEMBL1233887	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587940	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1nnc2cncc(Cl)n12		CHEMBL1968130	=	Ki	nM	39810.72	CHEMBL4599	Homo sapiens	pKi		4.4
inactive	9587941	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCCC(=O)O)cc2)n1		CHEMBL2003689	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587942	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CC)CCCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1996649	=	Ki	nM	1258.93	CHEMBL4599	Homo sapiens	pKi		5.9
inactive	9587943	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1986756	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587944	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	=	Ki	nM	794.33	CHEMBL4599	Homo sapiens	pKi		6.1
active	9587945	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=c1[nH]cnc2c(Cl)cccc12		CHEMBL1949855	=	Ki	nM	12589.25	CHEMBL4599	Homo sapiens	pKi		4.9
inactive	9587946	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9587947	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(CCC#N)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1974998	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587948	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(OCc2ccc(Cl)c(Cl)c2)ccc1CN1CC(C(=O)O)C1		CHEMBL1990223	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587949	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587950	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(c1cc(Br)c(O)c(I)c1)c1cc(Br)c(O)c(I)c1		CHEMBL1964382	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587951	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)CC(O)COc1ccc(Nc2nccc(Nc3cc(Cl)ccc3Cl)n2)cc1		CHEMBL101311	=	Ki	nM	251.19	CHEMBL4599	Homo sapiens	pKi		6.6
inactive	9587952	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	<	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
active	9587953	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1ccc2nc(-c3ccc([N+](=O)[O-])o3)cn2c1		CHEMBL1973359	=	Ki	nM	251.19	CHEMBL4599	Homo sapiens	pKi		6.6
active	9587954	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(=O)n2ccc(CN(C)C)c(O)c2n1		CHEMBL1988581	=	Ki	nM	63.1	CHEMBL4599	Homo sapiens	pKi		7.2
inactive	9587955	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2ccc(OCC(=O)O)cc2)n1		CHEMBL2005699	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587956	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(C(C)=O)c1ccc(Nc2nc(NC3CC3)c3nc[nH]c3n2)cc1		CHEMBL2006564	=	Ki	nM	79.43	CHEMBL4599	Homo sapiens	pKi		7.1
active	9587957	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
active	9587958	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCN(c2ccc(Nc3ncc(Cl)c(Nc4ccc5[nH]ncc5c4)n3)cc2)CC1		CHEMBL1979690	=	Ki	nM	63.1	CHEMBL4599	Homo sapiens	pKi		7.2
active	9587959	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1n[nH]c2c(-c3ccccc3)cccc12		CHEMBL1991008	=	Ki	nM	79432.82	CHEMBL4599	Homo sapiens	pKi		4.1
inactive	9587960	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587961	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCCCCCCCCN)cnc(N)c34)cc2)c1		CHEMBL1978166	=	Ki	nM	316.23	CHEMBL4599	Homo sapiens	pKi		6.5
inactive	9587962	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2ccccc21		CHEMBL1978167	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587963	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587964	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587965	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587966	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncnc2c1c(-c1ccc(Oc3ccc(CO)cc3)cc1)cn2C1CCOC1		CHEMBL1976376	=	Ki	nM	316.23	CHEMBL4599	Homo sapiens	pKi		6.5
active	9587967	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(NN=Cc1cc(Br)c(O)c(Br)c1)Nc1ccccc1		CHEMBL1983575	=	Ki	nM	630.96	CHEMBL4599	Homo sapiens	pKi		6.2
inactive	9587968	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1cccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)n1		CHEMBL1968868	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587969	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	=	Ki	nM	100.0	CHEMBL4599	Homo sapiens	pKi		7.0
inactive	9587970	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCC(=O)Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1		CHEMBL1998470	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587971	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1ccc([N+](=O)[O-])cc1)N1CCc2[nH]c3c(Cl)cc(Cl)cc3c2C1		CHEMBL1976196	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587972	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccccc1CNC(=N)Nc1nccc(-c2cccs2)n1		CHEMBL1997197	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587973	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccccc1-c1ccnc(Nc2cccc(S(C)(=O)=O)c2)n1		CHEMBL1975903	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587974	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	=	Ki	nM	19952.62	CHEMBL4599	Homo sapiens	pKi		4.7
active	9587975	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	158.49	CHEMBL4599	Homo sapiens	pKi		6.8
inactive	9587976	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	N#Cc1ccc2nc(N)n(-c3nccs3)c2c1		CHEMBL1988805	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587977	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	39.81	CHEMBL4599	Homo sapiens	pKi		7.4
inactive	9587978	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1ccc(-c2ccc3cn[nH]c3c2)cc1)Nc1cccc(F)c1		CHEMBL1969942	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587979	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587980	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cccc(C(C)NC(=O)c2sc(-c3ccncc3)nc2C)c1		CHEMBL1978567	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587981	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1Nc2ccccc2C1=Cc1ccc[nH]1		CHEMBL1996176	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587982	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1cc(=O)[nH]n1-c1ccccn1		CHEMBL1995765	=	Ki	nM	50118.72	CHEMBL4599	Homo sapiens	pKi		4.3
inactive	9587983	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCNC(=O)c1ccc(Nc2nc(CCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL1984760	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587984	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587985	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587986	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9587987	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)CC1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL360847	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587988	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cc(F)ccc1F		CHEMBL1995811	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587989	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1c(N)nc2sc(C(N)=O)cc21		CHEMBL2002802	=	Ki	nM	79432.82	CHEMBL4599	Homo sapiens	pKi		4.1
active	9587990	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CC)CCOc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1		CHEMBL49120	=	Ki	nM	1.259	CHEMBL4599	Homo sapiens	pKi		8.9
active	9587991	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	63.1	CHEMBL4599	Homo sapiens	pKi		7.2
active	9587992	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCC(=O)Nc1ccc(C(=O)N2CCNCC2)c(O)c1		CHEMBL1988141	=	Ki	nM	630.96	CHEMBL4599	Homo sapiens	pKi		6.2
inactive	9587993	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9587994	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1cccc2cn[nH]c12		CHEMBL451401	=	Ki	nM	31622.78	CHEMBL4599	Homo sapiens	pKi		4.5
active	9587995	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)cnc2c(-c3ccc4c(c3)OCO4)cnn12		CHEMBL1977134	=	Ki	nM	199.53	CHEMBL4599	Homo sapiens	pKi		6.7
inactive	9587996	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COCC#Cc1cccc2c1Cc1c(-c3cccs3)n[nH]c1-2		CHEMBL1985206	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587997	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587998	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9587999	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	C=CCc1cccc2c(=NO)cc(-c3ccccc3)oc12		CHEMBL1977749	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588000	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncnc2scc(-c3ccccc3)c12		CHEMBL1975212	=	Ki	nM	7943.28	CHEMBL4599	Homo sapiens	pKi		5.1
active	9588001	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=c1[nH][nH]c2ccc(Br)cc12		CHEMBL2001613	=	Ki	nM	31622.78	CHEMBL4599	Homo sapiens	pKi		4.5
inactive	9588002	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588003	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	pKi		6.0
inactive	9588004	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588005	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	3162.28	CHEMBL4599	Homo sapiens	pKi		5.5
inactive	9588006	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1cc2c(-c3ccc(Nc4nc5ccccc5o4)cc3)cnc(N)c2s1		CHEMBL1993904	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588007	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1ccc2[nH]cc(C=C3C(=O)Nc4ccccc43)c2c1		CHEMBL1997275	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588008	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2ccc(Cl)cc12		CHEMBL1967513	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588009	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	1258.93	CHEMBL4599	Homo sapiens	pKi		5.9
inactive	9588010	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(Cc1cc(Cl)c(O)c2ncccc12)C1CCCCC1		CHEMBL1982413	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588011	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(NCCc1cccs1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1987535	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588012	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(F)c1)Nc1cccc(-c2ccc3cn[nH]c3c2)c1		CHEMBL1983393	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588013	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(F)c(F)cc12		CHEMBL1981792	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588014	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Clc1cc(Nc2nc(NC3CC3)c3sccc3n2)ccc1N1CCOCC1		CHEMBL2002586	=	Ki	nM	630.96	CHEMBL4599	Homo sapiens	pKi		6.2
inactive	9588015	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCCC3CCO)nc12		CHEMBL2006674	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588016	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1981133	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588017	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cnccn1)Nc1cccc2c(O)cccc12		CHEMBL1992371	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588018	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)c1ccc(Nc2cc(-c3csc(Br)c3)[nH]n2)cc1		CHEMBL1984236	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588019	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)Oc1cc(Nc2nc(NC(C)c3ccc(F)cn3)ncc2Cl)n[nH]1		CHEMBL2007421	=	Ki	nM	25.12	CHEMBL4599	Homo sapiens	pKi		7.6
inactive	9588020	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cc(Nc2ccc(C(=O)N3CCOCC3)cn2)c(=O)n(C)c1		CHEMBL1973138	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588021	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(N3CC4COCC4C3)cc12		CHEMBL2002599	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588022	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=c1[nH]c2ccc(Cl)cc2c2ncnn12		CHEMBL1992673	=	Ki	nM	19952.62	CHEMBL4599	Homo sapiens	pKi		4.7
active	9588023	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	Ki	nM	31.62	CHEMBL4599	Homo sapiens	pKi		7.5
inactive	9588024	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588025	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)C1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1969151	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588026	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1n[nH]c2ccc(-c3cccnc3)cc12		CHEMBL1967252	=	Ki	nM	50118.72	CHEMBL4599	Homo sapiens	pKi		4.3
inactive	9588027	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1cc(-c2cc3nc(Br)cnc3[nH]2)c2cc(F)ccc21		CHEMBL1993335	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588028	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1nc(Cl)cc(-c2c[nH]c3ncccc23)n1		CHEMBL2007574	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588029	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)NC1=NNC(=O)C1=Cc1cc2ccccc2[nH]1		CHEMBL1988692	=	Ki	nM	398.11	CHEMBL4599	Homo sapiens	pKi		6.4
active	9588030	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL2004637	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9588031	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)C(C)Nc1ncc(Cl)c(Nc2nccs2)n1		CHEMBL1993374	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588032	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)N(CCCN)C(=O)c1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2cccc3ccccc23)c1		CHEMBL1994318	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588033	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)C(=O)c2cccc3ccccc23)n(-c2cccc(OCC(=O)NCCO)c2)n1		CHEMBL1998680	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588034	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588035	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCCCCC(=O)O)c2)n1		CHEMBL1999506	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588036	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	pKi		6.0
inactive	9588037	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588038	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCNC(=O)c1ccc(Nc2nc(CC)c3cc[nH]c3n2)cc1		CHEMBL1997007	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588039	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCOC(=O)c1c(C)n(-c2ccc(I)cc2)c2c1cc(O)c1ccccc12		CHEMBL1970352	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588040	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588041	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1nc2c(O)cccc2s1)Nc1ccccc1-c1ccccc1		CHEMBL2002690	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588042	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CN(C)c1ccc(-c2cc(-c3ccc([N+](=O)[O-])cc3)nc(NS(=O)(=O)c3ccc(N)cc3)n2)cc1		CHEMBL1980167	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588043	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588044	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588045	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588046	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	Ki	nM	199.53	CHEMBL4599	Homo sapiens	pKi		6.7
inactive	9588047	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C1Nc2ccccc2C1=Cc1c[nH]c2ccccc12		CHEMBL1986590	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588048	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCC(N)C3)c21		CHEMBL1870106	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588049	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CC(C)(C)n1nc(-c2ccc(Cl)cc2)c2c(N)ncnc21		CHEMBL406845	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	pKi		6.0
inactive	9588050	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	NCc1cc(Nc2ncnc(-c3ccccc3)n2)ccc1O		CHEMBL1980246	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588051	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(-c3ccc(CO)cc3)s1)CC2		CHEMBL1983980	=	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588052	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	=	Ki	nM	7.943	CHEMBL4599	Homo sapiens	pKi		8.1
active	9588053	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNc1nc(C)c(-c2ccnc(Nc3ccc(N4CCNCC4)cc3)n2)s1		CHEMBL1999484	=	Ki	nM	158.49	CHEMBL4599	Homo sapiens	pKi		6.8
inactive	9588054	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(C)c(NC(=O)c2cc(-c3ccco3)nc3ccccc23)c1		CHEMBL1984296	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588055	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588056	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	Cc1ccc(NCc2ccc(-c3ccc(F)cc3)nc2)cc1		CHEMBL1986899	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588057	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	1995.26	CHEMBL4599	Homo sapiens	pKi		5.7
active	9588058	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	3.981	CHEMBL4599	Homo sapiens	pKi		8.4
inactive	9588059	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
inactive	9588060	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	O=C(Nc1cc(-c2c[nH]c3ncccc23)cc(Cl)n1)c1c(F)cccc1F		CHEMBL1991410	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
active	9588061	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	CNCC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL1964441	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	pKi		6.0
active	9588062	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	1584.89	CHEMBL4599	Homo sapiens	pKi		5.8
inactive	9588063	CHEMBL1963777	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: ACK1	F	ON=C(c1nc2ccccc2[nH]1)c1nc2ccccc2[nH]1		CHEMBL546797	<	Ki	nM	3981.07	CHEMBL4599	Homo sapiens	pKi		5.4
	10838547	CHEMBL2014120	Inhibition of TNK2 at 10 uM	B	COc1ccc2c3ccnc(C(F)(F)F)c3n(CCCCN)c2c1		CHEMBL2012574	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
Active	10884071	CHEMBL2033680	Binding affinity to TNK2	B	C=CC(=O)Nc1cccc(N2C(=O)N(c3ccccc3)Cc3cnc(Nc4ccc(N5CCN(C)CC5)cc4OC)nc32)c1		CHEMBL2029436		Activity			CHEMBL4599	Homo sapiens	Activity		
	10981546	CHEMBL2067600	Inhibition of human ACK1 at 1 uM	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	>=	Inhibition	%	90.0	CHEMBL4599	Homo sapiens	INH	%	90.0
	10981561	CHEMBL2067585	Inhibition of human ACK1	B	COc1c(Nc2ncc(Cl)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc2c1CC[C@@H](N1CCOCC1)CC2		CHEMBL2064666	=	IC50	nM	41.0	CHEMBL4599	Homo sapiens	IC50	nM	41.0
	11003590	CHEMBL2090700	Inhibition of ACK1	B	Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL189977	=	Ki	nM	1000.0	CHEMBL4599	Homo sapiens	Ki	uM	1.0
Active	11003591	CHEMBL2090701	Competitive inhibition of ACK1 using ATP	B	Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL189977		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	11003592	CHEMBL2090702	Reversible inhibition of ACK1	B	Nc1ncnc2oc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL189977		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
	11003593	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087647	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003594	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	COc1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087648	=	Ki	nM	5.0	CHEMBL4599	Homo sapiens	Ki	uM	0.005
	11003595	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	COc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087649	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003596	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CS(=O)(=O)c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087650	=	Ki	nM	8.0	CHEMBL4599	Homo sapiens	Ki	uM	0.008
	11003597	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CS(=O)(=O)c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087651	=	Ki	nM	7.0	CHEMBL4599	Homo sapiens	Ki	uM	0.007
	11003598	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)S(=O)(=O)c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087652	=	Ki	nM	2.0	CHEMBL4599	Homo sapiens	Ki	uM	0.002
	11003599	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CNS(=O)(=O)c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087653	=	Ki	nM	4.0	CHEMBL4599	Homo sapiens	Ki	uM	0.004
	11003600	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CNS(=O)(=O)c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087654	=	Ki	nM	2.0	CHEMBL4599	Homo sapiens	Ki	uM	0.002
	11003601	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247479	=	Ki	nM	5.0	CHEMBL4599	Homo sapiens	Ki	uM	0.005
	11003602	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087655	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003603	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2c(-c3ccc(OCCN4CCOCC4)cc3)oc3ncnc(NC[C@@H]4CCCO4)c23)cc1		CHEMBL2087656	=	Ki	nM	4.0	CHEMBL4599	Homo sapiens	Ki	uM	0.004
	11003604	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2c(-c3ccc(OCCN4CCOCC4)cc3)[nH]c3ncnc(NC[C@@H]4CCCO4)c23)cc1		CHEMBL2087657	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003605	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)[nH]c3ncnc(NC[C@@H]4CCCO4)c23)cc1		CHEMBL2087658	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003606	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	O=C1CCCN1CCOc1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087659	=	Ki	nM	4.0	CHEMBL4599	Homo sapiens	Ki	uM	0.004
	11003607	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	O=C1CCCN1CCOc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087660	=	Ki	nM	4.0	CHEMBL4599	Homo sapiens	Ki	uM	0.004
	11003608	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)C(=O)c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087661	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	11003609	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)C(=O)c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087662	=	Ki	nM	2.0	CHEMBL4599	Homo sapiens	Ki	uM	0.002
	11003610	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CNC(=O)c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087663	=	Ki	nM	13.0	CHEMBL4599	Homo sapiens	Ki	uM	0.013
	11003611	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CNC(=O)c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087664	=	Ki	nM	3.0	CHEMBL4599	Homo sapiens	Ki	uM	0.003
	11003612	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	O=C(c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1)N1CCOCC1		CHEMBL2087665	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003613	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	O=C(c1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1)N1CCOCC1		CHEMBL2087666	=	Ki	nM	6.0	CHEMBL4599	Homo sapiens	Ki	uM	0.006
	11003614	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2C2=CCCCC2)cc1		CHEMBL2087667	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	11003615	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2C2=CCCC2)cc1		CHEMBL2087668	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	11003616	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CCCO4)c3c2C2CC2)cc1		CHEMBL2087669	=	Ki	nM	1980.0	CHEMBL4599	Homo sapiens	Ki	uM	1.98
	11003617	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1cncc(-c2c(-c3ccc(OCCN4CCCC4)cc3)[nH]c3ncnc(NC[C@@H]4CCCO4)c23)c1		CHEMBL2087670	=	Ki	nM	40.0	CHEMBL4599	Homo sapiens	Ki	uM	0.04
	11003618	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	COc1cccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)[nH]c3ncnc(NC[C@@H]4CCCO4)c23)c1		CHEMBL2087671	=	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	uM	0.01
	11003619	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	Cc1ccccc1-c1c(-c2ccc(OCCN3CCCC3)cc2)[nH]c2ncnc(NC[C@@H]3CCCO3)c12		CHEMBL2087871	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	11003620	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	Fc1ccccc1-c1c(-c2ccc(OCCN3CCCC3)cc2)[nH]c2ncnc(NC[C@@H]3CCCO3)c12		CHEMBL2087872	=	Ki	nM	4.0	CHEMBL4599	Homo sapiens	Ki	uM	0.004
	11003621	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NCC4SCCS4)c3c2-c2ccccc2)cc1		CHEMBL2087873	=	Ki	nM	0.3	CHEMBL4599	Homo sapiens	Ki	uM	0.0003
	11003622	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2oc3ncnc(NCC4SCCS4)c3c2-c2ccccc2)cc1		CHEMBL2087874	=	Ki	nM	0.2	CHEMBL4599	Homo sapiens	Ki	uM	0.0002
	11003623	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)[nH]c3ncnc(NCC4SCCS4)c23)cc1		CHEMBL2087875	=	Ki	nM	0.3	CHEMBL4599	Homo sapiens	Ki	uM	0.0003
	11003624	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2oc3ncnc(NCC4CCCS4)c3c2-c2ccccc2)cc1		CHEMBL2087876	=	Ki	nM	8.0	CHEMBL4599	Homo sapiens	Ki	uM	0.008
	11003625	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2oc3ncnc(NCC4OCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087877	=	Ki	nM	13.0	CHEMBL4599	Homo sapiens	Ki	uM	0.013
	11003626	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2oc3ncnc(NC[C@@H]4CCCCS4)c3c2-c2ccccc2)cc1		CHEMBL2087878	=	Ki	nM	69.0	CHEMBL4599	Homo sapiens	Ki	uM	0.069
	11003627	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2oc3ncnc(NCC4SCCCS4)c3c2-c2ccccc2)cc1		CHEMBL2087879	=	Ki	nM	4.0	CHEMBL4599	Homo sapiens	Ki	uM	0.004
	11003628	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NC[C@@H]4CC[C@H]4O)c3c2-c2ccccc2)cc1		CHEMBL2087880	=	Ki	nM	30.0	CHEMBL4599	Homo sapiens	Ki	uM	0.03
	11003629	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CO[C@@H]1CC[C@H]1CNc1ncnc2[nH]c(-c3ccc(OCCN(C)C)cc3)c(-c3ccccc3)c12		CHEMBL2087881	=	Ki	nM	20.0	CHEMBL4599	Homo sapiens	Ki	uM	0.02
	11003630	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CN(C)CCOc1ccc(-c2[nH]c3ncnc(NC[C@H]4CCC[C@H]4O)c3c2-c2ccccc2)cc1		CHEMBL2087882	=	Ki	nM	40.0	CHEMBL4599	Homo sapiens	Ki	uM	0.04
	11003631	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CO[C@@H]1CCC[C@@H]1CNc1ncnc2[nH]c(-c3ccc(OCCN(C)C)cc3)c(-c3ccccc3)c12		CHEMBL2087883	=	Ki	nM	50.0	CHEMBL4599	Homo sapiens	Ki	uM	0.05
	11003632	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	CO[C@@H]1CCC[C@H]1CNc1ncnc2[nH]c(-c3ccc(OCCN(C)C)cc3)c(-c3ccccc3)c12		CHEMBL2087884	=	Ki	nM	50.0	CHEMBL4599	Homo sapiens	Ki	uM	0.05
	11003685	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2sc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL2087885	>	Ki	nM	10000.0	CHEMBL4599	Homo sapiens	Ki	uM	10.0
	11003686	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2oc3nccc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL240429	=	Ki	nM	70.0	CHEMBL4599	Homo sapiens	Ki	uM	0.07
	11003687	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2nc3ncnc(NC[C@@H]4CCCO4)n3c2-c2ccccc2)cc1		CHEMBL2087887	=	Ki	nM	1800.0	CHEMBL4599	Homo sapiens	Ki	uM	1.8
	11003688	CHEMBL2090703	Inhibition of N-terminal His6-tagged ACK1 expressed in baculovirus infected Hi5 cells assessed as inhibition of autophosphorylation after 2 hrs by ELISA	B	c1ccc(-c2nc3ncnc(NC[C@@H]4CCCO4)c3n2-c2ccccc2)cc1		CHEMBL2087886	=	Ki	nM	7300.0	CHEMBL4599	Homo sapiens	Ki	uM	7.3
	12047362	CHEMBL2157715	Inhibition of TNK2 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	2.6	CHEMBL4599	Homo sapiens	INH	%	2.6
	12183798	CHEMBL2214463	Inhibition of TNK2	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	pIC50		5.0
	12221599	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	106.0	CHEMBL4599	Homo sapiens	Residual Activity	%	106.0
	12221600	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	73.0	CHEMBL4599	Homo sapiens	Residual Activity	%	73.0
	12221601	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12221602	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	90.0	CHEMBL4599	Homo sapiens	Residual Activity	%	90.0
	12221603	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	46.0	CHEMBL4599	Homo sapiens	Residual Activity	%	46.0
	12221604	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	91.0	CHEMBL4599	Homo sapiens	Residual Activity	%	91.0
	12221605	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	60.0	CHEMBL4599	Homo sapiens	Residual Activity	%	60.0
	12221606	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	34.0	CHEMBL4599	Homo sapiens	Residual Activity	%	34.0
	12221607	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	107.0	CHEMBL4599	Homo sapiens	Residual Activity	%	107.0
	12221608	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	66.0	CHEMBL4599	Homo sapiens	Residual Activity	%	66.0
	12221609	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	86.0	CHEMBL4599	Homo sapiens	Residual Activity	%	86.0
	12221610	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	81.0	CHEMBL4599	Homo sapiens	Residual Activity	%	81.0
	12221611	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12221612	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	6.0	CHEMBL4599	Homo sapiens	Residual Activity	%	6.0
	12221613	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12221614	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	73.0	CHEMBL4599	Homo sapiens	Residual Activity	%	73.0
	12221615	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	110.0	CHEMBL4599	Homo sapiens	Residual Activity	%	110.0
	12221616	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	84.0	CHEMBL4599	Homo sapiens	Residual Activity	%	84.0
	12221617	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221618	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	10.0	CHEMBL4599	Homo sapiens	Residual Activity	%	10.0
	12221619	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	72.0	CHEMBL4599	Homo sapiens	Residual Activity	%	72.0
	12221620	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12221621	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	83.0	CHEMBL4599	Homo sapiens	Residual Activity	%	83.0
	12221622	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	92.0	CHEMBL4599	Homo sapiens	Residual Activity	%	92.0
	12221623	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	100.0	CHEMBL4599	Homo sapiens	Residual Activity	%	100.0
	12221624	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	28.0	CHEMBL4599	Homo sapiens	Residual Activity	%	28.0
	12221625	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12221626	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	14.0	CHEMBL4599	Homo sapiens	Residual Activity	%	14.0
	12221627	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221628	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	45.0	CHEMBL4599	Homo sapiens	Residual Activity	%	45.0
	12221629	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221630	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	20.0	CHEMBL4599	Homo sapiens	Residual Activity	%	20.0
	12221631	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	98.0	CHEMBL4599	Homo sapiens	Residual Activity	%	98.0
	12221632	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	90.0	CHEMBL4599	Homo sapiens	Residual Activity	%	90.0
	12221633	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12221634	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221635	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	6.0	CHEMBL4599	Homo sapiens	Residual Activity	%	6.0
	12221636	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	82.0	CHEMBL4599	Homo sapiens	Residual Activity	%	82.0
	12221637	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	90.0	CHEMBL4599	Homo sapiens	Residual Activity	%	90.0
	12221638	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	54.0	CHEMBL4599	Homo sapiens	Residual Activity	%	54.0
	12221639	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	113.0	CHEMBL4599	Homo sapiens	Residual Activity	%	113.0
	12221640	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	94.0	CHEMBL4599	Homo sapiens	Residual Activity	%	94.0
	12221641	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	3.0	CHEMBL4599	Homo sapiens	Residual Activity	%	3.0
	12221642	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	57.0	CHEMBL4599	Homo sapiens	Residual Activity	%	57.0
	12221643	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	24.0	CHEMBL4599	Homo sapiens	Residual Activity	%	24.0
	12221644	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	80.0	CHEMBL4599	Homo sapiens	Residual Activity	%	80.0
	12221645	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	83.0	CHEMBL4599	Homo sapiens	Residual Activity	%	83.0
	12221646	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	52.0	CHEMBL4599	Homo sapiens	Residual Activity	%	52.0
	12221647	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	109.0	CHEMBL4599	Homo sapiens	Residual Activity	%	109.0
	12221648	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	78.0	CHEMBL4599	Homo sapiens	Residual Activity	%	78.0
	12221649	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	65.0	CHEMBL4599	Homo sapiens	Residual Activity	%	65.0
	12221650	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	4.0	CHEMBL4599	Homo sapiens	Residual Activity	%	4.0
	12221651	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12221652	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12221653	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	88.0	CHEMBL4599	Homo sapiens	Residual Activity	%	88.0
	12221654	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	71.0	CHEMBL4599	Homo sapiens	Residual Activity	%	71.0
	12221655	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	13.0	CHEMBL4599	Homo sapiens	Residual Activity	%	13.0
	12221656	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	83.0	CHEMBL4599	Homo sapiens	Residual Activity	%	83.0
	12221657	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	65.0	CHEMBL4599	Homo sapiens	Residual Activity	%	65.0
	12221658	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	76.0	CHEMBL4599	Homo sapiens	Residual Activity	%	76.0
	12221659	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	48.0	CHEMBL4599	Homo sapiens	Residual Activity	%	48.0
	12221660	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	11.0	CHEMBL4599	Homo sapiens	Residual Activity	%	11.0
	12221661	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	84.0	CHEMBL4599	Homo sapiens	Residual Activity	%	84.0
	12221662	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	94.0	CHEMBL4599	Homo sapiens	Residual Activity	%	94.0
	12221663	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	109.0	CHEMBL4599	Homo sapiens	Residual Activity	%	109.0
	12221664	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	89.0	CHEMBL4599	Homo sapiens	Residual Activity	%	89.0
	12221665	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	92.0	CHEMBL4599	Homo sapiens	Residual Activity	%	92.0
	12221666	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	88.0	CHEMBL4599	Homo sapiens	Residual Activity	%	88.0
	12221667	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	84.0	CHEMBL4599	Homo sapiens	Residual Activity	%	84.0
	12221668	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	28.0	CHEMBL4599	Homo sapiens	Residual Activity	%	28.0
	12221669	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	86.0	CHEMBL4599	Homo sapiens	Residual Activity	%	86.0
	12221670	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	25.0	CHEMBL4599	Homo sapiens	Residual Activity	%	25.0
	12221671	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	112.0	CHEMBL4599	Homo sapiens	Residual Activity	%	112.0
	12221672	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	22.0	CHEMBL4599	Homo sapiens	Residual Activity	%	22.0
	12221673	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221674	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12221675	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	96.0	CHEMBL4599	Homo sapiens	Residual Activity	%	96.0
	12221676	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	25.0	CHEMBL4599	Homo sapiens	Residual Activity	%	25.0
	12221677	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	96.0	CHEMBL4599	Homo sapiens	Residual Activity	%	96.0
	12221678	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	-2.0	CHEMBL4599	Homo sapiens	Residual Activity	%	-2.0
	12221679	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	100.0	CHEMBL4599	Homo sapiens	Residual Activity	%	100.0
	12221680	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12221681	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12221682	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	97.0	CHEMBL4599	Homo sapiens	Residual Activity	%	97.0
	12221683	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	13.0	CHEMBL4599	Homo sapiens	Residual Activity	%	13.0
	12221684	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	89.0	CHEMBL4599	Homo sapiens	Residual Activity	%	89.0
	12221685	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	90.0	CHEMBL4599	Homo sapiens	Residual Activity	%	90.0
	12221686	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	93.0	CHEMBL4599	Homo sapiens	Residual Activity	%	93.0
	12221687	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	89.0	CHEMBL4599	Homo sapiens	Residual Activity	%	89.0
	12221688	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	34.0	CHEMBL4599	Homo sapiens	Residual Activity	%	34.0
	12221689	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	83.0	CHEMBL4599	Homo sapiens	Residual Activity	%	83.0
	12221690	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	61.0	CHEMBL4599	Homo sapiens	Residual Activity	%	61.0
	12221691	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	13.0	CHEMBL4599	Homo sapiens	Residual Activity	%	13.0
	12221692	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	73.0	CHEMBL4599	Homo sapiens	Residual Activity	%	73.0
	12221693	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	83.0	CHEMBL4599	Homo sapiens	Residual Activity	%	83.0
	12221694	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	91.0	CHEMBL4599	Homo sapiens	Residual Activity	%	91.0
	12221695	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	100.0	CHEMBL4599	Homo sapiens	Residual Activity	%	100.0
	12221696	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	81.0	CHEMBL4599	Homo sapiens	Residual Activity	%	81.0
	12221697	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	80.0	CHEMBL4599	Homo sapiens	Residual Activity	%	80.0
	12221698	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	29.0	CHEMBL4599	Homo sapiens	Residual Activity	%	29.0
	12221699	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	38.0	CHEMBL4599	Homo sapiens	Residual Activity	%	38.0
	12221700	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	0.0	CHEMBL4599	Homo sapiens	Residual Activity	%	0.0
	12221701	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	83.0	CHEMBL4599	Homo sapiens	Residual Activity	%	83.0
	12221702	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	8.0	CHEMBL4599	Homo sapiens	Residual Activity	%	8.0
	12221703	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	44.0	CHEMBL4599	Homo sapiens	Residual Activity	%	44.0
	12221704	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	76.0	CHEMBL4599	Homo sapiens	Residual Activity	%	76.0
	12221705	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	81.0	CHEMBL4599	Homo sapiens	Residual Activity	%	81.0
	12221706	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221707	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	71.0	CHEMBL4599	Homo sapiens	Residual Activity	%	71.0
	12221708	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	24.0	CHEMBL4599	Homo sapiens	Residual Activity	%	24.0
	12221709	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12221710	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	74.0	CHEMBL4599	Homo sapiens	Residual Activity	%	74.0
	12221711	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	32.0	CHEMBL4599	Homo sapiens	Residual Activity	%	32.0
	12221712	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	84.0	CHEMBL4599	Homo sapiens	Residual Activity	%	84.0
	12221713	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221714	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221715	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	10.0	CHEMBL4599	Homo sapiens	Residual Activity	%	10.0
	12221716	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221717	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	76.0	CHEMBL4599	Homo sapiens	Residual Activity	%	76.0
	12221718	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	87.0	CHEMBL4599	Homo sapiens	Residual Activity	%	87.0
	12221719	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	26.0	CHEMBL4599	Homo sapiens	Residual Activity	%	26.0
	12221720	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	34.0	CHEMBL4599	Homo sapiens	Residual Activity	%	34.0
	12221721	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	14.0	CHEMBL4599	Homo sapiens	Residual Activity	%	14.0
	12221722	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	75.0	CHEMBL4599	Homo sapiens	Residual Activity	%	75.0
	12221723	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	14.0	CHEMBL4599	Homo sapiens	Residual Activity	%	14.0
	12221724	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	74.0	CHEMBL4599	Homo sapiens	Residual Activity	%	74.0
	12221725	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	45.0	CHEMBL4599	Homo sapiens	Residual Activity	%	45.0
	12221726	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	89.0	CHEMBL4599	Homo sapiens	Residual Activity	%	89.0
	12221727	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	24.0	CHEMBL4599	Homo sapiens	Residual Activity	%	24.0
	12221728	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	9.0	CHEMBL4599	Homo sapiens	Residual Activity	%	9.0
	12221729	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12221730	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221731	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12221732	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	78.0	CHEMBL4599	Homo sapiens	Residual Activity	%	78.0
	12221733	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	10.0	CHEMBL4599	Homo sapiens	Residual Activity	%	10.0
	12221734	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	29.0	CHEMBL4599	Homo sapiens	Residual Activity	%	29.0
	12221735	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221736	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	5.0	CHEMBL4599	Homo sapiens	Residual Activity	%	5.0
	12221737	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	14.0	CHEMBL4599	Homo sapiens	Residual Activity	%	14.0
	12221738	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	61.0	CHEMBL4599	Homo sapiens	Residual Activity	%	61.0
	12221739	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12221740	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221741	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	94.0	CHEMBL4599	Homo sapiens	Residual Activity	%	94.0
	12221742	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	63.0	CHEMBL4599	Homo sapiens	Residual Activity	%	63.0
	12221743	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12221744	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	63.0	CHEMBL4599	Homo sapiens	Residual Activity	%	63.0
	12221745	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	48.0	CHEMBL4599	Homo sapiens	Residual Activity	%	48.0
	12221746	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	51.0	CHEMBL4599	Homo sapiens	Residual Activity	%	51.0
	12221747	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	60.0	CHEMBL4599	Homo sapiens	Residual Activity	%	60.0
	12221748	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	88.0	CHEMBL4599	Homo sapiens	Residual Activity	%	88.0
	12221749	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	87.0	CHEMBL4599	Homo sapiens	Residual Activity	%	87.0
	12221750	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12221751	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	85.0	CHEMBL4599	Homo sapiens	Residual Activity	%	85.0
	12221752	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	82.0	CHEMBL4599	Homo sapiens	Residual Activity	%	82.0
	12221753	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	85.0	CHEMBL4599	Homo sapiens	Residual Activity	%	85.0
	12221754	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	81.0	CHEMBL4599	Homo sapiens	Residual Activity	%	81.0
	12221755	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	81.0	CHEMBL4599	Homo sapiens	Residual Activity	%	81.0
	12221756	CHEMBL2219371	Millipore: Percentage of residual kinase activity of TNK2 at 1uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	3.0	CHEMBL4599	Homo sapiens	Residual Activity	%	3.0
	12221757	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1cc(C=C(C#N)C#N)cc(Br)c1O		CHEMBL2218926	=	Residual Activity	%	73.0	CHEMBL4599	Homo sapiens	Residual Activity	%	73.0
	12221758	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12		CHEMBL266487	=	Residual Activity	%	21.0	CHEMBL4599	Homo sapiens	Residual Activity	%	21.0
	12221759	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1)C1CC1		CHEMBL387187	=	Residual Activity	%	26.0	CHEMBL4599	Homo sapiens	Residual Activity	%	26.0
	12221760	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(Cl)cc1NC(=O)Nc1cc(C)nc2ccccc12		CHEMBL439259	=	Residual Activity	%	80.0	CHEMBL4599	Homo sapiens	Residual Activity	%	80.0
	12221761	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CNc1cc2c(Nc3cccc(Br)c3)ncnc2cn1		CHEMBL53753	=	Residual Activity	%	11.0	CHEMBL4599	Homo sapiens	Residual Activity	%	11.0
	12221762	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL65063	=	Residual Activity	%	61.0	CHEMBL4599	Homo sapiens	Residual Activity	%	61.0
	12221763	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Residual Activity	%	36.0	CHEMBL4599	Homo sapiens	Residual Activity	%	36.0
	12221764	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC		CHEMBL7917	=	Residual Activity	%	6.0	CHEMBL4599	Homo sapiens	Residual Activity	%	6.0
	12221765	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc2cc3nc(-c4cccs4)cnc3cc2n1C		CHEMBL2218927	=	Residual Activity	%	74.0	CHEMBL4599	Homo sapiens	Residual Activity	%	74.0
	12221766	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1cnc2cc3c(Nc4cccc(Br)c4)ncnc3cc21		CHEMBL174426	=	Residual Activity	%	16.0	CHEMBL4599	Homo sapiens	Residual Activity	%	16.0
	12221767	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC#CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cn1		CHEMBL203644	=	Residual Activity	%	71.0	CHEMBL4599	Homo sapiens	Residual Activity	%	71.0
	12221768	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1nc2ccccc2n1CCN1CCOCC1)c1cccc([N+](=O)[O-])c1		CHEMBL379787	=	Residual Activity	%	55.0	CHEMBL4599	Homo sapiens	Residual Activity	%	55.0
	12221769	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCC(=O)Nc1ccc2ncnc(Nc3cccc(Br)c3)c2c1		CHEMBL188762	=	Residual Activity	%	36.0	CHEMBL4599	Homo sapiens	Residual Activity	%	36.0
	12221770	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)n1nc(Cc2cccc3ccccc23)c2c(N)ncnc21		CHEMBL573578	=	Residual Activity	%	2.0	CHEMBL4599	Homo sapiens	Residual Activity	%	2.0
	12221771	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NCCNc1ncc(C(N)=O)c(Nc2cccc(C(F)(F)F)c2)n1		CHEMBL471901	=	Residual Activity	%	16.0	CHEMBL4599	Homo sapiens	Residual Activity	%	16.0
	12221772	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccccc32)c1C		CHEMBL86943	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12221773	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC[n+]1c(/C=C/N(C)c2ccccc2)n(-c2ccccc2)c2ccc(-c3nc4ccccc4s3)cc21		CHEMBL1186409	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221774	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c[n+](C)c3c4cc5c(cc4ccc23)OCO5)c1OC		CHEMBL13045	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221775	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C(=O)Nc2sc3c(c2C(N)=O)CCCC3)cc1OC		CHEMBL210833	=	Residual Activity	%	54.0	CHEMBL4599	Homo sapiens	Residual Activity	%	54.0
	12221776	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)(C)c1nc2c3ccc(F)cc3c3c(=O)[nH]ccc3c2[nH]1		CHEMBL21156	=	Residual Activity	%	0.0	CHEMBL4599	Homo sapiens	Residual Activity	%	0.0
	12221777	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCC(=O)Oc1ccc2[nH]c(C(=O)c3cc4ccccc4[nH]3)cc2c1		CHEMBL266325	=	Residual Activity	%	65.0	CHEMBL4599	Homo sapiens	Residual Activity	%	65.0
	12221778	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2cc(Nc3ccc(F)cc3)c(Nc3ccc(F)cc3)cc21		CHEMBL7939	=	Residual Activity	%	34.0	CHEMBL4599	Homo sapiens	Residual Activity	%	34.0
	12221779	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])/C=C/c1ccc2c(c1)OCO2		CHEMBL596380	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12221780	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1ccc(Cl)cc1)c1ccccc1NCc1ccncc1		CHEMBL101683	=	Residual Activity	%	76.0	CHEMBL4599	Homo sapiens	Residual Activity	%	76.0
	12221781	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN1N=C(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL331237	=	Residual Activity	%	80.0	CHEMBL4599	Homo sapiens	Residual Activity	%	80.0
	12221782	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1cc2ncnc(Nc3cccc(Br)c3)c2cc1OCC		CHEMBL35820	=	Residual Activity	%	5.0	CHEMBL4599	Homo sapiens	Residual Activity	%	5.0
	12221783	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1cc2cc(O)ccc2[nH]1)c1cc2cc(O)ccc2[nH]1		CHEMBL377193	=	Residual Activity	%	24.0	CHEMBL4599	Homo sapiens	Residual Activity	%	24.0
	12221784	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(O)c(Br)c3)c2cc1OC		CHEMBL473773	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12221785	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(N3CCN(C(=O)Nc4ccc(Oc5ccccc5)cc4)CC3)c2cc1OC		CHEMBL102346	=	Residual Activity	%	54.0	CHEMBL4599	Homo sapiens	Residual Activity	%	54.0
	12221786	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCn3ccnc3)c3ccccc23)=C1Nc1ccccc1		CHEMBL366266	=	Residual Activity	%	11.0	CHEMBL4599	Homo sapiens	Residual Activity	%	11.0
	12221787	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12221788	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	=	Residual Activity	%	6.0	CHEMBL4599	Homo sapiens	Residual Activity	%	6.0
	12221789	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1[nH]c2ccccc2n1C1CCN(Cc2ccc(-c3nc4cc5[nH]cnc5cc4nc3-c3ccccc3)cc2)CC1		CHEMBL258844	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221790	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12		CHEMBL104468	=	Residual Activity	%	77.0	CHEMBL4599	Homo sapiens	Residual Activity	%	77.0
	12221791	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221792	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1		CHEMBL596674	=	Residual Activity	%	63.0	CHEMBL4599	Homo sapiens	Residual Activity	%	63.0
	12221793	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2c(cc1OC)-c1n[nH]c(Nc3cccc(F)c3)c1C2		CHEMBL120077	=	Residual Activity	%	3.0	CHEMBL4599	Homo sapiens	Residual Activity	%	3.0
	12221794	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	=	Residual Activity	%	63.0	CHEMBL4599	Homo sapiens	Residual Activity	%	63.0
	12221795	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cccc(-c2[nH]c(C(C)(C)C)nc2-c2ccc3c(c2)OCO3)n1		CHEMBL226838	=	Residual Activity	%	67.0	CHEMBL4599	Homo sapiens	Residual Activity	%	67.0
	12221796	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Br)cc2/C1=C\c1cc2c([nH]1)CCCC2		CHEMBL2218925	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12221797	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc21		CHEMBL1398474	=	Residual Activity	%	81.0	CHEMBL4599	Homo sapiens	Residual Activity	%	81.0
	12221798	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)c1ccc(N2CCOCC2)cc1O		CHEMBL1317546	=	Residual Activity	%	73.0	CHEMBL4599	Homo sapiens	Residual Activity	%	73.0
	12221799	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	=	Residual Activity	%	0.0	CHEMBL4599	Homo sapiens	Residual Activity	%	0.0
	12221800	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(-c3cccnc3)cc2/C1=C\c1ccc[nH]1		CHEMBL2218929	=	Residual Activity	%	20.0	CHEMBL4599	Homo sapiens	Residual Activity	%	20.0
	12221801	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2nccc(Oc3ccc(NC(=S)NC(=O)c4ccccc4C)cc3)c2cc1OC		CHEMBL2218930	=	Residual Activity	%	8.0	CHEMBL4599	Homo sapiens	Residual Activity	%	8.0
	12221802	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc2c(-c3ccncc3)c[nH]c2c1		CHEMBL380071	=	Residual Activity	%	49.0	CHEMBL4599	Homo sapiens	Residual Activity	%	49.0
	12221803	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(C=C(C#N)C#N)cc1		CHEMBL77456	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12221804	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(C)c(/C=C2\C(=O)Nc3ccccc32)[nH]1		CHEMBL276711	=	Residual Activity	%	18.0	CHEMBL4599	Homo sapiens	Residual Activity	%	18.0
	12221805	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-c2nc3nnnn3nc21		CHEMBL599894	=	Residual Activity	%	80.0	CHEMBL4599	Homo sapiens	Residual Activity	%	80.0
	12221806	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12221807	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)c(C1=C(c3c[nH]c4ccccc34)C(=O)NC1=O)cn2CCCN(C)C		CHEMBL261491	=	Residual Activity	%	21.0	CHEMBL4599	Homo sapiens	Residual Activity	%	21.0
	12221808	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2C1CCCC1		CHEMBL47940	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12221809	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc3ncsc3c2/C1=C/c1c[nH]cn1		CHEMBL235641	=	Residual Activity	%	17.0	CHEMBL4599	Homo sapiens	Residual Activity	%	17.0
	12221810	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cncc2cccc(S(=O)(=O)N3CCCN(C(=O)CN)C[C@H]3C)c12		CHEMBL2218931	=	Residual Activity	%	21.0	CHEMBL4599	Homo sapiens	Residual Activity	%	21.0
	12221811	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C\c1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL56543	=	Residual Activity	%	62.0	CHEMBL4599	Homo sapiens	Residual Activity	%	62.0
	12221812	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(-c2cnc3c(-c4ccsc4)cnn3c2)cc1		CHEMBL92461	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12221813	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(NC(=O)c4ccccc4)cc3)c2cc1OC		CHEMBL382590	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12221814	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1c2ccccc2[nH]c(=S)n1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1		CHEMBL261131	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12221815	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2n[nH]c3c2oc2ccccc23)cc1		CHEMBL406375	=	Residual Activity	%	51.0	CHEMBL4599	Homo sapiens	Residual Activity	%	51.0
	12221816	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12		CHEMBL98350	=	Residual Activity	%	58.0	CHEMBL4599	Homo sapiens	Residual Activity	%	58.0
	12221817	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccc(Cl)cc2/C1=C/c1cc(Cl)c(O)c(Cl)c1		CHEMBL2218932	=	Residual Activity	%	7.0	CHEMBL4599	Homo sapiens	Residual Activity	%	7.0
	12221818	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Residual Activity	%	-1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	-1.0
	12221819	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CC(C#N)=C(N)/C(C#N)=C/c1ccc(O)cc1		CHEMBL76589	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12221820	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O		CHEMBL478980	=	Residual Activity	%	72.0	CHEMBL4599	Homo sapiens	Residual Activity	%	72.0
	12221821	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Residual Activity	%	86.0	CHEMBL4599	Homo sapiens	Residual Activity	%	86.0
	12221822	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)c1ccc(/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL328710	=	Residual Activity	%	62.0	CHEMBL4599	Homo sapiens	Residual Activity	%	62.0
	12221823	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CO[C@H]1/C=C/C=C(\C)C(=O)NC2=CC(=O)C=C(C2=O)[C@H](OC)[C@@H](C)C[C@H](OC)[C@H](OC)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O		CHEMBL479533	=	Residual Activity	%	72.0	CHEMBL4599	Homo sapiens	Residual Activity	%	72.0
	12221824	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(N2CCNCC2)oc2c(-c3ccccc3)cccc12		CHEMBL1363184	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12221825	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C\c2ccc3nccnc3c2)S1		CHEMBL2218934	=	Residual Activity	%	66.0	CHEMBL4599	Homo sapiens	Residual Activity	%	66.0
	12221826	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2cc1OC		CHEMBL97771	=	Residual Activity	%	9.0	CHEMBL4599	Homo sapiens	Residual Activity	%	9.0
	12221827	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc2ncc(-c3ccccc3)nc2cc1C		CHEMBL7724	=	Residual Activity	%	59.0	CHEMBL4599	Homo sapiens	Residual Activity	%	59.0
	12221828	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1		CHEMBL383899	=	Residual Activity	%	5.0	CHEMBL4599	Homo sapiens	Residual Activity	%	5.0
	12221829	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)CCCn1cc(C2=C(c3c[nH]c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL7463	=	Residual Activity	%	45.0	CHEMBL4599	Homo sapiens	Residual Activity	%	45.0
	12221830	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2cc1OC		CHEMBL563845	=	Residual Activity	%	10.0	CHEMBL4599	Homo sapiens	Residual Activity	%	10.0
	12221831	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1ccc(-c2cnc(Nc3ccc(OCCN4CCCC4)cc3)s2)cc1		CHEMBL2218935	=	Residual Activity	%	16.0	CHEMBL4599	Homo sapiens	Residual Activity	%	16.0
	12221832	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC1=C(C(=O)N2CCN(C)CC2)C(C)=C(/C=C2\C(=O)Nc3ccc(S(=O)(=O)N(C)c4cccc(Cl)c4)cc32)C1		CHEMBL2218936	=	Residual Activity	%	29.0	CHEMBL4599	Homo sapiens	Residual Activity	%	29.0
	12221833	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)/C(=C/c2ccc3c(c2)OC(F)(F)O3)S1		CHEMBL1231533	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12221834	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(Cl)cc32)c1C		CHEMBL13485	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12221835	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc2ncc(-c3ccccc3)nc2cc1OC		CHEMBL71191	=	Residual Activity	%	56.0	CHEMBL4599	Homo sapiens	Residual Activity	%	56.0
	12221836	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Residual Activity	%	-1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	-1.0
	12221837	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN([C@@H](Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N1CCN(c2ccccc2)CC1)S(=O)(=O)c1cccc2cnccc12		CHEMBL28324	=	Residual Activity	%	87.0	CHEMBL4599	Homo sapiens	Residual Activity	%	87.0
	12221838	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	=	Residual Activity	%	9.0	CHEMBL4599	Homo sapiens	Residual Activity	%	9.0
	12221839	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1c1[nH]c3cc(Br)ccc3c21		CHEMBL64758	=	Residual Activity	%	61.0	CHEMBL4599	Homo sapiens	Residual Activity	%	61.0
	12221840	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[C@@H](N)[C@H]1CC[C@H](C(=O)Nc2ccncc2)CC1		CHEMBL559147	=	Residual Activity	%	95.0	CHEMBL4599	Homo sapiens	Residual Activity	%	95.0
	12221841	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cc3c([nH]1)CCCC3)C(=O)N2		CHEMBL605003	=	Residual Activity	%	8.0	CHEMBL4599	Homo sapiens	Residual Activity	%	8.0
	12224202	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(CCCc1ccc(-c2ccccc2F)cc1)Nc1ccc(O)cc1		CHEMBL235658	=	Residual Activity	%	75.0	CHEMBL4599	Homo sapiens	Residual Activity	%	75.0
	12224203	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1		CHEMBL111364	=	Residual Activity	%	50.0	CHEMBL4599	Homo sapiens	Residual Activity	%	50.0
	12224204	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	=	Residual Activity	%	39.0	CHEMBL4599	Homo sapiens	Residual Activity	%	39.0
	12224205	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1		CHEMBL222102	=	Residual Activity	%	84.0	CHEMBL4599	Homo sapiens	Residual Activity	%	84.0
	12224206	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=Nc1c(-c2c(O)[nH]c3ccccc23)[nH]c2ccccc12		CHEMBL126077	=	Residual Activity	%	4.0	CHEMBL4599	Homo sapiens	Residual Activity	%	4.0
	12224207	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(OC)c2c(=S)c3ccccc3[nH]c12		CHEMBL1331734	=	Residual Activity	%	57.0	CHEMBL4599	Homo sapiens	Residual Activity	%	57.0
	12224208	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL259551	=	Residual Activity	%	29.0	CHEMBL4599	Homo sapiens	Residual Activity	%	29.0
	12224209	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1cc(Nc2nc(-c3ccccc3)nc3ccccc23)n[nH]1		CHEMBL359482	=	Residual Activity	%	0.0	CHEMBL4599	Homo sapiens	Residual Activity	%	0.0
	12224210	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	=	Residual Activity	%	58.0	CHEMBL4599	Homo sapiens	Residual Activity	%	58.0
	12224211	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1ccc(Cl)cc1		CHEMBL91730	=	Residual Activity	%	66.0	CHEMBL4599	Homo sapiens	Residual Activity	%	66.0
	12224212	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	=	Residual Activity	%	85.0	CHEMBL4599	Homo sapiens	Residual Activity	%	85.0
	12224213	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(NC(NC(=S)Nc1ccc(F)c([N+](=O)[O-])c1)C(Cl)(Cl)Cl)C(c1ccccc1)c1ccccc1		CHEMBL1221601	=	Residual Activity	%	78.0	CHEMBL4599	Homo sapiens	Residual Activity	%	78.0
	12224214	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(S(=O)(=O)/C=C/C#N)cc1		CHEMBL403183	=	Residual Activity	%	75.0	CHEMBL4599	Homo sapiens	Residual Activity	%	75.0
	12224215	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1ccc(NC2=CC(=O)c3sc(C)nc3C2=O)cc1		CHEMBL290904	=	Residual Activity	%	71.0	CHEMBL4599	Homo sapiens	Residual Activity	%	71.0
	12224216	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4ccccc34)cc12		CHEMBL2218938	=	Residual Activity	%	14.0	CHEMBL4599	Homo sapiens	Residual Activity	%	14.0
	12224217	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3[nH]c1n1cncc21		CHEMBL413188	=	Residual Activity	%	23.0	CHEMBL4599	Homo sapiens	Residual Activity	%	23.0
	12224218	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Residual Activity	%	0.0	CHEMBL4599	Homo sapiens	Residual Activity	%	0.0
	12224219	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cccc(-c2cc(=O)c3ccccc3o2)c1N		CHEMBL35482	=	Residual Activity	%	70.0	CHEMBL4599	Homo sapiens	Residual Activity	%	70.0
	12224220	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)c2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCC3O1		CHEMBL304428	=	Residual Activity	%	13.0	CHEMBL4599	Homo sapiens	Residual Activity	%	13.0
	12224221	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Residual Activity	%	24.0	CHEMBL4599	Homo sapiens	Residual Activity	%	24.0
	12224222	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCO)nc21		CHEMBL83980	=	Residual Activity	%	58.0	CHEMBL4599	Homo sapiens	Residual Activity	%	58.0
	12224223	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN1/C(=C/C(C)=O)Sc2ccc(OC)cc21		CHEMBL408982	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12224224	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1c2ccccc2-[n+]2ccc3c([nH]c4ccccc43)c21		CHEMBL602937	=	Residual Activity	%	55.0	CHEMBL4599	Homo sapiens	Residual Activity	%	55.0
	12224225	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1cc(OC)c(/C=C2\C(=O)Nc3ccccc32)c(OC)c1		CHEMBL404941	=	Residual Activity	%	56.0	CHEMBL4599	Homo sapiens	Residual Activity	%	56.0
	12224226	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Residual Activity	%	3.0	CHEMBL4599	Homo sapiens	Residual Activity	%	3.0
	12224227	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=[N+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17331	=	Residual Activity	%	11.0	CHEMBL4599	Homo sapiens	Residual Activity	%	11.0
	12224228	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cc1nc(-c2ccccc2)c(-c2ccncc2)o1		CHEMBL36450	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12224229	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#CCCc1ccc2c(c1)-c1[nH]c3ccc([N+](=O)[O-])cc3c1CC(=O)N2		CHEMBL260138	=	Residual Activity	%	13.0	CHEMBL4599	Homo sapiens	Residual Activity	%	13.0
	12224230	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C\c1c(Cl)[nH]c2ccccc12		CHEMBL261425	=	Residual Activity	%	48.0	CHEMBL4599	Homo sapiens	Residual Activity	%	48.0
	12224231	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	=	Residual Activity	%	61.0	CHEMBL4599	Homo sapiens	Residual Activity	%	61.0
	12224232	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1sc(=O)n(Cc2ccccc2)c1=O		CHEMBL284861	=	Residual Activity	%	64.0	CHEMBL4599	Homo sapiens	Residual Activity	%	64.0
	12224233	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167	=	Residual Activity	%	2.0	CHEMBL4599	Homo sapiens	Residual Activity	%	2.0
	12224234	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(S(=O)(=O)N(CCO)c2ccccc2CN(C)C/C=C/c2ccc(Cl)cc2)cc1		CHEMBL155333	=	Residual Activity	%	60.0	CHEMBL4599	Homo sapiens	Residual Activity	%	60.0
	12224235	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Residual Activity	%	39.0	CHEMBL4599	Homo sapiens	Residual Activity	%	39.0
	12224236	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL313417	=	Residual Activity	%	79.0	CHEMBL4599	Homo sapiens	Residual Activity	%	79.0
	12224237	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	=	Residual Activity	%	6.0	CHEMBL4599	Homo sapiens	Residual Activity	%	6.0
	12224238	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCn1cnc2c(Nc3cccc(Cl)c3)nc(N[C@@H]3CCCC[C@@H]3N)nc21		CHEMBL367625	=	Residual Activity	%	4.0	CHEMBL4599	Homo sapiens	Residual Activity	%	4.0
	12224239	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)n1cnc2/c(=N/c3cccc(Cl)c3)nc(NCCO)[nH]c21		CHEMBL311228	=	Residual Activity	%	5.0	CHEMBL4599	Homo sapiens	Residual Activity	%	5.0
	12224240	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Ic1cccc(CSc2nnc(-c3ccncc3)o2)c1		CHEMBL288064	=	Residual Activity	%	60.0	CHEMBL4599	Homo sapiens	Residual Activity	%	60.0
	12224241	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2ccccc2/C1=C1/Nc2ccccc2/C1=N\OCCC(O)CO		CHEMBL1802727	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12224242	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(/N)SC1C=CC=CC1)c1cccc(C(O)c2ccncc2)c1		CHEMBL2218939	=	Residual Activity	%	65.0	CHEMBL4599	Homo sapiens	Residual Activity	%	65.0
	12224243	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cccc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL23327	=	Residual Activity	%	14.0	CHEMBL4599	Homo sapiens	Residual Activity	%	14.0
	12224244	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(Nc2nc(-c3ccc(Cl)cc3)cs2)cc1		CHEMBL1076555	=	Residual Activity	%	80.0	CHEMBL4599	Homo sapiens	Residual Activity	%	80.0
	12224245	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCCCc1c(-c2ccc(OC)cc2)[nH]c2nccnc12		CHEMBL306498	=	Residual Activity	%	5.0	CHEMBL4599	Homo sapiens	Residual Activity	%	5.0
	12224246	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=S)Nc1c(F)cccc1F		CHEMBL261720	=	Residual Activity	%	0.0	CHEMBL4599	Homo sapiens	Residual Activity	%	0.0
	12224247	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNc2nc(N(CCO)CCO)nc3c2ncn3C(C)C)cc1		CHEMBL80713	=	Residual Activity	%	51.0	CHEMBL4599	Homo sapiens	Residual Activity	%	51.0
	12224248	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	=	Residual Activity	%	55.0	CHEMBL4599	Homo sapiens	Residual Activity	%	55.0
	12224249	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Residual Activity	%	12.0	CHEMBL4599	Homo sapiens	Residual Activity	%	12.0
	12224250	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1C(Cl)=C(N2C(=O)CCC2=O)C(=O)c2ccccc21		CHEMBL404939	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12224251	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1cccc(-c2cc3c(Oc4cccc(O)c4)ncnc3[nH]2)c1		CHEMBL405759	=	Residual Activity	%	-1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	-1.0
	12224252	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)[C@H](CO)Nc1nc(Nc2cc(N)cc(Cl)c2)c2ncn(C(C)C)c2n1		CHEMBL286721	=	Residual Activity	%	9.0	CHEMBL4599	Homo sapiens	Residual Activity	%	9.0
	12224253	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1n[nH]c2nc3ccccc3nc12		CHEMBL259389	=	Residual Activity	%	40.0	CHEMBL4599	Homo sapiens	Residual Activity	%	40.0
	12224254	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCN(CC)C(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1		CHEMBL1802728	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12224255	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1Nc2cc(Br)ccc2/C1=C1/Nc2ccccc2/C1=N\O		CHEMBL409450	=	Residual Activity	%	2.0	CHEMBL4599	Homo sapiens	Residual Activity	%	2.0
	12224256	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Cn1nc2c3c(cccc31)C(=O)c1ccccc1-2		CHEMBL1802485	=	Residual Activity	%	31.0	CHEMBL4599	Homo sapiens	Residual Activity	%	31.0
	12224257	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C(\N)Sc1ccc(N)cc1)c1ccccc1C(F)(F)F		CHEMBL2218940	=	Residual Activity	%	43.0	CHEMBL4599	Homo sapiens	Residual Activity	%	43.0
	12224258	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=S(=O)(NCCNC/C=C/c1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL104264	=	Residual Activity	%	43.0	CHEMBL4599	Homo sapiens	Residual Activity	%	43.0
	12224259	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)c1ccc2c3c1cccc3c(=O)n1c3ccccc3nc21		CHEMBL1182777	=	Residual Activity	%	75.0	CHEMBL4599	Homo sapiens	Residual Activity	%	75.0
	12224260	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)ccn1		CHEMBL478629	=	Residual Activity	%	18.0	CHEMBL4599	Homo sapiens	Residual Activity	%	18.0
	12224261	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	NC(=O)c1ccc(-c2nc(-c3ccc4c(c3)OCCO4)c(-c3ccccn3)[nH]2)cc1		CHEMBL410456	=	Residual Activity	%	68.0	CHEMBL4599	Homo sapiens	Residual Activity	%	68.0
	12224262	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(C)c1nn(-c2c(Cl)cccc2Cl)c2nc(Cc3ccc(OCCO)cc3)[nH]c(=O)c12		CHEMBL258721	=	Residual Activity	%	31.0	CHEMBL4599	Homo sapiens	Residual Activity	%	31.0
	12224263	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CC(=O)O/N=C1C(=C2\C(=O)Nc3cc(Br)ccc32)\Nc2ccccc2\1		CHEMBL2218941	=	Residual Activity	%	15.0	CHEMBL4599	Homo sapiens	Residual Activity	%	15.0
	12224264	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#C/C(=C1/Nc2ccccc2S1)c1ccnc(NCCc2cccnc2)n1		CHEMBL191384	=	Residual Activity	%	12.0	CHEMBL4599	Homo sapiens	Residual Activity	%	12.0
	12224265	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ncnc2[nH]nc(Nc3ccc(F)cc3)c12		CHEMBL1240885	=	Residual Activity	%	17.0	CHEMBL4599	Homo sapiens	Residual Activity	%	17.0
	12224266	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	CCc1nc(-c2ccc(OC)cc2)[nH]c1-c1ccncc1		CHEMBL278724	=	Residual Activity	%	69.0	CHEMBL4599	Homo sapiens	Residual Activity	%	69.0
	12224267	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	COc1ccc2c(c1)/C(=C/c1cnc[nH]1)C(=O)N2		CHEMBL258805	=	Residual Activity	%	44.0	CHEMBL4599	Homo sapiens	Residual Activity	%	44.0
	12224268	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Residual Activity	%	63.0	CHEMBL4599	Homo sapiens	Residual Activity	%	63.0
	12224269	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N/C(=N\[N+](=O)[O-])N/N=C\c1ccc(-c2cccc([N+](=O)[O-])c2)o1		CHEMBL221271	=	Residual Activity	%	71.0	CHEMBL4599	Homo sapiens	Residual Activity	%	71.0
	12224270	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	O=C1NC(=O)C(c2cn(CCCO)c3ncccc23)=C1c1cnccn1		CHEMBL272629	=	Residual Activity	%	71.0	CHEMBL4599	Homo sapiens	Residual Activity	%	71.0
	12224271	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Residual Activity	%	61.0	CHEMBL4599	Homo sapiens	Residual Activity	%	61.0
	12224272	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1		CHEMBL522502	=	Residual Activity	%	55.0	CHEMBL4599	Homo sapiens	Residual Activity	%	55.0
	12224273	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	=	Residual Activity	%	27.0	CHEMBL4599	Homo sapiens	Residual Activity	%	27.0
	12224274	CHEMBL2219372	Millipore: Percentage of residual kinase activity of TNK2 at 10uM relative to control. Control inhibitor: Staurosporine at 10.0uM. Buffer: 8 mM MOPS pH 7.0, 0.2 mM EDTA	B	N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1		CHEMBL200381	=	Residual Activity	%	1.0	CHEMBL4599	Homo sapiens	Residual Activity	%	1.0
	12660164	CHEMBL2329217	Inhibition of ACK1 (unknown origin) at 1 uM	B	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL2325940	=	Inhibition	%	100.0	CHEMBL4599	Homo sapiens	INH	%	100.0
	12660222	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL2325940	=	IC50	nM	35.0	CHEMBL4599	Homo sapiens	IC50	uM	0.035
	12660223	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(F)c3F)c3c(N)nccn32)C1		CHEMBL2325939	=	IC50	nM	51.0	CHEMBL4599	Homo sapiens	IC50	uM	0.051
	12660224	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL2325938	=	IC50	nM	84.0	CHEMBL4599	Homo sapiens	IC50	uM	0.084
	12660225	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(F)(F)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325937	=	IC50	nM	170.0	CHEMBL4599	Homo sapiens	IC50	uM	0.17
	12660226	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Cc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325936	=	IC50	nM	58.0	CHEMBL4599	Homo sapiens	IC50	uM	0.058
	12660227	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)cc3F)c3c(N)nccn32)C1		CHEMBL2325960	=	IC50	nM	28.0	CHEMBL4599	Homo sapiens	IC50	uM	0.028
	12660228	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL2325959	=	IC50	nM	29.0	CHEMBL4599	Homo sapiens	IC50	uM	0.029
	12660229	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c(F)c3)c3c(N)nccn32)C1		CHEMBL2325958	=	IC50	nM	30.0	CHEMBL4599	Homo sapiens	IC50	uM	0.03
	12660230	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL2325940	=	IC50	nM	110.0	CHEMBL4599	Homo sapiens	IC50	uM	0.11
	12660231	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(F)c3F)c3c(N)nccn32)C1		CHEMBL2325939	=	IC50	nM	130.0	CHEMBL4599	Homo sapiens	IC50	uM	0.13
	12660232	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL2325938	=	IC50	nM	220.0	CHEMBL4599	Homo sapiens	IC50	uM	0.22
	12660233	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(F)(F)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325937	=	IC50	nM	450.0	CHEMBL4599	Homo sapiens	IC50	uM	0.45
	12660234	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Cc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325936	=	IC50	nM	230.0	CHEMBL4599	Homo sapiens	IC50	uM	0.23
	12660235	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)cc3F)c3c(N)nccn32)C1		CHEMBL2325960	=	IC50	nM	88.0	CHEMBL4599	Homo sapiens	IC50	uM	0.088
	12660236	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL2325959	=	IC50	nM	110.0	CHEMBL4599	Homo sapiens	IC50	uM	0.11
	12660237	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c(F)c3)c3c(N)nccn32)C1		CHEMBL2325958	=	IC50	nM	140.0	CHEMBL4599	Homo sapiens	IC50	uM	0.14
	12660238	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325957	=	IC50	nM	160.0	CHEMBL4599	Homo sapiens	IC50	uM	0.16
	12660239	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4csc5ccccc45)cc3)c12		CHEMBL2325956	=	IC50	nM	4090.0	CHEMBL4599	Homo sapiens	IC50	uM	4.09
	12660240	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc4c(c3)ncn4-c3ccccc3)c12		CHEMBL2325955	=	IC50	nM	3350.0	CHEMBL4599	Homo sapiens	IC50	uM	3.35
	12660241	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL2325954	=	IC50	nM	90.0	CHEMBL4599	Homo sapiens	IC50	uM	0.09
	12660242	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(O)c4ccccc4)cc3)c12		CHEMBL2325953	=	IC50	nM	280.0	CHEMBL4599	Homo sapiens	IC50	uM	0.28
	12660243	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)cc3)c12		CHEMBL2325952	=	IC50	nM	87.0	CHEMBL4599	Homo sapiens	IC50	uM	0.087
	12660244	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Cc4ccccc4)cc3)c12		CHEMBL2325951	=	IC50	nM	570.0	CHEMBL4599	Homo sapiens	IC50	uM	0.57
	12660245	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Nc4ccccc4)cc3)c12		CHEMBL2325950	=	IC50	nM	380.0	CHEMBL4599	Homo sapiens	IC50	uM	0.38
	12660246	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Sc4ccccc4)cc3)c12		CHEMBL2325949	=	IC50	nM	330.0	CHEMBL4599	Homo sapiens	IC50	uM	0.33
	12660247	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	CCOc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL2325948	=	IC50	nM	470.0	CHEMBL4599	Homo sapiens	IC50	uM	0.47
	12660248	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	COc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL2325947	=	IC50	nM	75.0	CHEMBL4599	Homo sapiens	IC50	uM	0.075
	12660249	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3Cl)c12		CHEMBL2325946	=	IC50	nM	1060.0	CHEMBL4599	Homo sapiens	IC50	uM	1.06
	12660250	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Cc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL2325945	=	IC50	nM	370.0	CHEMBL4599	Homo sapiens	IC50	uM	0.37
	12660251	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3F)c12		CHEMBL2325944	=	IC50	nM	220.0	CHEMBL4599	Homo sapiens	IC50	uM	0.22
	12660252	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccn(Cc4ccccc4)c(=O)c3)c12		CHEMBL2325943	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	12660253	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	NC(=O)c1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325942	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	12660254	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	CC(=O)Nc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325941	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	12660255	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Cc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325974	=	IC50	nM	6280.0	CHEMBL4599	Homo sapiens	IC50	uM	6.28
	12660256	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(Cl)c3)c12		CHEMBL2325973	=	IC50	nM	1690.0	CHEMBL4599	Homo sapiens	IC50	uM	1.69
	12660257	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(F)c3)c12		CHEMBL2325972	=	IC50	nM	88.0	CHEMBL4599	Homo sapiens	IC50	uM	0.088
	12660258	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325971	=	IC50	nM	48.0	CHEMBL4599	Homo sapiens	IC50	uM	0.048
	12660259	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccn4)cc3)c12		CHEMBL2325970	=	IC50	nM	1900.0	CHEMBL4599	Homo sapiens	IC50	uM	1.9
	12660260	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c12		CHEMBL2325969	=	IC50	nM	1870.0	CHEMBL4599	Homo sapiens	IC50	uM	1.87
	12660261	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Cc1ccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)cc1		CHEMBL2325968	=	IC50	nM	900.0	CHEMBL4599	Homo sapiens	IC50	uM	0.9
	12660262	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc(F)cc4)cc3)c12		CHEMBL2325967	=	IC50	nM	5460.0	CHEMBL4599	Homo sapiens	IC50	uM	5.46
	12660263	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(Cl)c4)cc3)c12		CHEMBL2325966	=	IC50	nM	3190.0	CHEMBL4599	Homo sapiens	IC50	uM	3.19
	12660264	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Cc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL2325965	=	IC50	nM	240.0	CHEMBL4599	Homo sapiens	IC50	uM	0.24
	12660265	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(F)c4)cc3)c12		CHEMBL2325964	=	IC50	nM	110.0	CHEMBL4599	Homo sapiens	IC50	uM	0.11
	12660266	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4Cl)cc3)c12		CHEMBL2325963	=	IC50	nM	740.0	CHEMBL4599	Homo sapiens	IC50	uM	0.74
	12660267	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Cc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL2325962	=	IC50	nM	240.0	CHEMBL4599	Homo sapiens	IC50	uM	0.24
	12660268	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4F)cc3)c12		CHEMBL2325961	=	IC50	nM	100.0	CHEMBL4599	Homo sapiens	IC50	uM	0.1
	12660269	CHEMBL2329236	Inhibition of ACK1 (unknown origin) by biochemical assay	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL245408	=	IC50	nM	190.0	CHEMBL4599	Homo sapiens	IC50	uM	0.19
	12660270	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247070	=	IC50	nM	620.0	CHEMBL4599	Homo sapiens	IC50	uM	0.62
	12660271	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	c1ccc(-c2c(-c3ccc(OCCN4CCCC4)cc3)[nH]c3ncnc(NCC4SCCS4)c23)cc1		CHEMBL2087875	=	IC50	nM	10.0	CHEMBL4599	Homo sapiens	IC50	nM	10.0
	12660272	CHEMBL2329235	Inhibition of ACK1 (unknown origin) by cellular mechanistic assay	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(OCCN4CCCC4)c(F)c3)nc21		CHEMBL502156	=	IC50	nM	20.0	CHEMBL4599	Homo sapiens	IC50	nM	20.0
	12693261	CHEMBL2343946	Inhibition of ACK1 (unknown origin)	B	Cc1c(C(=O)N2CCOc3ccc(-c4ccc(N)nc4)cc3C2)ccc(S(C)(=O)=O)c1F		CHEMBL2333365	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
	13301300	CHEMBL2382837	Inhibition of ACK1 (unknown origin)	B	O=C(Nc1ccc(Nc2ccnc3[nH]c(=O)c4ccccc4c23)cc1)c1ccccc1		CHEMBL2380845	=	IC50	nM	149.0	CHEMBL4599	Homo sapiens	IC50	nM	149.0
	13374321	CHEMBL2405486	Inhibition of TNK2 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	13439736	CHEMBL2428861	Competitive binding affinity to TNK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	13442601	CHEMBL2428861	Competitive binding affinity to TNK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	13445569	CHEMBL2428861	Competitive binding affinity to TNK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	13448733	CHEMBL2428029	Competitive binding affinity to ACK1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	13451528	CHEMBL2428029	Competitive binding affinity to ACK1 (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	13451556	CHEMBL2428861	Competitive binding affinity to TNK2 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	13507663	CHEMBL2444021	Inhibition of ACK1 (unknown origin)	B	CN(C)c1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C4CCC5(CC4)OCCO5)CC3)no2)cc1		CHEMBL2443026	>	IC50	nM	10.0	CHEMBL4599	Homo sapiens	IC50	nM	10.0
	13507664	CHEMBL2444021	Inhibition of ACK1 (unknown origin)	B	CC(C)Nc1ccc(Oc2cc(O)cc(O)c2-c2cc(C(=O)NC3CCN(C)CC3)no2)cc1		CHEMBL2443139	>	IC50	nM	10.0	CHEMBL4599	Homo sapiens	IC50	nM	10.0
	13507665	CHEMBL2444021	Inhibition of ACK1 (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc(N(C)C)cc3)on2)CC1		CHEMBL2443138	>	IC50	nM	10.0	CHEMBL4599	Homo sapiens	IC50	nM	10.0
	13507666	CHEMBL2444021	Inhibition of ACK1 (unknown origin)	B	CN1CCC(NC(=O)c2cc(-c3c(O)cc(O)cc3Oc3ccc([N+](=O)[O-])cc3)on2)CC1		CHEMBL2443044	>	IC50	nM	10.0	CHEMBL4599	Homo sapiens	IC50	nM	10.0
	13872211	CHEMBL3102398	Inhibition of human ACK1 assessed as residual activity at 1 uM relative to control	B	O=C1Nc2ncccc2/C1=C1/Nc2ncccc2C1=O		CHEMBL3099673	=	Activity	%	97.0	CHEMBL4599	Homo sapiens	Activity	%	97.0
	13941190	CHEMBL3129255	Inhibition of TNK2 (unknown origin) using Km levels of ATP	B	Cc1nc([C@](C)(O)CO)sc1-c1cnc(N)c(O[C@H](C)c2cc(F)ccc2-n2nccn2)c1		CHEMBL3128069	=	IC50	nM	15.0	CHEMBL4599	Homo sapiens	IC50	nM	15.0
	14545788	CHEMBL3224496	Inhibition of ACK1 (unknown origin) assessed as residual activity at 1 uM	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	Activity	%	96.9	CHEMBL4599	Homo sapiens	Activity	%	96.9
	14545811	CHEMBL3224478	Inhibition of ACK1 (unknown origin)	B	CS(=O)(=O)O.O=C(NCc1cccc(O)c1)Nc1nc(-c2ccncc2)cs1		CHEMBL3218297	=	IC50	nM	14.27	CHEMBL4599	Homo sapiens	IC50	nM	14.27
	14585344	CHEMBL3240761	Inhibition of human TNK2 assessed as enzyme activity at 1 uM relative to control	B	CCCS(=O)(=O)Nc1cccc(Nc2ccc3ncn(C)c(=O)c3c2)c1C#N		CHEMBL3236464	=	Activity	%	104.0	CHEMBL4599	Homo sapiens	Activity	%	104.0
	14722522	CHEMBL3293406	Inhibition of TNK2 (unknown origin) by TR-FRET-based Z'-LYTE assay	B	C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21		CHEMBL3286830	=	IC50	nM	17.0	CHEMBL4599	Homo sapiens	IC50	nM	17.0
	14751161	CHEMBL3301294	Inhibition of ACK1 (unknown origin)	B	CC(C)(C)CNC(=O)CC1CNC(=O)c2cc(-c3ccsc3)cn21		CHEMBL3298400	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	14751162	CHEMBL3301294	Inhibition of ACK1 (unknown origin)	B	CN1CCN(C[C@@H](NC(=O)C[C@H]2CNC(=O)c3cc(-c4cccc(Cl)c4)cn32)C2CCCCC2)CC1		CHEMBL3297762	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15036708	CHEMBL3381057	Inhibition of ACK1 (unknown origin)	B	Nc1nc2c3c(F)cccc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309990	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15036709	CHEMBL3381057	Inhibition of ACK1 (unknown origin)	B	Nc1ccc2c(c1)nc(Cc1ccc3c(c1)OCO3)n1nc(N)nc21		CHEMBL3309995	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15036710	CHEMBL3381057	Inhibition of ACK1 (unknown origin)	B	OCCCNc1ccc2c(c1)nc(-c1ccc3c(c1)OCO3)n1ncnc21		CHEMBL3309997	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15036711	CHEMBL3381057	Inhibition of ACK1 (unknown origin)	B	Nc1nc2c3ccc(NCCO)cc3nc(Cc3ccc4c(c3)OCO4)n2n1		CHEMBL3309998	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15036712	CHEMBL3381057	Inhibition of ACK1 (unknown origin)	B	CN1CCN(c2cc(F)c3c(c2)nc(Cc2ccc4c(c2)OCO4)n2nc(N)nc32)CC1		CHEMBL3310151	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15249205	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426871	=	Inhibition	%	90.5	CHEMBL4599	Homo sapiens	INH	%	90.5
	15249206	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426870	=	Inhibition	%	89.5	CHEMBL4599	Homo sapiens	INH	%	89.5
	15249207	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Brc1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426869	=	Inhibition	%	85.5	CHEMBL4599	Homo sapiens	INH	%	85.5
	15249208	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Clc1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426868	=	Inhibition	%	82.0	CHEMBL4599	Homo sapiens	INH	%	82.0
	15249209	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1		CHEMBL3426867	=	Inhibition	%	82.0	CHEMBL4599	Homo sapiens	INH	%	82.0
	15249210	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Brc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1		CHEMBL3426866	=	Inhibition	%	89.0	CHEMBL4599	Homo sapiens	INH	%	89.0
	15249211	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Clc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1		CHEMBL3426865	=	Inhibition	%	89.0	CHEMBL4599	Homo sapiens	INH	%	89.0
	15249212	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	COc1ccc(Nc2ncc(C(=O)Nc3c(F)cccc3Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426864	=	Inhibition	%	68.0	CHEMBL4599	Homo sapiens	INH	%	68.0
	15249213	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	COc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1		CHEMBL3426863	=	Inhibition	%	67.0	CHEMBL4599	Homo sapiens	INH	%	67.0
	15249214	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cc1cc(Nc2ncc(Br)c(NCC3CCCO3)n2)ccc1O		CHEMBL3426862	=	Inhibition	%	75.5	CHEMBL4599	Homo sapiens	INH	%	75.5
	15249215	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(O)cc2)nc1NCC1CCCO1		CHEMBL3426861	=	Inhibition	%	85.0	CHEMBL4599	Homo sapiens	INH	%	85.0
	15249216	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Oc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1		CHEMBL3426860	=	Inhibition	%	83.0	CHEMBL4599	Homo sapiens	INH	%	83.0
	15249217	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Oc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426859	=	Inhibition	%	65.0	CHEMBL4599	Homo sapiens	INH	%	65.0
	15249218	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(O)c(F)c2)nc1NCC1CCCO1		CHEMBL3426858	=	Inhibition	%	66.0	CHEMBL4599	Homo sapiens	INH	%	66.0
	15249219	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Oc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1F		CHEMBL3426857	=	Inhibition	%	76.0	CHEMBL4599	Homo sapiens	INH	%	76.0
	15249220	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cc1cnc(Nc2ccc(O)c(F)c2)nc1NCC1CCCO1		CHEMBL3426856	=	Inhibition	%	49.0	CHEMBL4599	Homo sapiens	INH	%	49.0
	15249221	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Oc1ccc(Nc2ncc(F)c(NCC3CCCO3)n2)cc1F		CHEMBL3426855	=	Inhibition	%	41.0	CHEMBL4599	Homo sapiens	INH	%	41.0
	15249222	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	O=C(O)C1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426889	=	Inhibition	%	83.3	CHEMBL4599	Homo sapiens	INH	%	83.3
	15249223	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	CN1CCN(c2ccc(Nc3ncc(Br)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426872	=	Inhibition	%	93.0	CHEMBL4599	Homo sapiens	INH	%	93.0
	15249224	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	CN1CCN(c2ccc(Nc3ncc(C(=O)Nc4c(F)cccc4Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426873	=	Inhibition	%	97.0	CHEMBL4599	Homo sapiens	INH	%	97.0
	15249225	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	CN1CCN(c2ccc(Nc3nccc(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426854	=	Inhibition	%	16.0	CHEMBL4599	Homo sapiens	INH	%	16.0
	15249226	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Clc1cnc(Nc2ccc(C3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426874	=	Inhibition	%	79.5	CHEMBL4599	Homo sapiens	INH	%	79.5
	15249227	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Brc1cnc(Nc2ccc(C3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426875	=	Inhibition	%	84.5	CHEMBL4599	Homo sapiens	INH	%	84.5
	15249228	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(C3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426876	=	Inhibition	%	97.0	CHEMBL4599	Homo sapiens	INH	%	97.0
	15249229	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(O)C1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426877	=	Inhibition	%	93.0	CHEMBL4599	Homo sapiens	INH	%	93.0
	15249230	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(O)C1CCN(c2ccc(Nc3ncc(Br)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426878	=	Inhibition	%	85.0	CHEMBL4599	Homo sapiens	INH	%	85.0
	15249231	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCC(C(=O)O)CC3)cc2)nc1NCC1CCCO1		CHEMBL3426879	=	Inhibition	%	98.0	CHEMBL4599	Homo sapiens	INH	%	98.0
	15249232	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	CCCC(=O)N1CCN(c2ccc(Nc3ncc(C(=O)Nc4c(F)cccc4Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426880	=	Inhibition	%	89.0	CHEMBL4599	Homo sapiens	INH	%	89.0
	15249233	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cl.O=C(O)CCc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426881	=	Inhibition	%	74.0	CHEMBL4599	Homo sapiens	INH	%	74.0
	15249234	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cl.O=C(O)CCCc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426882	=	Inhibition	%	60.0	CHEMBL4599	Homo sapiens	INH	%	60.0
	15249235	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	CN(C)CCNC(=O)CCc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1.Cl		CHEMBL3426883	=	Inhibition	%	68.0	CHEMBL4599	Homo sapiens	INH	%	68.0
	15249236	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cl.O=C(O)Cc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1		CHEMBL3426884	=	Inhibition	%	61.0	CHEMBL4599	Homo sapiens	INH	%	61.0
	15249237	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cl.O=C(O)CCc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1		CHEMBL3426885	=	Inhibition	%	74.5	CHEMBL4599	Homo sapiens	INH	%	74.5
	15249238	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cl.O=C(O)CCC(=O)N1CCN(c2ccc(Nc3ncc(Br)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426886	=	Inhibition	%	92.0	CHEMBL4599	Homo sapiens	INH	%	92.0
	15249239	CHEMBL3428295	Inhibition of human ACK1 kinase activity using biotinylated ATGRYYAMKIL - AKT peptide substrate assessed as phosphorylation at 10 uM by ELISA	B	Cl.O=C(O)Cc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426887	=	Inhibition	%	76.5	CHEMBL4599	Homo sapiens	INH	%	76.5
Not Determined	15249240	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Oc1ccc(Nc2ncc(F)c(NCC3CCCO3)n2)cc1F		CHEMBL3426855		IC50			CHEMBL4599	Homo sapiens	IC50		
Not Determined	15249241	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Cc1cnc(Nc2ccc(O)c(F)c2)nc1NCC1CCCO1		CHEMBL3426856		IC50			CHEMBL4599	Homo sapiens	IC50		
	15249242	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Oc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1F		CHEMBL3426857	=	IC50	nM	299.0	CHEMBL4599	Homo sapiens	IC50	nM	299.0
Not Determined	15249243	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(O)c(F)c2)nc1NCC1CCCO1		CHEMBL3426858		IC50			CHEMBL4599	Homo sapiens	IC50		
Not Determined	15249244	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Oc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426859		IC50			CHEMBL4599	Homo sapiens	IC50		
	15249245	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Oc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1		CHEMBL3426860	=	IC50	nM	164.0	CHEMBL4599	Homo sapiens	IC50	nM	164.0
	15249246	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(O)cc2)nc1NCC1CCCO1		CHEMBL3426861	=	IC50	nM	54.4	CHEMBL4599	Homo sapiens	IC50	nM	54.4
	15249247	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Cc1cc(Nc2ncc(Br)c(NCC3CCCO3)n2)ccc1O		CHEMBL3426862	=	IC50	nM	99.0	CHEMBL4599	Homo sapiens	IC50	nM	99.0
Not Determined	15249248	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	COc1ccc(Nc2ncc(Br)c(NCC3CCCO3)n2)cc1		CHEMBL3426863		IC50			CHEMBL4599	Homo sapiens	IC50		
Not Determined	15249249	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	COc1ccc(Nc2ncc(C(=O)Nc3c(F)cccc3Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426864		IC50			CHEMBL4599	Homo sapiens	IC50		
	15249250	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Clc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1		CHEMBL3426865	=	IC50	nM	67.5	CHEMBL4599	Homo sapiens	IC50	nM	67.5
	15249251	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Brc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1		CHEMBL3426866	=	IC50	nM	106.0	CHEMBL4599	Homo sapiens	IC50	nM	106.0
	15249252	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1		CHEMBL3426867	=	IC50	nM	47.7	CHEMBL4599	Homo sapiens	IC50	nM	47.7
	15249253	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Clc1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426868	=	IC50	nM	81.3	CHEMBL4599	Homo sapiens	IC50	nM	81.3
	15249254	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Brc1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426869	=	IC50	nM	94.7	CHEMBL4599	Homo sapiens	IC50	nM	94.7
	15249255	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426870	=	IC50	nM	33.2	CHEMBL4599	Homo sapiens	IC50	nM	33.2
	15249256	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426871	=	IC50	nM	54.4	CHEMBL4599	Homo sapiens	IC50	nM	54.4
	15249257	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(Br)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426872	=	IC50	nM	48.0	CHEMBL4599	Homo sapiens	IC50	nM	48.0
	15249258	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(C(=O)Nc4c(F)cccc4Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426873	=	IC50	nM	48.3	CHEMBL4599	Homo sapiens	IC50	nM	48.3
Not Determined	15249259	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3nccc(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426854		IC50			CHEMBL4599	Homo sapiens	IC50		
	15249260	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Clc1cnc(Nc2ccc(C3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426874	=	IC50	nM	231.0	CHEMBL4599	Homo sapiens	IC50	nM	231.0
	15249261	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	Brc1cnc(Nc2ccc(C3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426875	=	IC50	nM	169.0	CHEMBL4599	Homo sapiens	IC50	nM	169.0
	15249262	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(C3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426876	=	IC50	nM	53.3	CHEMBL4599	Homo sapiens	IC50	nM	53.3
	15249263	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(O)C1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426877	=	IC50	nM	85.0	CHEMBL4599	Homo sapiens	IC50	nM	85.0
Not Determined	15249264	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(O)C1CCN(c2ccc(Nc3ncc(Br)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426878		IC50			CHEMBL4599	Homo sapiens	IC50		
	15249265	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCC(C(=O)O)CC3)cc2)nc1NCC1CCCO1		CHEMBL3426879	=	IC50	nM	34.2	CHEMBL4599	Homo sapiens	IC50	nM	34.2
	15249266	CHEMBL3428296	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate by 33P Hotspot assay	B	CCCC(=O)N1CCN(c2ccc(Nc3ncc(C(=O)Nc4c(F)cccc4Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426880	=	IC50	nM	28.4	CHEMBL4599	Homo sapiens	IC50	nM	28.4
	15249268	CHEMBL3428298	Inhibition of human ACK1 using EAIYAAPFAKKK peptide substrate at 1 uM by 33P Hotspot assay	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426891	=	Inhibition	%	99.8	CHEMBL4599	Homo sapiens	INH	%	99.8
	15250021	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	c1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247070	=	Inhibition	%	70.0	CHEMBL4599	Homo sapiens	INH	%	70.0
	15250022	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(O)cc2)nc1NCC1CCCO1		CHEMBL3426861	=	Inhibition	%	34.3	CHEMBL4599	Homo sapiens	INH	%	34.3
	15250023	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	Clc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NC[C@H]1CCCO1	Outside typical range	CHEMBL3426888	=	Inhibition	%	-22.1	CHEMBL4599	Homo sapiens	INH	%	-22.1
	15250024	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NCC1CCCO1	Outside typical range	CHEMBL3426867	=	Inhibition	%	-32.6	CHEMBL4599	Homo sapiens	INH	%	-32.6
	15250025	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	Brc1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426869	=	Inhibition	%	58.3	CHEMBL4599	Homo sapiens	INH	%	58.3
	15250026	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	O=C(Nc1c(F)cccc1Cl)c1cnc(Nc2ccc(N3CCNCC3)cc2)nc1NCC1CCCO1		CHEMBL3426870	=	Inhibition	%	36.7	CHEMBL4599	Homo sapiens	INH	%	36.7
	15250027	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426871	=	Inhibition	%	65.3	CHEMBL4599	Homo sapiens	INH	%	65.3
	15250028	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	O=C(O)C1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426877	=	Inhibition	%	1.2	CHEMBL4599	Homo sapiens	INH	%	1.2
	15250029	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	CCCC(=O)N1CCN(c2ccc(Nc3ncc(C(=O)Nc4c(F)cccc4Cl)c(NCC4CCCO4)n3)cc2)CC1		CHEMBL3426880	=	Inhibition	%	74.5	CHEMBL4599	Homo sapiens	INH	%	74.5
	15250030	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	Cl.O=C(O)Cc1ccc(Nc2ncc(Cl)c(NCC3CCCO3)n2)cc1		CHEMBL3426887	=	Inhibition	%	74.5	CHEMBL4599	Homo sapiens	INH	%	74.5
	15250031	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	Clc1cnc(Nc2ccc(N3CCOCC3)cc2)nc1NC[C@@H]1CCCO1		CHEMBL3426890	=	Inhibition	%	39.3	CHEMBL4599	Homo sapiens	INH	%	39.3
	15250032	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426891	=	Inhibition	%	93.5	CHEMBL4599	Homo sapiens	INH	%	93.5
	15250033	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@@H]4CCCO4)n3)cc2)CC1		CHEMBL3426892	=	Inhibition	%	78.7	CHEMBL4599	Homo sapiens	INH	%	78.7
	15250034	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	=	Inhibition	%	86.8	CHEMBL4599	Homo sapiens	INH	%	86.8
	15250035	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	COC(=O)C1CCN(c2ccc(Nc3ncc(Cl)c(NCC4CCCO4)n3)cc2)CC1	Outside typical range	CHEMBL3426893	=	Inhibition	%	-12.0	CHEMBL4599	Homo sapiens	INH	%	-12.0
	15250036	CHEMBL3429140	Inhibition of ACK1 Tyr284 phosphorylation in human LAPC4 cells at 5 uM after 16 hrs by immunoblotting analysis	B	O=C(Nc1c(F)cccc1Cl)c1cnc(N2CCC(C(=O)O)(c3ccccc3)CC2)nc1NCC1CCCO1	Outside typical range	CHEMBL3426975	=	Inhibition	%	-49.3	CHEMBL4599	Homo sapiens	INH	%	-49.3
	15250059	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	CN(C)CCOc1ccc(-c2oc3ncnc(NC[C@@H]4CCCO4)c3c2-c2ccccc2)cc1		CHEMBL247479	=	IC50	nM	11.0	CHEMBL4599	Homo sapiens	IC50	nM	11.0
	15250060	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	CN(C)CCOc1ccc(-c2oc3ncnc(NCC4SCCS4)c3c2-c2ccccc2)cc1		CHEMBL2087874	=	Ki	nM	0.3	CHEMBL4599	Homo sapiens	Ki	nM	0.3
	15250061	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccccc3)nc21		CHEMBL487242	=	IC50	nM	2.0	CHEMBL4599	Homo sapiens	IC50	nM	2.0
	15250062	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	COC(C)(C)CCn1nc(Nc2c(C)cccc2C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc21		CHEMBL472392	=	IC50	nM	20.0	CHEMBL4599	Homo sapiens	IC50	nM	20.0
	15250063	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL1672987	=	Kd	nM	2.0	CHEMBL4599	Homo sapiens	Kd	nM	2.0
	15250064	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL2325940	=	IC50	nM	110.0	CHEMBL4599	Homo sapiens	IC50	nM	110.0
	15250065	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	6.0	CHEMBL4599	Homo sapiens	Kd	nM	6.0
	15250066	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	IC50	nM	2.7	CHEMBL4599	Homo sapiens	IC50	nM	2.7
	15250067	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@H]4CCCO4)n3)cc2)CC1		CHEMBL3426891	=	IC50	nM	56.0	CHEMBL4599	Homo sapiens	IC50	nM	56.0
	15250068	CHEMBL3429155	Inhibition of ACK1 kinase (unknown origin)	B	CN1CCN(c2ccc(Nc3ncc(Cl)c(NC[C@@H]4CCCO4)n3)cc2)CC1		CHEMBL3426892	=	IC50	nM	82.0	CHEMBL4599	Homo sapiens	IC50	nM	82.0
	15250069	CHEMBL3429156	Inhibition of ACK1 kinase (unknown origin) by cell-based assay	B	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL2325940	=	IC50	nM	35.0	CHEMBL4599	Homo sapiens	IC50	nM	35.0
	15622518	CHEMBL3588250	Inhibition of human recombinant TNK2 by LanthaScreen Binding assay	B	Cc1cc2cn[nH]c2cc1-c1cccc2c(N)c(C(N)=O)nnc12		CHEMBL3586447	=	IC50	nM	11.0	CHEMBL4599	Homo sapiens	IC50	nM	11.0
	15685869	CHEMBL3607945	Inhibition of human ACK1	B	NC(=O)c1cc(F)cc2c1C(=O)N(C1CCN(C3CCC(F)(F)CC3)CC1)C2		CHEMBL3606021	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	15745691	CHEMBL3625496	Inhibition of human ACK expressed in bacterial expression system assessed as remaining activity at 1 uM relative to control	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3nc(C)c(C)s3)nc21		CHEMBL3622137	=	Activity	%	9.4	CHEMBL4599	Homo sapiens	Activity	%	9.4
	15756120	CHEMBL3631608	Inhibition of ACK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	96.45	CHEMBL4599	Homo sapiens	INH	%	96.45
	15757715	CHEMBL3631608	Inhibition of ACK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	21.57	CHEMBL4599	Homo sapiens	INH	%	21.57
	15757979	CHEMBL3631608	Inhibition of ACK1 (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	16.41	CHEMBL4599	Homo sapiens	INH	%	16.41
	16425385	CHEMBL3751207	Inhibition of TNK2 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	15.9	CHEMBL4599	Homo sapiens	INH	%	15.9
	16431722	CHEMBL3749730	Inhibition of human ACK1 using [EAIYAAPFAKKK] as substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	16451628	CHEMBL3761209	Inhibition of TNK2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	7.8	CHEMBL4599	Homo sapiens	INH	%	7.8
	16495330	CHEMBL3776643	Inhibition of N-terminal His6-tagged recombinant human ACK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	-30.0	CHEMBL4599	Homo sapiens	Activity	%	-30.0
	16508099	CHEMBL3776643	Inhibition of N-terminal His6-tagged recombinant human ACK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	14.0	CHEMBL4599	Homo sapiens	Activity	%	14.0
	16509076	CHEMBL3776643	Inhibition of N-terminal His6-tagged recombinant human ACK1 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	-7.0	CHEMBL4599	Homo sapiens	Activity	%	-7.0
	16534392	CHEMBL3789042	Inhibition of human ACK1 at 1 uM after 30 mins by fluorescence assay in presence of ATP	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC(N)C2(C)C		CHEMBL3786892	=	Inhibition	%	100.0	CHEMBL4599	Homo sapiens	INH	%	100.0
	16562729	CHEMBL3802280	Inhibition of AcK1 (unknown origin) using peptide substrate incubated for 30 mins by europium donor dye-based plate reader analysis	B	CC(C)(C)C(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2		CHEMBL513703	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	16562730	CHEMBL3802280	Inhibition of AcK1 (unknown origin) using peptide substrate incubated for 30 mins by europium donor dye-based plate reader analysis	B	CCCCC(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2		CHEMBL3797480	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	16562731	CHEMBL3802280	Inhibition of AcK1 (unknown origin) using peptide substrate incubated for 30 mins by europium donor dye-based plate reader analysis	B	CCCC(=O)Nc1ccc2c(c1)/C(=C1/Nc3ccccc3/C1=N\O)C(=O)N2		CHEMBL3799585	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	16586950	CHEMBL3807412	Inhibition of ACK1 (unknown origin) in presence of gamma33-ATP	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	IC50	nM	70.0	CHEMBL4599	Homo sapiens	IC50	uM	0.07
	16605030	CHEMBL3811830	Inhibition of human recombinant GST-tagged TNK2 expressed in baculovirus at 1 uM by lanthascreen assay	B	COc1cc(-c2cnn(C)c2)ccc1Nc1ncc2ccnc(N[C@@H](C)C(C)(C)C)c2n1		CHEMBL3809829	>	Inhibition	%	80.0	CHEMBL4599	Homo sapiens	INH	%	80.0
	16613760	CHEMBL3816553	Inhibition of human ACK1 at 1 uM using [EAIYAAPFAKKK] as substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	85.0	CHEMBL4599	Homo sapiens	INH	%	85.0
214300	17603438	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCCCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651305	=	IC50	nM	988.6	CHEMBL4599	Homo sapiens	IC50	nM	988.6
214301	17603439	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651306	=	IC50	nM	270.6	CHEMBL4599	Homo sapiens	IC50	nM	270.6
214302	17603440	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651307	=	IC50	nM	212.0	CHEMBL4599	Homo sapiens	IC50	nM	212.0
214303	17603441	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CNC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651308	=	IC50	nM	3721.6	CHEMBL4599	Homo sapiens	IC50	nM	3721.6
214304	17603442	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCc1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3651309	=	IC50	nM	358.0	CHEMBL4599	Homo sapiens	IC50	nM	358.0
214305	17603443	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3651310	=	IC50	nM	95.8	CHEMBL4599	Homo sapiens	IC50	nM	95.8
214306	17603444	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCOCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651311	=	IC50	nM	2065.9	CHEMBL4599	Homo sapiens	IC50	nM	2065.9
214307	17603445	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(C)c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3651312	=	IC50	nM	330.0	CHEMBL4599	Homo sapiens	IC50	nM	330.0
214308	17603446	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN1CCN([C@H]2C[C@@H](c3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)nccn43)C2)CC1		CHEMBL3651313	=	IC50	nM	2242.8	CHEMBL4599	Homo sapiens	IC50	nM	2242.8
214309	17603447	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1C[C@@H](O)C1		CHEMBL3651314	=	IC50	nM	152.6	CHEMBL4599	Homo sapiens	IC50	nM	152.6
214310	17603448	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(OC3CCCCO3)cc1)nc2[C@H]1C[C@@H](O)C1		CHEMBL3651315	=	IC50	nM	50.0	CHEMBL4599	Homo sapiens	IC50	nM	50.0
214311	17603449	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)[C@H]1C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3651316	=	IC50	nM	1531.3	CHEMBL4599	Homo sapiens	IC50	nM	1531.3
214312	17603450	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CC(F)(F)C3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651317	=	IC50	nM	1147.4	CHEMBL4599	Homo sapiens	IC50	nM	1147.4
214313	17603451	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=C(F)F)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3651318	=	IC50	nM	5530.0	CHEMBL4599	Homo sapiens	IC50	nM	5530.0
214314	17603452	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](CNC(=O)OCc2ccccc2)CC1		CHEMBL3651319	=	IC50	nM	4986.0	CHEMBL4599	Homo sapiens	IC50	nM	4986.0
214315	17603453	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)CC(=O)N1CCC(c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)CC1		CHEMBL3651320	=	IC50	nM	6853.4	CHEMBL4599	Homo sapiens	IC50	nM	6853.4
214316	17603454	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCNCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3651321	=	IC50	nM	6986.3	CHEMBL4599	Homo sapiens	IC50	nM	6986.3
214317	17603455	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CSc1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3651322	=	IC50	nM	990.0	CHEMBL4599	Homo sapiens	IC50	nM	990.0
214318	17603456	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325971	=	IC50	nM	48.7	CHEMBL4599	Homo sapiens	IC50	nM	48.7
214319	17603457	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(F)c3)c12		CHEMBL2325972	=	IC50	nM	88.0	CHEMBL4599	Homo sapiens	IC50	nM	88.0
214320	17603458	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)c(F)cc1Oc1ccccc1		CHEMBL3651323	=	IC50	nM	1780.1	CHEMBL4599	Homo sapiens	IC50	nM	1780.1
214321	17603459	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3C(F)(F)F)c12		CHEMBL3651324	=	IC50	nM	7224.9	CHEMBL4599	Homo sapiens	IC50	nM	7224.9
214322	17603460	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL3651325	=	IC50	nM	3121.1	CHEMBL4599	Homo sapiens	IC50	nM	3121.1
214323	17603461	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3Cl)c12		CHEMBL2325946	=	IC50	nM	1063.1	CHEMBL4599	Homo sapiens	IC50	nM	1063.1
214324	17603462	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCOc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL2325948	=	IC50	nM	474.5	CHEMBL4599	Homo sapiens	IC50	nM	474.5
214325	17603463	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3OC(F)(F)F)c12		CHEMBL3651326	=	IC50	nM	4220.0	CHEMBL4599	Homo sapiens	IC50	nM	4220.0
214326	17603464	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(Cl)c3)c12		CHEMBL2325973	=	IC50	nM	1689.1	CHEMBL4599	Homo sapiens	IC50	nM	1689.1
214327	17603465	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c([N+](=O)[O-])c3)c12		CHEMBL3651327	=	IC50	nM	1521.4	CHEMBL4599	Homo sapiens	IC50	nM	1521.4
214328	17603466	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL2325945	=	IC50	nM	369.4	CHEMBL4599	Homo sapiens	IC50	nM	369.4
214329	17603467	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325974	=	IC50	nM	6281.8	CHEMBL4599	Homo sapiens	IC50	nM	6281.8
214330	17603468	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4[N+](=O)[O-])cc3)c12		CHEMBL3651328	=	IC50	nM	905.9	CHEMBL4599	Homo sapiens	IC50	nM	905.9
214331	17603469	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1C		CHEMBL3651329	=	IC50	nM	1349.2	CHEMBL4599	Homo sapiens	IC50	nM	1349.2
214332	17603470	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1cccc(F)c1		CHEMBL3651330	=	IC50	nM	1152.8	CHEMBL4599	Homo sapiens	IC50	nM	1152.8
214333	17603471	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1cccc(C)c1		CHEMBL3651331	=	IC50	nM	997.4	CHEMBL4599	Homo sapiens	IC50	nM	997.4
214334	17603472	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3cc(F)c(Oc4ccccc4)cc3F)c12		CHEMBL3651332	=	IC50	nM	559.0	CHEMBL4599	Homo sapiens	IC50	nM	559.0
214335	17603473	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1Cl		CHEMBL3651333	=	IC50	nM	621.3	CHEMBL4599	Homo sapiens	IC50	nM	621.3
214336	17603474	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)cc3)c12		CHEMBL2325952	=	IC50	nM	86.5	CHEMBL4599	Homo sapiens	IC50	nM	86.5
214337	17603475	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCOc1ccc(-c2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)cc1		CHEMBL3651334	=	IC50	nM	10301.3	CHEMBL4599	Homo sapiens	IC50	nM	10301.3
214338	17603476	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(N(c4ccccc4)c4ccccc4)cc3)c12		CHEMBL3651335	=	IC50	nM	9026.4	CHEMBL4599	Homo sapiens	IC50	nM	9026.4
214339	17603477	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4ccccc4)c(F)c3)c12		CHEMBL3651336	=	IC50	nM	1395.2	CHEMBL4599	Homo sapiens	IC50	nM	1395.2
214340	17603478	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Cc4ccccc4)cc3)c12		CHEMBL2325951	=	IC50	nM	572.9	CHEMBL4599	Homo sapiens	IC50	nM	572.9
214341	17603479	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Nc4ccccc4)cc3)c12		CHEMBL2325950	=	IC50	nM	380.6	CHEMBL4599	Homo sapiens	IC50	nM	380.6
214342	17603480	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CO/N=C(\c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3651337	=	IC50	nM	6434.8	CHEMBL4599	Homo sapiens	IC50	nM	6434.8
214343	17603481	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)C4CCCCO4)cc3)c12		CHEMBL3651338	=	IC50	nM	612.2	CHEMBL4599	Homo sapiens	IC50	nM	612.2
214344	17603482	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(SC4CCCCO4)cc3)c12		CHEMBL3651339	=	IC50	nM	205.3	CHEMBL4599	Homo sapiens	IC50	nM	205.3
214345	17603483	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c(F)c3)c12		CHEMBL3651340	=	IC50	nM	181.3	CHEMBL4599	Homo sapiens	IC50	nM	181.3
214346	17603484	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL2325954	=	IC50	nM	90.0	CHEMBL4599	Homo sapiens	IC50	nM	90.0
214347	17603485	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL3651341	=	IC50	nM	35.2	CHEMBL4599	Homo sapiens	IC50	nM	35.2
214348	17603486	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)cc3F)c12		CHEMBL3651342	=	IC50	nM	60.4	CHEMBL4599	Homo sapiens	IC50	nM	60.4
214349	17603487	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c([N+](=O)[O-])c3)c12		CHEMBL3651343	=	IC50	nM	582.3	CHEMBL4599	Homo sapiens	IC50	nM	582.3
214350	17603488	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c4ccccc34)c12		CHEMBL3651344	=	IC50	nM	1597.3	CHEMBL4599	Homo sapiens	IC50	nM	1597.3
214351	17603489	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c(Cl)c3)c12		CHEMBL3651345	=	IC50	nM	233.0	CHEMBL4599	Homo sapiens	IC50	nM	233.0
214352	17603490	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(N=O)c4ccccc4)cc3)c12		CHEMBL3651346	=	IC50	nM	3782.7	CHEMBL4599	Homo sapiens	IC50	nM	3782.7
214353	17603491	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3651347	=	IC50	nM	7562.7	CHEMBL4599	Homo sapiens	IC50	nM	7562.7
214354	17603492	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(CC4CCCCO4)cc3)c12		CHEMBL3651348	=	IC50	nM	2784.0	CHEMBL4599	Homo sapiens	IC50	nM	2784.0
214355	17603493	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3651349	=	IC50	nM	9824.8	CHEMBL4599	Homo sapiens	IC50	nM	9824.8
214356	17603494	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(CC4CCCO4)cc3)c12		CHEMBL3651350	=	IC50	nM	2949.1	CHEMBL4599	Homo sapiens	IC50	nM	2949.1
214357	17603495	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(F)(F)c4ccccc4)cc3)c12		CHEMBL3651351	=	IC50	nM	2294.8	CHEMBL4599	Homo sapiens	IC50	nM	2294.8
214358	17603496	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1)c1cccc(F)c1		CHEMBL3651352	=	IC50	nM	2124.7	CHEMBL4599	Homo sapiens	IC50	nM	2124.7
214359	17603497	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1C(C)(O)c1ccccc1		CHEMBL3651353	=	IC50	nM	631.2	CHEMBL4599	Homo sapiens	IC50	nM	631.2
214360	17603498	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)c(F)c1		CHEMBL3651354	=	IC50	nM	364.5	CHEMBL4599	Homo sapiens	IC50	nM	364.5
214361	17603499	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(C(C)(O)c2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL3651355	=	IC50	nM	853.2	CHEMBL4599	Homo sapiens	IC50	nM	853.2
214362	17603500	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1)c1ccccc1F		CHEMBL3651356	=	IC50	nM	1096.5	CHEMBL4599	Homo sapiens	IC50	nM	1096.5
214363	17603501	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(C(C)(O)c2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL3651357	=	IC50	nM	188.3	CHEMBL4599	Homo sapiens	IC50	nM	188.3
214364	17603502	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)c(Cl)c1		CHEMBL3651358	=	IC50	nM	315.1	CHEMBL4599	Homo sapiens	IC50	nM	315.1
214365	17603503	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(C(=O)c2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL3651359	=	IC50	nM	203.1	CHEMBL4599	Homo sapiens	IC50	nM	203.1
214366	17603504	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(C(=O)c2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL3651360	=	IC50	nM	404.6	CHEMBL4599	Homo sapiens	IC50	nM	404.6
214367	17603505	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)cc3Cl)c12		CHEMBL3651361	=	IC50	nM	181.0	CHEMBL4599	Homo sapiens	IC50	nM	181.0
214368	17603506	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)nc3)c12		CHEMBL3651362	=	IC50	nM	1970.0	CHEMBL4599	Homo sapiens	IC50	nM	1970.0
214369	17603507	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OC4CCCCO4)cc3)c12		CHEMBL3651363	=	IC50	nM	100.0	CHEMBL4599	Homo sapiens	IC50	nM	100.0
214370	17603508	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(Oc2ccccc2)ccc1-c1nc(C2CCC2)n2ccnc(N)c12		CHEMBL2325947	=	IC50	nM	75.0	CHEMBL4599	Homo sapiens	IC50	nM	75.0
214371	17603509	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cccc(F)c1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3651364	=	IC50	nM	2500.0	CHEMBL4599	Homo sapiens	IC50	nM	2500.0
214372	17603510	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)cc(OC)c1Oc1ccccc1		CHEMBL3651365	=	IC50	nM	770.0	CHEMBL4599	Homo sapiens	IC50	nM	770.0
214373	17603511	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)cc(Cl)c1Oc1ccccc1		CHEMBL3651366	=	IC50	nM	6370.0	CHEMBL4599	Homo sapiens	IC50	nM	6370.0
214374	17603512	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(F)c3F)c12		CHEMBL3651367	=	IC50	nM	230.0	CHEMBL4599	Homo sapiens	IC50	nM	230.0
214375	17603513	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)c(C)cc1Oc1ccccc1		CHEMBL3651368	=	IC50	nM	550.0	CHEMBL4599	Homo sapiens	IC50	nM	550.0
214376	17603514	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(NC=O)c3)c12		CHEMBL3651369	=	IC50	nM	2350.0	CHEMBL4599	Homo sapiens	IC50	nM	2350.0
214377	17603515	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OCC(F)(F)F)c(F)c3)c12		CHEMBL3651370	=	IC50	nM	9560.0	CHEMBL4599	Homo sapiens	IC50	nM	9560.0
214378	17603516	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4c(F)cccc4F)cc3)c12		CHEMBL3651371	=	IC50	nM	320.0	CHEMBL4599	Homo sapiens	IC50	nM	320.0
214379	17603517	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=C(F)F)c4ccccc4)cc3)c12		CHEMBL3651372	=	IC50	nM	7950.0	CHEMBL4599	Homo sapiens	IC50	nM	7950.0
214380	17603518	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OC4CCCCC4)cc3)c12		CHEMBL3651373	=	IC50	nM	800.0	CHEMBL4599	Homo sapiens	IC50	nM	800.0
214381	17603519	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OC4CCCC4)cc3)c12		CHEMBL3651374	=	IC50	nM	5190.0	CHEMBL4599	Homo sapiens	IC50	nM	5190.0
214382	17603520	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc4c(c3)[nH]c3ccccc34)c12		CHEMBL3651375	=	IC50	nM	6750.0	CHEMBL4599	Homo sapiens	IC50	nM	6750.0
214383	17603521	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc4c(c3)ncn4-c3ccccc3)c12		CHEMBL2325955	=	IC50	nM	3350.0	CHEMBL4599	Homo sapiens	IC50	nM	3350.0
214384	17603522	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(O)c3)c12		CHEMBL3651376	=	IC50	nM	58.9	CHEMBL4599	Homo sapiens	IC50	nM	58.9
214385	17603523	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccn4)cc3)c12		CHEMBL2325970	=	IC50	nM	1900.0	CHEMBL4599	Homo sapiens	IC50	nM	1900.0
214386	17603524	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3651377	=	IC50	nM	183.2	CHEMBL4599	Homo sapiens	IC50	nM	183.2
214387	17603525	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325957	=	IC50	nM	492.0	CHEMBL4599	Homo sapiens	IC50	nM	492.0
214388	17603526	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3651378	=	IC50	nM	459.0	CHEMBL4599	Homo sapiens	IC50	nM	459.0
214389	17603527	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(OC4CCCCO4)cc3)c3c(N)nccn32)C1		CHEMBL3651379	=	IC50	nM	178.2	CHEMBL4599	Homo sapiens	IC50	nM	178.2
214390	17603528	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(F)c3)c3c(N)nccn32)C1		CHEMBL3651380	=	IC50	nM	114.6	CHEMBL4599	Homo sapiens	IC50	nM	114.6
214391	17603529	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Nc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3651381	=	IC50	nM	1459.9	CHEMBL4599	Homo sapiens	IC50	nM	1459.9
214392	17603530	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL2325940	=	IC50	nM	118.8	CHEMBL4599	Homo sapiens	IC50	nM	118.8
214393	17603531	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Cc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325936	=	IC50	nM	233.8	CHEMBL4599	Homo sapiens	IC50	nM	233.8
214394	17603532	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3651382	=	IC50	nM	1979.6	CHEMBL4599	Homo sapiens	IC50	nM	1979.6
214395	17603533	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(SC4CCCCO4)cc3)c3c(N)nccn32)C1		CHEMBL3651383	=	IC50	nM	242.4	CHEMBL4599	Homo sapiens	IC50	nM	242.4
214396	17603534	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)C4CCCCO4)cc3)c3c(N)nccn32)C1		CHEMBL3651384	=	IC50	nM	2540.1	CHEMBL4599	Homo sapiens	IC50	nM	2540.1
214397	17603535	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1Oc1ccccc1C		CHEMBL3651385	=	IC50	nM	1470.0	CHEMBL4599	Homo sapiens	IC50	nM	1470.0
214398	17603536	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1Oc1cccc(F)c1		CHEMBL3651386	=	IC50	nM	4083.1	CHEMBL4599	Homo sapiens	IC50	nM	4083.1
214399	17603537	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1Oc1cccc(C)c1		CHEMBL3655105	=	IC50	nM	1205.4	CHEMBL4599	Homo sapiens	IC50	nM	1205.4
214400	17603538	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cccc(F)c1Oc1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655106	=	IC50	nM	7849.5	CHEMBL4599	Homo sapiens	IC50	nM	7849.5
214401	17603539	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc(OC)c1Oc1ccccc1		CHEMBL3655107	=	IC50	nM	2624.6	CHEMBL4599	Homo sapiens	IC50	nM	2624.6
214402	17603540	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc(Cl)c1Oc1ccccc1		CHEMBL3655108	=	IC50	nM	6865.0	CHEMBL4599	Homo sapiens	IC50	nM	6865.0
214403	17603541	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c(F)c3)c3c(N)nccn32)C1		CHEMBL2325958	=	IC50	nM	139.6	CHEMBL4599	Homo sapiens	IC50	nM	139.6
214404	17603542	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL2325938	=	IC50	nM	216.1	CHEMBL4599	Homo sapiens	IC50	nM	216.1
214405	17603543	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL2325959	=	IC50	nM	116.8	CHEMBL4599	Homo sapiens	IC50	nM	116.8
214406	17603544	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(F)c3F)c3c(N)nccn32)C1		CHEMBL2325939	=	IC50	nM	137.1	CHEMBL4599	Homo sapiens	IC50	nM	137.1
214407	17603545	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)cc3F)c3c(N)nccn32)C1		CHEMBL2325960	=	IC50	nM	88.6	CHEMBL4599	Homo sapiens	IC50	nM	88.6
214408	17603546	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)c(C)cc1Oc1ccccc1		CHEMBL3655109	=	IC50	nM	891.4	CHEMBL4599	Homo sapiens	IC50	nM	891.4
214409	17603547	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c([N+](=O)[O-])c3)c3c(N)nccn32)C1		CHEMBL3655110	=	IC50	nM	1188.3	CHEMBL4599	Homo sapiens	IC50	nM	1188.3
214410	17603548	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c4ccccc34)c3c(N)nccn32)C1		CHEMBL3655111	=	IC50	nM	1514.1	CHEMBL4599	Homo sapiens	IC50	nM	1514.1
214411	17603549	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c(Cl)c3)c3c(N)nccn32)C1		CHEMBL3655112	=	IC50	nM	221.1	CHEMBL4599	Homo sapiens	IC50	nM	221.1
214412	17603550	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c([N+](=O)[O-])c3)c3c(N)nccn32)C1		CHEMBL3655113	=	IC50	nM	3263.4	CHEMBL4599	Homo sapiens	IC50	nM	3263.4
214413	17603551	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(OCC(F)(F)F)c(F)c3)c3c(N)nccn32)C1		CHEMBL3655114	=	IC50	nM	6822.9	CHEMBL4599	Homo sapiens	IC50	nM	6822.9
214414	17603552	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(N=O)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655115	=	IC50	nM	5587.8	CHEMBL4599	Homo sapiens	IC50	nM	5587.8
214415	17603553	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(CC4CCCO4)cc3)c3c(N)nccn32)C1		CHEMBL3655116	=	IC50	nM	5325.1	CHEMBL4599	Homo sapiens	IC50	nM	5325.1
214416	17603554	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(F)(F)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL2325937	=	IC50	nM	451.8	CHEMBL4599	Homo sapiens	IC50	nM	451.8
214417	17603555	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(NC=O)c3)c3c(N)nccn32)C1		CHEMBL3655117	=	IC50	nM	8527.9	CHEMBL4599	Homo sapiens	IC50	nM	8527.9
214418	17603556	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1)c1cccc(F)c1		CHEMBL3655118	=	IC50	nM	5578.2	CHEMBL4599	Homo sapiens	IC50	nM	5578.2
214419	17603557	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3Cl)c3c(N)nccn32)C1		CHEMBL3655119	=	IC50	nM	757.6	CHEMBL4599	Homo sapiens	IC50	nM	757.6
214420	17603558	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)c(F)c1		CHEMBL3655120	=	IC50	nM	429.3	CHEMBL4599	Homo sapiens	IC50	nM	429.3
214421	17603559	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(C(C)(O)c2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL3655121	=	IC50	nM	1048.1	CHEMBL4599	Homo sapiens	IC50	nM	1048.1
214422	17603560	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL3655122	=	IC50	nM	1881.7	CHEMBL4599	Homo sapiens	IC50	nM	1881.7
214423	17603561	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(C(C)(O)c2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL3655123	=	IC50	nM	344.7	CHEMBL4599	Homo sapiens	IC50	nM	344.7
214424	17603562	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)c(Cl)c1		CHEMBL3655124	=	IC50	nM	477.9	CHEMBL4599	Homo sapiens	IC50	nM	477.9
214425	17603563	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(C(=O)c2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL3655125	=	IC50	nM	415.7	CHEMBL4599	Homo sapiens	IC50	nM	415.7
214426	17603564	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(C(=O)c2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL3655126	=	IC50	nM	524.4	CHEMBL4599	Homo sapiens	IC50	nM	524.4
214427	17603565	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)cc3Cl)c3c(N)nccn32)C1		CHEMBL3655127	=	IC50	nM	217.2	CHEMBL4599	Homo sapiens	IC50	nM	217.2
214428	17603566	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCOc1cc(Oc2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ccnc(N)c12		CHEMBL3655128	=	IC50	nM	350.4	CHEMBL4599	Homo sapiens	IC50	nM	350.4
214429	17603567	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3OC(F)(F)F)c3c(N)nccn32)C1		CHEMBL3655129	=	IC50	nM	2159.0	CHEMBL4599	Homo sapiens	IC50	nM	2159.0
214430	17603568	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)nc3)c3c(N)nccn32)C1		CHEMBL3655130	=	IC50	nM	3796.9	CHEMBL4599	Homo sapiens	IC50	nM	3796.9
214431	17603569	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4c(F)cccc4F)cc3)c3c(N)nccn32)C1		CHEMBL3655131	=	IC50	nM	730.0	CHEMBL4599	Homo sapiens	IC50	nM	730.0
214432	17603570	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3cc[nH]n3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655132	=	IC50	nM	255.2	CHEMBL4599	Homo sapiens	IC50	nM	255.2
214433	17603571	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccsc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655133	=	IC50	nM	3343.5	CHEMBL4599	Homo sapiens	IC50	nM	3343.5
214434	17603572	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCN(CC)CCOc1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655134	=	IC50	nM	352.5	CHEMBL4599	Homo sapiens	IC50	nM	352.5
214435	17603573	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccccc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655135	=	IC50	nM	2587.4	CHEMBL4599	Homo sapiens	IC50	nM	2587.4
214436	17603574	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(C)OC(=O)n1cccc1-c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3655136	=	IC50	nM	5975.3	CHEMBL4599	Homo sapiens	IC50	nM	5975.3
214437	17603575	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)Oc1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655137	=	IC50	nM	650.5	CHEMBL4599	Homo sapiens	IC50	nM	650.5
214438	17603576	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccc(O)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655138	=	IC50	nM	392.0	CHEMBL4599	Homo sapiens	IC50	nM	392.0
214439	17603577	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655139	=	IC50	nM	183.4	CHEMBL4599	Homo sapiens	IC50	nM	183.4
214440	17603578	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655140	=	IC50	nM	992.7	CHEMBL4599	Homo sapiens	IC50	nM	992.7
214441	17603579	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655141	=	IC50	nM	1419.2	CHEMBL4599	Homo sapiens	IC50	nM	1419.2
214442	17603580	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3cccc(O)c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655142	=	IC50	nM	347.8	CHEMBL4599	Homo sapiens	IC50	nM	347.8
214443	17603581	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655143	=	IC50	nM	335.3	CHEMBL4599	Homo sapiens	IC50	nM	335.3
214444	17603582	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	N#Cc1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655144	=	IC50	nM	5670.4	CHEMBL4599	Homo sapiens	IC50	nM	5670.4
214445	17603583	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccco3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655145	=	IC50	nM	286.1	CHEMBL4599	Homo sapiens	IC50	nM	286.1
214446	17603584	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccoc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655146	=	IC50	nM	145.0	CHEMBL4599	Homo sapiens	IC50	nM	145.0
214447	17603585	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(C)OC(=O)N1CC=C(c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)CC1		CHEMBL3655147	=	IC50	nM	1969.6	CHEMBL4599	Homo sapiens	IC50	nM	1969.6
214448	17603586	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)Cc1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655148	=	IC50	nM	2717.1	CHEMBL4599	Homo sapiens	IC50	nM	2717.1
214449	17603587	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)c1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655149	=	IC50	nM	669.3	CHEMBL4599	Homo sapiens	IC50	nM	669.3
214450	17603588	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)CCOc1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655150	=	IC50	nM	428.0	CHEMBL4599	Homo sapiens	IC50	nM	428.0
214451	17603589	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)CCOc1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655151	=	IC50	nM	43.9	CHEMBL4599	Homo sapiens	IC50	nM	43.9
214452	17603590	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)c1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655152	=	IC50	nM	997.8	CHEMBL4599	Homo sapiens	IC50	nM	997.8
214453	17603591	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN1CCN(c2ccc(-c3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)nccn34)cc2)CC1		CHEMBL3655153	=	IC50	nM	66.7	CHEMBL4599	Homo sapiens	IC50	nM	66.7
214454	17603592	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccc(N4CCOCC4)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3639540	=	IC50	nM	3684.0	CHEMBL4599	Homo sapiens	IC50	nM	3684.0
214455	17603593	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(C)OC(=O)N1CCC(n2cc(-c3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)nccn34)cn2)CC1		CHEMBL3655154	=	IC50	nM	3628.5	CHEMBL4599	Homo sapiens	IC50	nM	3628.5
214456	17603594	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccc(OCCN4CCOCC4)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655155	=	IC50	nM	676.7	CHEMBL4599	Homo sapiens	IC50	nM	676.7
214457	17603595	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3cc[nH]c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655156	=	IC50	nM	121.7	CHEMBL4599	Homo sapiens	IC50	nM	121.7
214458	17603596	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccncc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655157	=	IC50	nM	2626.7	CHEMBL4599	Homo sapiens	IC50	nM	2626.7
214459	17603597	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccc4cc[nH]c4c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655158	=	IC50	nM	3344.9	CHEMBL4599	Homo sapiens	IC50	nM	3344.9
214460	17603598	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccc(C(=O)O)cc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655159	=	IC50	nM	2269.5	CHEMBL4599	Homo sapiens	IC50	nM	2269.5
214461	17603599	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC(=O)c1ccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc1		CHEMBL3655160	=	IC50	nM	188.0	CHEMBL4599	Homo sapiens	IC50	nM	188.0
214462	17603600	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3ccc4cn[nH]c4c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655161	=	IC50	nM	3873.0	CHEMBL4599	Homo sapiens	IC50	nM	3873.0
214463	17603601	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3cn[nH]c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655162	=	IC50	nM	391.8	CHEMBL4599	Homo sapiens	IC50	nM	391.8
214464	17603602	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cn1cc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cn1		CHEMBL3655163	=	IC50	nM	811.4	CHEMBL4599	Homo sapiens	IC50	nM	811.4
214465	17603603	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ccccc1-c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3655164	=	IC50	nM	6876.2	CHEMBL4599	Homo sapiens	IC50	nM	6876.2
214466	17603604	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3cccc(C(=O)O)c3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655165	=	IC50	nM	1677.4	CHEMBL4599	Homo sapiens	IC50	nM	1677.4
214467	17603605	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC(=O)c1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655166	=	IC50	nM	4423.5	CHEMBL4599	Homo sapiens	IC50	nM	4423.5
214468	17603606	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	N#Cc1ccccc1-c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3655167	=	IC50	nM	1853.6	CHEMBL4599	Homo sapiens	IC50	nM	1853.6
214469	17603607	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc(F)cc4)cc3)c12		CHEMBL2325967	=	IC50	nM	5455.4	CHEMBL4599	Homo sapiens	IC50	nM	5455.4
214470	17603608	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4F)cc3F)c12		CHEMBL3655168	=	IC50	nM	698.0	CHEMBL4599	Homo sapiens	IC50	nM	698.0
214471	17603609	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1F		CHEMBL3655169	=	IC50	nM	355.3	CHEMBL4599	Homo sapiens	IC50	nM	355.3
214472	17603610	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Sc1ccccc1		CHEMBL3655170	=	IC50	nM	1130.0	CHEMBL4599	Homo sapiens	IC50	nM	1130.0
214473	17603611	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(Cl)c4)cc3)c12		CHEMBL2325966	=	IC50	nM	3195.9	CHEMBL4599	Homo sapiens	IC50	nM	3195.9
214474	17603612	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655171	=	IC50	nM	3876.3	CHEMBL4599	Homo sapiens	IC50	nM	3876.3
214475	17603613	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)c1ccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)cc1		CHEMBL3655172	=	IC50	nM	1419.6	CHEMBL4599	Homo sapiens	IC50	nM	1419.6
214476	17603614	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	N#Cc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655173	=	IC50	nM	2161.4	CHEMBL4599	Homo sapiens	IC50	nM	2161.4
214477	17603615	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1ccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)cc1		CHEMBL2325968	=	IC50	nM	898.6	CHEMBL4599	Homo sapiens	IC50	nM	898.6
214478	17603616	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL2325962	=	IC50	nM	243.0	CHEMBL4599	Homo sapiens	IC50	nM	243.0
214479	17603617	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL2325965	=	IC50	nM	238.0	CHEMBL4599	Homo sapiens	IC50	nM	238.0
214480	17603618	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(F)c4)cc3)c12		CHEMBL2325964	=	IC50	nM	109.0	CHEMBL4599	Homo sapiens	IC50	nM	109.0
214481	17603619	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1ccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)cc1		CHEMBL3655174	=	IC50	nM	1510.0	CHEMBL4599	Homo sapiens	IC50	nM	1510.0
214482	17603620	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(OC(F)(F)F)c4)cc3)c12		CHEMBL3655175	=	IC50	nM	5562.4	CHEMBL4599	Homo sapiens	IC50	nM	5562.4
214483	17603621	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL3655176	=	IC50	nM	2168.1	CHEMBL4599	Homo sapiens	IC50	nM	2168.1
214484	17603622	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc5ccccc5c4)cc3)c12		CHEMBL3655177	=	IC50	nM	6928.8	CHEMBL4599	Homo sapiens	IC50	nM	6928.8
214485	17603623	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc5c(c4)OCO5)cc3)c12		CHEMBL3655178	=	IC50	nM	1729.1	CHEMBL4599	Homo sapiens	IC50	nM	1729.1
214486	17603624	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4F)cc3)c12		CHEMBL2325961	=	IC50	nM	95.2	CHEMBL4599	Homo sapiens	IC50	nM	95.2
214487	17603625	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc(Cl)cc4)cc3)c12		CHEMBL2325969	=	IC50	nM	1868.5	CHEMBL4599	Homo sapiens	IC50	nM	1868.5
214488	17603626	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc5ccccc45)cc3)c12		CHEMBL3655179	=	IC50	nM	5954.2	CHEMBL4599	Homo sapiens	IC50	nM	5954.2
214489	17603627	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4Cl)cc3)c12		CHEMBL2325963	=	IC50	nM	737.9	CHEMBL4599	Homo sapiens	IC50	nM	737.9
214490	17603628	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655180	=	IC50	nM	9429.5	CHEMBL4599	Homo sapiens	IC50	nM	9429.5
214491	17603629	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc(OC(F)(F)F)cc4)cc3)c12		CHEMBL3655181	=	IC50	nM	6575.6	CHEMBL4599	Homo sapiens	IC50	nM	6575.6
214492	17603630	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COC(=O)c1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655182	=	IC50	nM	12853.0	CHEMBL4599	Homo sapiens	IC50	nM	12853.0
214493	17603631	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc([N+](=O)[O-])c4)cc3)c12		CHEMBL3655183	=	IC50	nM	841.1	CHEMBL4599	Homo sapiens	IC50	nM	841.1
214494	17603632	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)c1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655184	=	IC50	nM	2964.8	CHEMBL4599	Homo sapiens	IC50	nM	2964.8
214495	17603633	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(=O)c1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655185	=	IC50	nM	3466.3	CHEMBL4599	Homo sapiens	IC50	nM	3466.3
214496	17603634	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(-c5ccccc5)c4)cc3)c12		CHEMBL3655186	=	IC50	nM	3878.9	CHEMBL4599	Homo sapiens	IC50	nM	3878.9
214497	17603635	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1nc2cc(Oc3ccc(-c4nc(C5CCC5)n5ccnc(N)c45)cc3)ccc2s1		CHEMBL3655187	=	IC50	nM	3304.0	CHEMBL4599	Homo sapiens	IC50	nM	3304.0
214498	17603636	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)c1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655188	=	IC50	nM	8475.9	CHEMBL4599	Homo sapiens	IC50	nM	8475.9
214499	17603637	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4OC(F)(F)F)cc3)c12		CHEMBL3655189	=	IC50	nM	4245.0	CHEMBL4599	Homo sapiens	IC50	nM	4245.0
214500	17603638	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)c1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655190	=	IC50	nM	4527.7	CHEMBL4599	Homo sapiens	IC50	nM	4527.7
214501	17603639	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(F)c4F)cc3)c12		CHEMBL3655191	=	IC50	nM	4019.3	CHEMBL4599	Homo sapiens	IC50	nM	4019.3
214502	17603640	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cccc(C)c1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655192	=	IC50	nM	3616.5	CHEMBL4599	Homo sapiens	IC50	nM	3616.5
214503	17603641	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cccc(F)c1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3651364	=	IC50	nM	2527.6	CHEMBL4599	Homo sapiens	IC50	nM	2527.6
214504	17603642	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccc(O)cc4)cc3)c12		CHEMBL3655193	=	IC50	nM	3583.0	CHEMBL4599	Homo sapiens	IC50	nM	3583.0
214505	17603643	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccnc4)cc3)c12		CHEMBL3655194	=	IC50	nM	11600.0	CHEMBL4599	Homo sapiens	IC50	nM	11600.0
214506	17603644	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1F		CHEMBL3655195	=	IC50	nM	3901.7	CHEMBL4599	Homo sapiens	IC50	nM	3901.7
214507	17603645	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4cccc(F)c4)c(F)c3)c12		CHEMBL3655196	=	IC50	nM	3308.6	CHEMBL4599	Homo sapiens	IC50	nM	3308.6
214508	17603646	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4F)c(F)c3)c12		CHEMBL3655197	=	IC50	nM	1950.7	CHEMBL4599	Homo sapiens	IC50	nM	1950.7
214509	17603647	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4Cl)c(F)c3)c12		CHEMBL3655198	=	IC50	nM	7378.4	CHEMBL4599	Homo sapiens	IC50	nM	7378.4
214510	17603648	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2F)c1		CHEMBL3655199	=	IC50	nM	4146.3	CHEMBL4599	Homo sapiens	IC50	nM	4146.3
214511	17603649	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Sc4ccccc4)c(F)c3)c12		CHEMBL3655200	=	IC50	nM	2210.0	CHEMBL4599	Homo sapiens	IC50	nM	2210.0
214512	17603650	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Sc4ccccc4)cc3)c12		CHEMBL2325949	=	IC50	nM	330.0	CHEMBL4599	Homo sapiens	IC50	nM	330.0
214513	17603651	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3F)c12		CHEMBL2325944	=	IC50	nM	219.4	CHEMBL4599	Homo sapiens	IC50	nM	219.4
214514	17603652	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)c(F)c1		CHEMBL3655201	=	IC50	nM	2988.0	CHEMBL4599	Homo sapiens	IC50	nM	2988.0
214515	17603653	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(C3=CCN(C(=O)c4ccccc4)CC3)c12		CHEMBL3655202	=	IC50	nM	2353.3	CHEMBL4599	Homo sapiens	IC50	nM	2353.3
214516	17603654	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(C3=CCN(C(=O)C4CCCCC4)CC3)c12		CHEMBL3655203	=	IC50	nM	5012.0	CHEMBL4599	Homo sapiens	IC50	nM	5012.0
214517	17603655	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(C3=CCN(C(=O)c4ccccc4F)CC3)c12		CHEMBL3655204	=	IC50	nM	6414.2	CHEMBL4599	Homo sapiens	IC50	nM	6414.2
214518	17603656	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(C3=CCN(C(=O)Cc4ccccc4)CC3)c12		CHEMBL3655205	=	IC50	nM	7055.1	CHEMBL4599	Homo sapiens	IC50	nM	7055.1
214519	17603657	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(C3=CCN(S(=O)(=O)c4ccccc4)CC3)c12		CHEMBL3655206	=	IC50	nM	1172.3	CHEMBL4599	Homo sapiens	IC50	nM	1172.3
214520	17603658	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(C)OC(=O)N1CC=C(c2nc(C3CCC3)n3ccnc(N)c23)CC1		CHEMBL3655207	=	IC50	nM	1861.7	CHEMBL4599	Homo sapiens	IC50	nM	1861.7
214521	17603659	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(-c3ccc(N4CCN(C)CC4)cc3)n3ccnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL3655208	=	IC50	nM	30.0	CHEMBL4599	Homo sapiens	IC50	nM	30.0
214522	17603660	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(-c3cc[nH]n3)n3ccnc(N)c23)cc1		CHEMBL3655209	=	IC50	nM	640.0	CHEMBL4599	Homo sapiens	IC50	nM	640.0
214523	17603661	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(Oc2ccccc2)ccc1-c1nc(-c2cc[nH]n2)n2ccnc(N)c12		CHEMBL3655210	=	IC50	nM	660.0	CHEMBL4599	Homo sapiens	IC50	nM	660.0
214524	17603662	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(-c3cc[nH]n3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655211	=	IC50	nM	740.0	CHEMBL4599	Homo sapiens	IC50	nM	740.0
214525	17603663	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](C(N)=O)CC1		CHEMBL3655212	=	IC50	nM	634.0	CHEMBL4599	Homo sapiens	IC50	nM	634.0
214526	17603664	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CNC(=O)[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)CC1		CHEMBL3655213	=	IC50	nM	1011.3	CHEMBL4599	Homo sapiens	IC50	nM	1011.3
214527	17603665	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)C(=O)[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)CC1		CHEMBL3655214	=	IC50	nM	3302.8	CHEMBL4599	Homo sapiens	IC50	nM	3302.8
214528	17603666	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN1CCN(C(=O)[C@H]2CC[C@H](c3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)nccn43)CC2)CC1		CHEMBL3655215	=	IC50	nM	1679.4	CHEMBL4599	Homo sapiens	IC50	nM	1679.4
214529	17603667	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](C(=O)O)CC1		CHEMBL3655216	=	IC50	nM	3502.5	CHEMBL4599	Homo sapiens	IC50	nM	3502.5
214530	17603668	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COC(=O)[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)CC1		CHEMBL3655217	=	IC50	nM	5481.6	CHEMBL4599	Homo sapiens	IC50	nM	5481.6
214531	17603669	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)CC1		CHEMBL3655218	=	IC50	nM	401.1	CHEMBL4599	Homo sapiens	IC50	nM	401.1
214532	17603670	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3CC[C@H](CN)CC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655219	=	IC50	nM	400.0	CHEMBL4599	Homo sapiens	IC50	nM	400.0
214533	17603671	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3CC[C@H](CNC(=O)OCc4ccccc4)CC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655220	=	IC50	nM	3190.0	CHEMBL4599	Homo sapiens	IC50	nM	3190.0
214534	17603672	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CNC[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)CC1		CHEMBL3655221	=	IC50	nM	153.6	CHEMBL4599	Homo sapiens	IC50	nM	153.6
214535	17603673	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](CO)CC1		CHEMBL3655222	=	IC50	nM	219.4	CHEMBL4599	Homo sapiens	IC50	nM	219.4
214536	17603674	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)C[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)CC1		CHEMBL3655223	=	IC50	nM	75.1	CHEMBL4599	Homo sapiens	IC50	nM	75.1
214537	17603675	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN1CCN(C[C@H]2CC[C@H](c3nc(-c4ccc(Oc5ccccc5)cc4)c4c(N)nccn43)CC2)CC1		CHEMBL3655224	=	IC50	nM	503.4	CHEMBL4599	Homo sapiens	IC50	nM	503.4
214538	17603676	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1C[C@H](CO)C1		CHEMBL3655225	=	IC50	nM	138.7	CHEMBL4599	Homo sapiens	IC50	nM	138.7
214539	17603677	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)C[C@H]1C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655226	=	IC50	nM	1157.9	CHEMBL4599	Homo sapiens	IC50	nM	1157.9
214540	17603678	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1C[C@@H](CN2CCCC2)C1		CHEMBL3655227	=	IC50	nM	2498.1	CHEMBL4599	Homo sapiens	IC50	nM	2498.1
214541	17603679	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC[C@H]1C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655228	=	IC50	nM	328.0	CHEMBL4599	Homo sapiens	IC50	nM	328.0
214542	17603680	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)C[C@H]1C[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655229	=	IC50	nM	4007.3	CHEMBL4599	Homo sapiens	IC50	nM	4007.3
214543	17603681	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1C[C@H](CN2CCCC2)C1		CHEMBL3655230	=	IC50	nM	4205.2	CHEMBL4599	Homo sapiens	IC50	nM	4205.2
214544	17603682	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@H]1C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655231	=	IC50	nM	433.6	CHEMBL4599	Homo sapiens	IC50	nM	433.6
214545	17603683	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@H]1C[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655232	=	IC50	nM	702.8	CHEMBL4599	Homo sapiens	IC50	nM	702.8
214546	17603684	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COC[C@H]1C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655233	=	IC50	nM	1352.7	CHEMBL4599	Homo sapiens	IC50	nM	1352.7
214547	17603685	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc([S+]([O-])c4ccccc4)cc3)c12		CHEMBL3655234	=	IC50	nM	6918.0	CHEMBL4599	Homo sapiens	IC50	nM	6918.0
214548	17603686	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	N#Cc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655235	=	IC50	nM	1780.0	CHEMBL4599	Homo sapiens	IC50	nM	1780.0
214549	17603687	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	N#Cc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655236	=	IC50	nM	360.0	CHEMBL4599	Homo sapiens	IC50	nM	360.0
214550	17603688	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(C(=O)c3ccccc3)cc1)nc2[C@H]1C[C@@H](O)C1		CHEMBL3655237	=	IC50	nM	112.0	CHEMBL4599	Homo sapiens	IC50	nM	112.0
214551	17603689	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(C(=O)c3ccccc3)cc1)nc2[C@H]1CC[C@H](CO)CC1		CHEMBL3655238	=	IC50	nM	297.0	CHEMBL4599	Homo sapiens	IC50	nM	297.0
214552	17603690	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(O)c4ccccc4)cc3)c3c(N)nccn32)C1		CHEMBL3655239	=	IC50	nM	682.3	CHEMBL4599	Homo sapiens	IC50	nM	682.3
214553	17603691	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(C(O)c3ccccc3)cc1)nc2[C@H]1C[C@@H](O)C1		CHEMBL3655240	=	IC50	nM	2760.0	CHEMBL4599	Homo sapiens	IC50	nM	2760.0
214554	17603692	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1ccc(C(O)c3ccccc3)cc1)nc2[C@H]1CC[C@H](CO)CC1		CHEMBL3655241	=	IC50	nM	3187.0	CHEMBL4599	Homo sapiens	IC50	nM	3187.0
214555	17603693	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)cc2)c1		CHEMBL3655242	=	IC50	nM	430.0	CHEMBL4599	Homo sapiens	IC50	nM	430.0
214556	17603694	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655243	=	IC50	nM	109.8	CHEMBL4599	Homo sapiens	IC50	nM	109.8
214557	17603695	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(N)c3)c3c(N)nccn32)C1		CHEMBL3655244	=	IC50	nM	464.6	CHEMBL4599	Homo sapiens	IC50	nM	464.6
214558	17603696	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ccccc1Oc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655245	=	IC50	nM	4831.9	CHEMBL4599	Homo sapiens	IC50	nM	4831.9
214559	17603697	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL3655246	=	IC50	nM	36.9	CHEMBL4599	Homo sapiens	IC50	nM	36.9
214560	17603698	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c(N)c3)c3c(N)nccn32)C1		CHEMBL3655247	=	IC50	nM	50.0	CHEMBL4599	Homo sapiens	IC50	nM	50.0
214561	17603699	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4cc5ccccc5s4)cc3)c12		CHEMBL3655248	=	IC50	nM	9950.5	CHEMBL4599	Homo sapiens	IC50	nM	9950.5
214562	17603700	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C=C(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655249	=	IC50	nM	443.9	CHEMBL4599	Homo sapiens	IC50	nM	443.9
214563	17603701	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4csc5ccccc45)cc3)c12		CHEMBL2325956	=	IC50	nM	4091.0	CHEMBL4599	Homo sapiens	IC50	nM	4091.0
214564	17603702	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4cc5ccccc5[nH]4)cc3)c12		CHEMBL3655250	=	IC50	nM	4702.6	CHEMBL4599	Homo sapiens	IC50	nM	4702.6
214565	17603703	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4cc5ccccc5o4)cc3)c12		CHEMBL3655251	=	IC50	nM	1077.0	CHEMBL4599	Homo sapiens	IC50	nM	1077.0
214566	17603704	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(-c4c[nH]c5ccccc45)cc3)c12		CHEMBL3655252	=	IC50	nM	3493.4	CHEMBL4599	Homo sapiens	IC50	nM	3493.4
214567	17603705	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](CNC(=O)OCc2ccccc2)CC1		CHEMBL3639541	=	IC50	nM	4930.0	CHEMBL4599	Homo sapiens	IC50	nM	4930.0
214568	17603706	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COC(=O)[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnn32)CC1		CHEMBL3655253	=	IC50	nM	17000.0	CHEMBL4599	Homo sapiens	IC50	nM	17000.0
214569	17603707	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnn32)CC1		CHEMBL3655254	=	IC50	nM	175.9	CHEMBL4599	Homo sapiens	IC50	nM	175.9
214570	17603708	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](CO)CC1		CHEMBL3655255	=	IC50	nM	199.1	CHEMBL4599	Homo sapiens	IC50	nM	199.1
214571	17603709	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)CCNC[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnn32)CC1		CHEMBL3655256	=	IC50	nM	216.4	CHEMBL4599	Homo sapiens	IC50	nM	216.4
214572	17603710	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)C[C@H]1CC[C@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnn32)CC1		CHEMBL3655257	=	IC50	nM	404.6	CHEMBL4599	Homo sapiens	IC50	nM	404.6
214573	17603711	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c1c(-c1ccc(Oc3ccccc3)cc1)nc2[C@H]1CC[C@H](CNCCO)CC1		CHEMBL3655258	=	IC50	nM	609.7	CHEMBL4599	Homo sapiens	IC50	nM	609.7
214574	17603712	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3655259	=	IC50	nM	201.4	CHEMBL4599	Homo sapiens	IC50	nM	201.4
214575	17603713	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(F)c3)c12		CHEMBL3655260	=	IC50	nM	196.7	CHEMBL4599	Homo sapiens	IC50	nM	196.7
214576	17603714	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(Cc4ccccc4)cc3)c12		CHEMBL3655261	=	IC50	nM	1979.8	CHEMBL4599	Homo sapiens	IC50	nM	1979.8
214577	17603715	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(Oc4c(F)cccc4F)cc3)c12		CHEMBL3655262	=	IC50	nM	4113.9	CHEMBL4599	Homo sapiens	IC50	nM	4113.9
214578	17603716	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ncnc(N)c23)ccc1Oc1ccccc1C		CHEMBL3655263	=	IC50	nM	3247.1	CHEMBL4599	Homo sapiens	IC50	nM	3247.1
214579	17603717	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ncnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655264	=	IC50	nM	1170.6	CHEMBL4599	Homo sapiens	IC50	nM	1170.6
214580	17603718	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c(F)c3)c12		CHEMBL3655265	=	IC50	nM	939.0	CHEMBL4599	Homo sapiens	IC50	nM	939.0
214581	17603719	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c(Cl)c3)c12		CHEMBL3655266	=	IC50	nM	1676.5	CHEMBL4599	Homo sapiens	IC50	nM	1676.5
214582	17603720	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(C3CCC3)n3ncnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL3655267	=	IC50	nM	319.9	CHEMBL4599	Homo sapiens	IC50	nM	319.9
214583	17603721	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ncnc(N)c23)cc1		CHEMBL3655268	=	IC50	nM	263.0	CHEMBL4599	Homo sapiens	IC50	nM	263.0
214584	17603722	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)cc3F)c12		CHEMBL3655269	=	IC50	nM	136.0	CHEMBL4599	Homo sapiens	IC50	nM	136.0
214585	17603723	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1ncnn2c(C3CCC3)nc(-c3ccc(C(=O)c4ccccc4)c(O)c3)c12		CHEMBL3655270	=	IC50	nM	1227.7	CHEMBL4599	Homo sapiens	IC50	nM	1227.7
214586	17603724	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnn32)C1		CHEMBL3655271	=	IC50	nM	831.4	CHEMBL4599	Homo sapiens	IC50	nM	831.4
214587	17603725	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ncnc(N)c23)cc1		CHEMBL3655272	=	IC50	nM	797.4	CHEMBL4599	Homo sapiens	IC50	nM	797.4
214588	17603726	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)c(F)c3)c3c(N)ncnn32)C1		CHEMBL3655273	=	IC50	nM	975.6	CHEMBL4599	Homo sapiens	IC50	nM	975.6
214589	17603727	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ncnc(N)c23)ccc1C(=O)c1ccccc1		CHEMBL3655274	=	IC50	nM	598.4	CHEMBL4599	Homo sapiens	IC50	nM	598.4
214590	17603728	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(C(=O)c2ccccc2)ccc1-c1nc([C@H]2C[C@@](C)(O)C2)n2ncnc(N)c12		CHEMBL3655275	=	IC50	nM	1364.9	CHEMBL4599	Homo sapiens	IC50	nM	1364.9
214591	17603729	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Cc4ccccc4)cc3)c3c(N)ncnn32)C1		CHEMBL3655276	=	IC50	nM	622.8	CHEMBL4599	Homo sapiens	IC50	nM	622.8
214592	17603730	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(F)c3)c3c(N)ncnn32)C1		CHEMBL3655277	=	IC50	nM	1252.0	CHEMBL4599	Homo sapiens	IC50	nM	1252.0
214593	17603731	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Nc4ccccc4)cc3)c3c(N)ncnn32)C1		CHEMBL3655278	=	IC50	nM	3803.7	CHEMBL4599	Homo sapiens	IC50	nM	3803.7
214594	17603732	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ncnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655279	=	IC50	nM	2046.7	CHEMBL4599	Homo sapiens	IC50	nM	2046.7
214595	17603733	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)c4ccccc4)cc3)c3c(N)ncnn32)C1		CHEMBL3655280	=	IC50	nM	487.9	CHEMBL4599	Homo sapiens	IC50	nM	487.9
214596	17603734	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cccc(Oc2ccc(-c3nc(C4CCC4)n4ccnc(N)c34)c(F)c2)c1		CHEMBL3655281	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214597	17603735	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(Cl)c3)c3c(N)ncnn32)C1		CHEMBL3655282	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214598	17603736	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(O)C4CCCCO4)cc3)c12		CHEMBL3655283	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214599	17603737	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Cc1cc(-c2nc(C3CCC3)n3ncnc(N)c23)ccc1Oc1ccccc1		CHEMBL3655284	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214600	17603738	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CO/N=C(\c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655285	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214601	17603739	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3cccc(Oc4ccccc4)c3)c12		CHEMBL3655286	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214602	17603740	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3cc(F)c(Oc4ccccc4)c(Cl)c3)c12		CHEMBL3655287	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214603	17603741	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)c(C(F)(F)F)c3)c12		CHEMBL3655288	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214604	17603742	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(C(F)(F)F)c3)c3c(N)nccn32)C1		CHEMBL3655289	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214605	17603743	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(CC(=O)O)cc3)c12		CHEMBL3655290	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214606	17603744	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(OC4CCOCC4)cc3)c3c(N)nccn32)C1		CHEMBL3655291	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214607	17603745	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OC4CCOCC4)cc3)c12		CHEMBL3655292	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214608	17603746	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCOC(=O)COc1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655293	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214609	17603747	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3cccc(Nc4ccccc4)c3)c12		CHEMBL3655294	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214610	17603748	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3cccc(Nc4ccccc4)c3)c3c(N)nccn32)C1		CHEMBL3655295	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214611	17603749	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	N#Cc1cccc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)c1		CHEMBL3655296	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214612	17603750	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COCCOc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655297	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214613	17603751	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1cc(-c2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)nccn23)cc(OC)c1OC		CHEMBL3655298	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214614	17603752	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(=O)Cc1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655299	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214615	17603753	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(=O)Cc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655300	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214616	17603754	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CONC(=O)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655301	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214617	17603755	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CONC(=O)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655302	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214618	17603756	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CON(C)C(=O)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1		CHEMBL3655303	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214619	17603757	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CON(C)C(=O)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655304	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214620	17603758	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)N4CCCCC4)cc3)c12		CHEMBL3655305	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214621	17603759	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OC4CCOC4)cc3)c12		CHEMBL3655306	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214622	17603760	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(OC4CCOC4)cc3)c3c(N)nccn32)C1		CHEMBL3655307	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214623	17603761	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)N4CCCCC4)cc3)c3c(N)nccn32)C1		CHEMBL3655308	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214624	17603762	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(N=O)c4ccccc4)cc3)c12		CHEMBL3651346	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214625	17603763	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(C(=O)N4CCSC4)cc3)c12		CHEMBL3655309	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214626	17603764	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(C(=O)N4CCSC4)cc3)c3c(N)nccn32)C1		CHEMBL3655310	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214627	17603765	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1Cl		CHEMBL3655311	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214628	17603766	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(OC4CCCNC4)cc3)c12		CHEMBL3655312	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214629	17603767	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(OC4CCCNC4)cc3)c3c(N)nccn32)C1		CHEMBL3890029	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214630	17603768	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(C)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655313	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214631	17603769	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1Cl		CHEMBL3655314	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214632	17603770	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ncnc(N)c23)cc1Cl		CHEMBL3655315	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214633	17603771	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(CC4CCCCO4)cc3)c3c(N)nccn32)C1		CHEMBL3655316	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214634	17603772	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCC(O)(c1ccccc1)c1ccc(-c2nc(C3CCC3)n3ncnc(N)c23)cc1		CHEMBL3655317	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214635	17603773	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CCC(O)(c1ccccc1)c1ccc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)cc1		CHEMBL3655318	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214636	17603774	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(=O)Nc1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325941	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214637	17603775	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CC(=O)Nc1cc(-c2nc([C@H]3C[C@@](C)(O)C3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL3659465	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214638	17603776	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC(=O)c1cc(-c2nc(C3CCC3)n3ccnc(N)c23)ccc1Oc1ccccc1		CHEMBL2325942	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214639	17603777	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc(Oc4ccccc4)c(C(N)=O)c3)c3c(N)nccn32)C1		CHEMBL3659466	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214640	17603778	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(-c3cccnc3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL3659467	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214641	17603779	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC(=O)c1ccccc1-c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3659468	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214642	17603780	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	CN(C)Cc1ccccc1-c1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)nccn12		CHEMBL3659469	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214643	17603781	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	NC[C@H]1C[C@@H](c2nc(-c3cccc(OCc4ccccc4)c3)c3c(N)nccn32)C1		CHEMBL392788	=	IC50	nM	10200.0	CHEMBL4599	Homo sapiens	IC50	nM	10200.0
214644	17603782	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL392106	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214645	17603783	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	COc1ccc(-c2nc(C3CCC3)n3ccnc(N)c23)cc1OCc1ccccc1		CHEMBL392107	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
214646	17603784	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c(C3CCC3)nc(-c3ccc(Oc4ccccc4)cc3)c12		CHEMBL245408	=	IC50	nM	147.8	CHEMBL4599	Homo sapiens	IC50	nM	147.8
214647	17603785	CHEMBL3705264	AlphaScreen Assay: Compounds of the invention were tested for ACK1 inhibition activity. 1 uL compounds prepared at 15 in 4 mM DMSO were combined with 9 uL ATP solution in assay buffer containing 50 mM Hepes, 1% glycerol, 1.665 mM MnCl2 and Poly-(GT)-Biotin (Cisbio #61GT0BLD, 1:1500 dilution) in ProxiPlate-384 Plus plate (PerkinElmer #6008280). Final DMSO concentration was 0.25% with an ATP final concentration of 100 uM. The reaction was started by adding 5 uL ACK1 solution (Carna, 15 pg/uL final in assay) in an enzyme buffer containing 50 mM Hepes, 0.24 mM EGTA, 0.024% Brij-35, 3 mM DTT, 0.01% BSA. Reaction was allowed to occur for 20 min., shaking, at RT. Anti PT66 acceptor beads and Streptavidin donor beads (PerkinElmer #6760602R) were prepared by adding each at 1:160 dilution in a detection buffer containing 25 mM Tris-HCl, 250 mM NaCl, 100 mM EDTA, 0.25% BSA. Prepared beads were added to assay plate at 5 uL well and allowed to incubate protected from light, shaking, for 2 hrs at RT. Plates were read on AlphaQuest reader.	B	Nc1nccn2c1c(-c1cccc(OCc3ccccc3)c1)nc2[C@H]1CC[C@H](CN2CCCCC2)CC1		CHEMBL3659470	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
421752	17784811	CHEMBL3888883	"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 l of ATP solution (in H2O), 20 l of assay buffer (see below), 5 l of test sample in 10% DMSO, 10 l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 M Na-orthovanadate, 1.2 mM DTT, 50 g/ml PEG20000, 1 M [-33P]-ATP (approx. 810^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 g/ml Phosphatidylserine and 1 g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30 C. for 80 minutes. The reaction was stopped with 50 l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac)."	B	Nc1c(-c2ccc(F)cc2)c(-c2ccncc2)nn1-c1c(Cl)cc(Cl)cc1Cl		CHEMBL2011291	=	IC50	nM	33.0	CHEMBL4599	Homo sapiens	IC50	nM	33.0
421768	17784827	CHEMBL3888883	"Kinase Assay: FlashPlates from Perkin Elmer (Boston, Mass., USA) with a 50 l reaction volume are used. The reaction cocktail was pipetted in 4 steps in the following order: 15 l of ATP solution (in H2O), 20 l of assay buffer (see below), 5 l of test sample in 10% DMSO, 10 l of enzyme/substrate mixture (in H2O). The assay for all enzymes contained 60 mM HEPES-NaOH, pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 3 M Na-orthovanadate, 1.2 mM DTT, 50 g/ml PEG20000, 1 M [-33P]-ATP (approx. 810^5 cpm per well), protein kinase (variable amounts; see Table 1), and substrate (variable amounts). Certain assays also contained 1 mM CaCl2, 4 mM EDTA, 5 g/ml Phosphatidylserine and 1 g/ml 1.2-Dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, DAPK2 and EEF2K assays additionally contained 1 g/ml Calmodulin and 0.5 mM CaCl2. The PRKG1 and PRKG2 assays additionally contained 1 M cGMP. Recombinant Protein Kinases: All protein kinases were expressed in Sf9 insect cells or in E. coli as recombinant GST-fusion proteins or His-tagged proteins. All kinases were produced from human cDNAs, except JAK2, for which the mouse cDNA was used. Kinases were purified by affinity chromatography using either GSH-agarose (Sigma) or Ni-NTH-agarose (Qiagen). The purity of the protein kinases was examined by SDS-PAGE/coomassie staining. The identity of the protein kinases was checked by mass spectroscopy. Assays were made under license from Chemicon International Inc. for JAK2. The reaction cocktails were incubated at 30 C. for 80 minutes. The reaction was stopped with 50 l of 2% (v/v) H3PO4, plates were aspirated and washed two times with 200 l 0.9% (w/v) NaCl. All assays were performed with a BeckmanCoulter Biomek 2000/SL robotic system. Incorporation of 33Pi (counting of ""cpm"") was determined with a microplate scintillation counter (Microbeta, Wallac)."	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	=	IC50	nM	2300.0	CHEMBL4599	Homo sapiens	IC50	nM	2300.0
Inactive	17945669	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC		CHEMBL283120	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945670	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945671	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945672	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945673	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c(F)c2)ccn1		CHEMBL1738757	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945674	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1		CHEMBL3301622	=	Kd	nM	3149.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	3149.0
Active	17945675	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)C1(Cc2cccc(Nc3nccs3)n2)CCC(Oc2cccc(Cl)c2F)CC1		CHEMBL3182444	=	Kd	nM	473.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	473.0
Inactive	17945676	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(C(=O)N(C2CC2)C2CC2)cc2c3c(ncn3C)c(Nc3cc(C)n(C)n3)nc21		CHEMBL3545215	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945677	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNS(=O)(=O)Nc1nccc(Cc2c(C)c3ccc(Oc4ncccn4)cc3oc2=O)c1F		CHEMBL3264002	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945678	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	=	Kd	nM	420.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	420.0
Inactive	17945679	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945680	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)c1		CHEMBL254760	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945681	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Kd	nM	1358.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1358.0
Inactive	17945682	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945683	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945684	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F		CHEMBL3188267	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945685	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945686	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1		CHEMBL3545157	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945687	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1.Cl		CHEMBL3991929	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945688	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OP(C)(C)=O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL2103839	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945689	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)N[C@@H](C)CNc1nccc(-c2cn(C(C)C)nc2-c2cc(Cl)cc(NS(C)(=O)=O)c2F)n1		CHEMBL3301612	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945690	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)NCc2cc(F)ccc2Oc2ccc3c(cnn3CCO)c2)cc1		CHEMBL3991932	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945691	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O		CHEMBL189963	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945692	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc2cc(Oc3ccnc4cc(OCC5(N)CC5)c(OC)cc34)ccc12		CHEMBL2220486	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945693	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Oc3cccc(NC(=O)Nc4cc(C(C)(C)C(F)(F)F)on4)c3)c2cc1OC		CHEMBL2029988	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945694	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945695	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1		CHEMBL2180604	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945696	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1		CHEMBL3218578	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945697	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2ccccc12		CHEMBL1614710	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945698	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCc1c(-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)c(F)c2)c2c(N)ncnn2c1CN1CCOCC1		CHEMBL3991934	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945699	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2[C@H]1C[C@H](N2CCC2)C1		CHEMBL551064	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945700	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)[C@@]1(O)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL281948	=	Kd	nM	1717.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1717.0
Inactive	17945701	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@@H]1CO.Cl		CHEMBL3991935	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945702	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945703	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945704	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945705	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945706	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1		CHEMBL2028663	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945707	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(CN(C)C)cc1)c1ccccc1		CHEMBL3699142	=	Kd	nM	1549.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1549.0
Inactive	17945708	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1		CHEMBL2103842	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945709	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1201182	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945710	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL3545154	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945711	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B			CHEMBL4084193	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945712	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cc2c(cc1N1CCC(N3CCOCC3)CC1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL1738797	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945713	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945714	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21		CHEMBL3218576	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945715	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1		CHEMBL592445	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945716	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC		CHEMBL2105717	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945717	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@](C)(Nc1ccnc(-c2c[nH]c3ncccc23)n1)C(=O)NCC(F)(F)F		CHEMBL3039513	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945718	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945719	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1)C1CCCN1		CHEMBL3545328	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945720	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL574737	=	Kd	nM	162.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	162.0
Inactive	17945721	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)n[nH]2)c2cccn2n1		CHEMBL575448	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945722	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1c[nH]nc1-c1nc2ccc(CN3CCOCC3)cc2[nH]1)NC1CC1		CHEMBL495727	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945723	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(C(=O)NOCCO)c(Nc2ccc(I)cc2F)n(C)c1=O		CHEMBL3182621	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945724	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945725	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl		CHEMBL3137336	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945726	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1		CHEMBL3402762	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945727	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945728	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1ccc(N(C(N)=O)c2c(F)cccc2F)nc1-c1ccc(F)cc1F		CHEMBL1090090	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945729	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Kd	nM	929.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	929.0
Active	17945730	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncnc(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL3545360	=	Kd	nM	5.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	5.0
Inactive	17945731	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945732	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945733	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1		CHEMBL3590106	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945734	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)CN1CCC(Oc2cc3c(Nc4cccc(Cl)c4F)ncnc3cc2OC)CC1		CHEMBL2408045	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945735	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1		CHEMBL2035187	=	Kd	nM	9334.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	9334.0
Inactive	17945736	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(C2=Nc3cc(NC(=O)C(N)C4CCCCC4)cc4c3C2=CNNC4=O)cn1		CHEMBL3545137	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945737	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1		CHEMBL3039517	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945738	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl		CHEMBL2219422	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945739	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N[C@@H]1CCCN(c2c(/C=C3\SC(=O)NC3=O)cccc2-c2ccccc2)C1		CHEMBL2048872	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945740	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)[C@@H](c2cn3c4c(cccc24)CCC3)[C@@H]1c1c[nH]c2ccccc12		CHEMBL2103882	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945741	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1		CHEMBL3186534	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945742	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945743	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1csc(-c2nnc(Nc3ccc(Oc4ncccc4-c4ccnc(N)n4)cc3)c3ccccc23)c1		CHEMBL2140408	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945744	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945745	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F		CHEMBL1236962	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945746	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1		CHEMBL2110732	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945747	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1C#CC(C)(C)N1CCN(C)CC1		CHEMBL2138625	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945748	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945749	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945750	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945751	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945752	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(F)cc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC(C)(C)C)cn1		CHEMBL1088752	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945753	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945754	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945755	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945756	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1		CHEMBL1236682	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945757	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	303.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	303.0
Inactive	17945758	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945759	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	64.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	64.0
Inactive	17945760	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)c1cnc2ccc(-c3cc(Cl)c(O)c(Cl)c3)nc2c1N[C@H]1CC[C@H](CN(C)C)CC1		CHEMBL3688339	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945761	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC(=O)Nc1cc(-c2cccc(F)c2)sc1C(=O)N[C@H]1CCCNC1		CHEMBL2041933	=	Kd	nM	1091.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1091.0
Inactive	17945762	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945763	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(CN2CCN(C(=O)[C@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL1922094	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945764	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1		CHEMBL2087361	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945765	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(NC(=O)OC[C@@H]2COCCN2)cn2ncnc(Nc3ccc4c(cnn4Cc4cccc(F)c4)c3)c12		CHEMBL1645462	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945766	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945767	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945768	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL1873475	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945769	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1		CHEMBL571546	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945770	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1		CHEMBL3989868	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17945771	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	=	Kd	nM	1062.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1062.0
Active	17945772	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	=	Kd	nM	27.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	27.0
Inactive	17945773	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnc3ccc4ccc(CS(=O)(=O)NCc5ccccn5)cc4c(=O)c3c2)cn1		CHEMBL2323775	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945774	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL564829	=	Kd	nM	900.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	900.0
Inactive	17945775	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945776	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1		CHEMBL1952329	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945777	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL2376648	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945778	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC		CHEMBL1289494	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945779	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1		CHEMBL2386889	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945780	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	1419.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1419.0
Inactive	17945781	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1		CHEMBL1946170	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945782	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Nc2ccc3nsnc3c2)cc1		CHEMBL3218575	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945783	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	c1cc(OCCN2CCCCC2)cc(-c2n[nH]c3ccc(-c4nnc[nH]4)cc23)c1		CHEMBL1614713	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945784	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1		CHEMBL2216870	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945785	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN1CCN(Cc2ccc(-c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)cc2)CC1		CHEMBL587723	=	Kd	nM	1006.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1006.0
Inactive	17945786	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](N)c1ccc(C(=O)Nc2ccnc3[nH]ccc23)cc1		CHEMBL571948	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945787	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1		CHEMBL460702	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945788	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1cc(Cl)ccc1O		CHEMBL536151	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945789	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@]1(O)C[C@@H](c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn32)C1		CHEMBL1091644	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945790	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1		CHEMBL496102	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945791	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1		CHEMBL372764	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945792	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1		CHEMBL217092	=	Kd	nM	4650.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	4650.0
Inactive	17945793	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOCCO)c1cc(CN2OCCCC2=O)c(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL1614766	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945794	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC1(COc2ccc3c(c2)ncn3-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1		CHEMBL2105728	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945795	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1		CHEMBL270995	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945796	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](c1ccc2nccn2c1)n1nnc2ncc(-c3cnn(C)c3)nc21		CHEMBL3334567	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945797	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O		CHEMBL1289601	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945798	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1c(=O)c(-c2cc[nH]n2)cc2c(C)nc(N)nc21		CHEMBL3545366	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945799	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(Nc2[nH]nc3c2CN(C(=O)N[C@H](CN(C)C)c2ccccc2)C3(C)C)c2sccc2n1		CHEMBL3128043	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945800	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1		CHEMBL2103875	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945801	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945802	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1		CHEMBL2017974	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945803	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(O)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL400402	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945804	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945805	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCn1cc(-c2ccnc3[nH]c(-c4cccc(CN(C)C)c4)cc23)c(-c2ccc(NC(=O)N(C)C)cc2)n1		CHEMBL1090479	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945806	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc3c2cc1OCCCCCN(C)Cc1ccc(Br)cc1N3		CHEMBL3109738	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945807	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1		CHEMBL2146883	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945808	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Nc1cc(F)cc(F)c1)c1cc(C(=O)N(C)C)cc2c(=O)cc(N3CCOCC3)oc12		CHEMBL3408248	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945809	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C#Cc1cccc(Nc2ncnc3cc(OC)c(OCCCCCCC(=O)NO)cc23)c1		CHEMBL598797	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945810	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945811	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F		CHEMBL1229517	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945812	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21		CHEMBL3187723	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945813	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C1NC(=O)/C(=C/c2ccc3nccc(-c4ccncc4)c3c2)S1		CHEMBL3544966	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945814	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc([C@@H](C)Nc2ccccc2C(=O)O)c2nc(N3CCOCC3)cc(=O)n2c1		CHEMBL2165191	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945815	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945816	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]c(C2CCCN2)nc2c1oc1ccc(Cl)cc12		CHEMBL3544944	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945817	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL2325741	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945818	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1		CHEMBL3039525	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945819	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1		CHEMBL1234354	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945820	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CCNC(=O)c1ccc(-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)cc1		CHEMBL1078178	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945821	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)c(F)c(Nc2ccc(I)cc2F)c2c(=O)n(C[C@@H](O)CO)cnc21		CHEMBL1615025	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945822	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1		CHEMBL1241855	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945823	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	OCCn1cc(-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2)cn1		CHEMBL2001019	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945824	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1		CHEMBL3545085	=	Kd	nM	76.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	76.0
Inactive	17945825	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ncc(-c2ccnc(Nc3ccc(S(C)(=O)=O)cc3)n2)n1C(C)C		CHEMBL488436	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945826	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2		CHEMBL1094408	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945827	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1nccc1Nc1nccc(-c2ccn([C@H](CO)c3ccc(Cl)c(F)c3)c(=O)c2)n1		CHEMBL3544964	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945828	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1		CHEMBL3813873	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945829	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1		CHEMBL1950289	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17945830	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	1597.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	1597.0
Inactive	17945831	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(-c2cc(OC(=O)c3ccccc3)ccc2Cl)cc2nnc(Nc3ccc(OCCN4CCCC4)cc3)nc12		CHEMBL403989	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945832	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)CC(=O)Nc1n[nH]c2c1CN(C(=O)C1CCN(C)CC1)C2(C)C		CHEMBL1230607	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945833	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1		CHEMBL3545110	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945834	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945835	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL3353410	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945836	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1		CHEMBL2336325	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945837	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945838	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc(F)c(C(F)(F)F)c2)nc1C1CCN(c2ncnc3[nH]ncc23)CC1		CHEMBL3545076	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945839	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945840	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O		CHEMBL415049	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945841	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945842	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc2cc(-c3nc([C@H]4CC[C@H](C(=O)O)CC4)n4ncnc(N)c34)[nH]c12		CHEMBL3120215	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945843	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945844	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1		CHEMBL2364611	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945845	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CN(C(=O)c2cc3c(C(=O)C(=O)N(C)C)cn(C)c3cc2Cl)[C@H](C)CN1Cc1ccc(F)cc1		CHEMBL514201	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945846	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL413	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945847	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945848	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1		CHEMBL2105759	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945849	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=S(=O)(c1cccc2c(O)nccc12)N1CCCNCC1		CHEMBL1233300	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945850	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945851	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945852	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(/C=C/c3ccccc3)n2)n[nH]1		CHEMBL482968	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945853	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21		CHEMBL1614725	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945854	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C		CHEMBL1233528	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945855	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1C/C=C/CCOc2cccc(c2)-c2ccnc(n2)Nc2cccc(c2)C1		CHEMBL1944698	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945856	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C		CHEMBL1908360	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945857	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2ncnc(Nc3ccc(O)cc3)c2cc1OC		CHEMBL405130	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945858	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL274654	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945859	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(N3CCCC[C@H]3CCO)nc12		CHEMBL2103840	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945860	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1		CHEMBL3991933	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945861	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945862	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945863	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1		CHEMBL3544932	=	Kd	nM	281.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	281.0
Inactive	17945864	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC[C@@](O)(c1ccc(Cl)cc1)c1ccc(-c2cn[nH]c2)cc1		CHEMBL3544960	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945865	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	FC(F)(F)c1ccc(/C=C/c2nc(COc3ccc(CCCCn4ccnn4)cc3)co2)cc1		CHEMBL1614707	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945866	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL2103830	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945867	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2nc(N[C@@H](C)c3ncc(F)cn3)ncc2Cl)[nH]n1		CHEMBL1231124	=	Kd	nM	515.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	515.0
Inactive	17945868	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1		CHEMBL1088751	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945869	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945870	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945871	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945872	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NC[C@H](O)CO)c1ccncc1Nc1ccc(I)cc1F		CHEMBL2107832	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945873	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	=	Kd	nM	208.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	208.0
Inactive	17945874	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cc(-c2ccc3nnc(C(F)(F)c4ccc5ncccc5c4)n3n2)cn1		CHEMBL2133806	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945875	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN1N=C(N)c2cn([C@@H]3O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]3O)c3ncnc1c23		CHEMBL462018	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945876	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945877	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	=	Kd	nM	138.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	138.0
Inactive	17945878	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C[C@@H]1COCCO1)S(=O)(=O)Nc1ccc2ccc3ncc(-c4cnn(C)c4)cc3c(=O)c2c1		CHEMBL1822792	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945879	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1cc(COc2nnc(Nc3ccc(Cl)cc3)c3ccoc23)ccn1		CHEMBL2079588	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945880	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945881	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COCCN1CCN(Cc2ccc(-c3n[nH]c4c3C(=O)c3c(NC(=O)NN5CCOCC5)cccc3-4)cc2)CC1		CHEMBL3545083	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945882	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12		CHEMBL3426621	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Active	17945883	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CO[C@@H](C(=O)N1Cc2n[nH]c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL402548	=	Kd	nM	59.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	59.0
Inactive	17945884	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	S=C(NCc1ccc2c(c1)OCO2)N1CCN(c2ncnc3c2oc2ccccc23)CC1		CHEMBL2103851	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945885	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)N1CCC[C@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1		CHEMBL3991931	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945886	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945887	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(NOC[C@H](O)CO)c1ccc(F)c(F)c1Nc1ccc(I)cc1F		CHEMBL507361	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945888	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	NC1(c2ccc(-c3nc4ccn5c(=O)[nH]nc5c4cc3-c3ccccc3)cc2)CCC1		CHEMBL1079175	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945889	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945890	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1		CHEMBL3348923	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945891	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc2ccc(-n3ncc(C(=O)c4cc5ccccc5[nH]4)c3N)cc2[nH]1		CHEMBL3907479	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945892	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(S(=O)(=O)N(C(C)=O)c2ccccc2/C=C/c2cc[n+]([O-])cc2)cc1		CHEMBL3991927	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945893	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21		CHEMBL1879463	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945894	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945895	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc32)cccc1C(F)(F)F		CHEMBL3188551	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945896	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1		CHEMBL2396661	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945897	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(NC(=O)c2ccc(CN3CC[C@H](N(C)C)C3)c(C(F)(F)F)c2)cc1Nc1nccc(-c2cncnc2)n1		CHEMBL206834	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945898	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945899	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1		CHEMBL3545308	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945900	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C		CHEMBL411907	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945901	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945902	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1		CHEMBL3301607	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945903	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1cccc(C(C)(C)O)n1		CHEMBL1976040	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945904	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO		CHEMBL1801204	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Uncertain	17945905	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc(CCc2cc(NC(=O)c3ccc(N4CC(C)NC(C)C4)cc3)n[nH]2)cc(OC)c1		CHEMBL3184679	=	Kd	nM	148.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	148.0
Inactive	17945906	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945907	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1		CHEMBL3545307	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945908	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945909	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1		CHEMBL3544983	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945910	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	O=c1[nH]ccc2cc(OC3CCNCC3)ccc12		CHEMBL1667969	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
Inactive	17945911	CHEMBL3991914	Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	B	Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12		CHEMBL1171837	>	Kd	nM	30000.0	CHEMBL4599	Homo sapiens	Kd apparent	nM	30000.0
	18031885	CHEMBL4007751	Inhibition of TNK2 (unknown origin) after 60 mins by TR-FRET assay	B	CCCNC(=O)c1ccc(Nc2nc(NCC(F)(F)F)c3cc[nH]c3n2)cc1		CHEMBL2006765	=	IC50	nM	558.0	CHEMBL4599	Homo sapiens	IC50	uM	0.558
	18031886	CHEMBL4007751	Inhibition of TNK2 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc(N3CCOCC3)c(Cl)c2)nc2ccoc12		CHEMBL4078893	=	IC50	nM	4020.0	CHEMBL4599	Homo sapiens	IC50	uM	4.02
	18031887	CHEMBL4007751	Inhibition of TNK2 (unknown origin) after 60 mins by TR-FRET assay	B	FC(F)(F)CNc1nc(Nc2ccc3cn[nH]c3c2)nc2ccoc12		CHEMBL4066664	=	IC50	nM	3460.0	CHEMBL4599	Homo sapiens	IC50	uM	3.46
	18031888	CHEMBL4007751	Inhibition of TNK2 (unknown origin) after 60 mins by TR-FRET assay	B	CC1(C)OCC(=O)Nc2cc(Nc3nc(NCC(F)(F)F)c4occc4n3)ccc21		CHEMBL4069365	=	IC50	nM	1330.0	CHEMBL4599	Homo sapiens	IC50	uM	1.33
	18031889	CHEMBL4007751	Inhibition of TNK2 (unknown origin) after 60 mins by TR-FRET assay	B	Cc1n[nH]c2cc(Nc3nc(NC4CC4)c4occc4n3)ccc12		CHEMBL4062803	=	IC50	nM	1320.0	CHEMBL4599	Homo sapiens	IC50	uM	1.32
	18114887	CHEMBL4025417	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	95.0	CHEMBL4599	Homo sapiens	Activity	%	95.0
	18153355	CHEMBL4034249	Inhibition of ACK (unknown origin) labeling at conserved Lysine1 at 10 uM relative to control	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	-6.8	CHEMBL4599	Homo sapiens	INH	%	-6.8
	18203941	CHEMBL4044228	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in Escherichia coli BL21 assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	18211671	CHEMBL4045630	Inhibition of ACK labeling at ATP binding site (TVSVAVKCLKPDVLSQPEAMDDFIR) in human PBMC at 1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1		CHEMBL3971067	=	Inhibition	%	-5.7	CHEMBL4599	Homo sapiens	INH	%	-5.7
	18211777	CHEMBL4045873	Inhibition of ACK labeling at ATP binding site (TVSVAVKCLKPDVLSQPEAMDDFIR) in human PBMC at 0.1 uM	B	CC(C)n1cc(-c2cc(-c3ccc(CN4CCOCC4)cc3)cnc2N)nn1	Outside typical range	CHEMBL3971067	=	Inhibition	%	-23.8	CHEMBL4599	Homo sapiens	INH	%	-23.8
	18248634	CHEMBL4053917	Inhibition of TNK2 (unknown origin) at 1 uM relative to control	B	C=CC(=O)Nc1cc(Nc2nccc(-c3cn4c5c(cccc35)CCC4)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4104658	=	Inhibition	%	75.0	CHEMBL4599	Homo sapiens	INH	%	75.0
	18253417	CHEMBL4054992	Inhibition of wild-type human partial length ACK (S159 to D474 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	73.0	CHEMBL4599	Homo sapiens	Activity	%	73.0
	18253418	CHEMBL4054992	Inhibition of wild-type human partial length ACK (S159 to D474 residues) expressed in bacterial expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	18274737	CHEMBL4118291	Inhibition of ACK in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TVSVAVKCLKPDVLSQPEAMDDFIR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1Cl		CHEMBL3883384	=	Inhibition	%	45.1	CHEMBL4599	Homo sapiens	INH	%	45.1
	18274738	CHEMBL4118291	Inhibition of ACK in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TVSVAVKCLKPDVLSQPEAMDDFIR probe by mass-spectrometric analysis relative to control	B	C=CC(=O)Nc1ccccc1Oc1nc(Nc2cnn(CCOC)c2)ncc1Cl	Outside typical range	CHEMBL3884839	=	Inhibition	%	-32.2	CHEMBL4599	Homo sapiens	INH	%	-32.2
	18274739	CHEMBL4118291	Inhibition of ACK in human SKCO1 cells at 1 uM after 4 hrs using biotin labeled TVSVAVKCLKPDVLSQPEAMDDFIR probe by mass-spectrometric analysis relative to control	B	COc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\C[C@H](C)OC2=O	Outside typical range	CHEMBL1077979	=	Inhibition	%	-17.2	CHEMBL4599	Homo sapiens	INH	%	-17.2
	18282180	CHEMBL4120135	Inhibition of recombinant GST-tagged human TNK2 catalytic/cytoplasmic domain (110 to 476 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	1.3	CHEMBL4599	Homo sapiens	INH	%	1.3
	18282499	CHEMBL4120135	Inhibition of recombinant GST-tagged human TNK2 catalytic/cytoplasmic domain (110 to 476 residues) expressed in baculovirus expression system at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	0.3	CHEMBL4599	Homo sapiens	INH	%	0.3
	18282856	CHEMBL4120441	Inhibition of ACK (unknown origin) at 0.45 uM relative to control	B	Cc1n[nH]c(C)c1-c1ccc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2c1		CHEMBL4095072	=	Inhibition	%	13.0	CHEMBL4599	Homo sapiens	INH	%	13.0
	18283027	CHEMBL4120612	Inhibition of ACK (unknown origin) at 0.19 uM relative to control	B	Cc1[nH]nc(C2CC2)c1-c1ccc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2c1		CHEMBL4125807	=	Inhibition	%	3.0	CHEMBL4599	Homo sapiens	INH	%	3.0
	18283251	CHEMBL4120836	Inhibition of ACK (unknown origin) at 0.164 uM relative to control	B	COC(=O)Nc1cc(-c2c(C3CC3)n[nH]c2C)cc2[nH]ncc12		CHEMBL4129737	=	Inhibition	%	0.7	CHEMBL4599	Homo sapiens	INH	%	0.7
	18440483	CHEMBL4157307	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	88.0	CHEMBL4599	Homo sapiens	Activity	%	88.0
	18450770	CHEMBL4178427	Inhibition of GST-tagged recombinant human ACK catalytic domain (110 to 476 residues) expressed in Baculovirus expression system at 1 uM by FRET-based Z'-LYTE assay	B	C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F		CHEMBL3989970	>	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	18477357	CHEMBL4183792	Inhibition of human N-terminal GST-tagged ACK catalytic domain expressed in baculovirus expression system at 10 nM relative to control	B	N[C@H]1CC[C@H](Nc2nc(Nc3ccc(CN4CCOCC4)cc3)c3ncn(C4CCCC4)c3n2)CC1		CHEMBL4204373	>	Inhibition	%	90.0	CHEMBL4599	Homo sapiens	INH	%	90.0
	18484439	CHEMBL4186086	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	96.0	CHEMBL4599	Homo sapiens	Activity	%	96.0
	18484923	CHEMBL4186086	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in Escherichia coli BL21 at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	86.0	CHEMBL4599	Homo sapiens	Activity	%	86.0
	18507909	CHEMBL4190853	Inhibition of recombinant human ACK1 (1 to 389 residues) at 1 uM using EFPIYDFLPAKKK as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	44.0	CHEMBL4599	Homo sapiens	INH	%	44.0
	18558364	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL1214141	=	IC50	nM	25.0	CHEMBL4599	Homo sapiens	IC50	nM	25.0
	18558366	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(Nc3ccccc3)nc2N(C)C1=O		CHEMBL1214142	=	IC50	nM	37.0	CHEMBL4599	Homo sapiens	IC50	nM	37.0
	18558367	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cc2)CC1		CHEMBL4209948	=	IC50	nM	20.0	CHEMBL4599	Homo sapiens	IC50	nM	20.0
	18558368	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CCN1CCN(c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4214863	=	IC50	nM	28.0	CHEMBL4599	Homo sapiens	IC50	nM	28.0
	18558369	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CC(=O)N1CCN(c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4214342	=	IC50	nM	8.0	CHEMBL4599	Homo sapiens	IC50	nM	8.0
	18558370	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CCN1CCN(C(=O)c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4202685	=	IC50	nM	13.0	CHEMBL4599	Homo sapiens	IC50	nM	13.0
	18558371	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(Nc3cnn(C)c3)nc2N(C)C1=O		CHEMBL4217421	=	IC50	nM	20.0	CHEMBL4599	Homo sapiens	IC50	nM	20.0
	18558372	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1cc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)n(C)n1		CHEMBL4213673	=	IC50	nM	9.0	CHEMBL4599	Homo sapiens	IC50	nM	9.0
	18558373	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(NC3CC3)nc2N(C)C1=O		CHEMBL4210482	=	IC50	nM	35.0	CHEMBL4599	Homo sapiens	IC50	nM	35.0
	18558374	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(NC3CCCCC3)nc2N(C)C1=O		CHEMBL4211395	=	IC50	nM	60.0	CHEMBL4599	Homo sapiens	IC50	nM	60.0
	18558375	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(NCCO)nc2N(C)C1=O		CHEMBL4215989	=	IC50	nM	21.0	CHEMBL4599	Homo sapiens	IC50	nM	21.0
	18558376	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850	=	IC50	nM	18.0	CHEMBL4599	Homo sapiens	IC50	nM	18.0
	18558377	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccccc4)ccc2C)C3)cn1		CHEMBL4209082	=	IC50	nM	21.0	CHEMBL4599	Homo sapiens	IC50	nM	21.0
	18558378	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(C)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4212809	=	IC50	nM	20.0	CHEMBL4599	Homo sapiens	IC50	nM	20.0
	18558379	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cc(N5CCOCC5)cc(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4218831	=	IC50	nM	26.0	CHEMBL4599	Homo sapiens	IC50	nM	26.0
	18558380	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cc(N5CCC(O)CC5)cc(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4205942	=	IC50	nM	40.0	CHEMBL4599	Homo sapiens	IC50	nM	40.0
	18558381	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cc(-n5cnc(C)c5)cc(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4211880	=	IC50	nM	53.0	CHEMBL4599	Homo sapiens	IC50	nM	53.0
	18558382	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(-n5cccc5)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4212150	=	IC50	nM	10.0	CHEMBL4599	Homo sapiens	IC50	nM	10.0
	18558383	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(N5CCN(C)CC5)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4211976	=	IC50	nM	28.0	CHEMBL4599	Homo sapiens	IC50	nM	28.0
	18558384	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(CN5CCN(C)CC5)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4207100	=	IC50	nM	26.0	CHEMBL4599	Homo sapiens	IC50	nM	26.0
	18558385	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(CN5CCC(N(C)C)C5)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4207036	=	IC50	nM	6.0	CHEMBL4599	Homo sapiens	IC50	nM	6.0
	18558386	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CCN1C(=O)N(c2cc(NC(=O)c3ccc(C)c(C(F)(F)F)c3)ccc2C)Cc2cnc(Nc3ccc(C)nc3)nc21		CHEMBL4203337	=	IC50	nM	23.0	CHEMBL4599	Homo sapiens	IC50	nM	23.0
	18558387	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C2CC2)C(=O)N(c2cc(NC(=O)c4ccc(C)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4213945	=	IC50	nM	36.0	CHEMBL4599	Homo sapiens	IC50	nM	36.0
	18558388	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(C2CCCCC2)C(=O)N(c2cc(NC(=O)c4ccc(C)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4210185	=	IC50	nM	94.0	CHEMBL4599	Homo sapiens	IC50	nM	94.0
	18558389	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(c2ccccc2)C(=O)N(c2cc(NC(=O)c4ccc(C)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4215916	=	IC50	nM	15.0	CHEMBL4599	Homo sapiens	IC50	nM	15.0
	18558390	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(Nc2ncc3c(n2)N(Cc2ccccc2)C(=O)N(c2cc(NC(=O)c4ccc(C)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4206139	=	IC50	nM	40.0	CHEMBL4599	Homo sapiens	IC50	nM	40.0
	18558391	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CC(=O)N1CCN(c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5ccc(CN6CCC(N(C)C)C6)c(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4216786	=	IC50	nM	25.0	CHEMBL4599	Homo sapiens	IC50	nM	25.0
	18558392	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	CCN1CCN(C(=O)c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5ccc(CN6CCC(N(C)C)C6)c(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4213019	=	IC50	nM	21.0	CHEMBL4599	Homo sapiens	IC50	nM	21.0
	18558393	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCC(N(C)C)C3)c(C(F)(F)F)c2)cc1N1Cc2cnc(Nc3cnn(C)c3)nc2N(C)C1=O		CHEMBL4207753	=	IC50	nM	25.0	CHEMBL4599	Homo sapiens	IC50	nM	25.0
	18558394	CHEMBL4201008	Inhibition of ACK1 (unknown origin) by radiometric biochemical kinase assay	B	Cc1cc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(CN5CCC(N(C)C)C5)c(C(F)(F)F)c4)ccc2C)C3)n(C)n1		CHEMBL4212663	=	IC50	nM	11.0	CHEMBL4599	Homo sapiens	IC50	nM	11.0
Active	18558606	CHEMBL4201032	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in P70S6K1 phosphorylation at Thr421/Ser424 at 1 uM after 2 hrs by Western blot analysis	B	CCN1CCN(C(=O)c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4202685		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558607	CHEMBL4201032	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in P70S6K1 phosphorylation at Thr421/Ser424 at 1 uM after 2 hrs by Western blot analysis	B	Cc1cc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)n(C)n1		CHEMBL4213673		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558608	CHEMBL4201032	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in P70S6K1 phosphorylation at Thr421/Ser424 at 1 uM after 2 hrs by Western blot analysis	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558609	CHEMBL4201032	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in P70S6K1 phosphorylation at Thr421/Ser424 at 1 uM after 2 hrs by Western blot analysis	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(CN5CCC(N(C)C)C5)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4207036		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558610	CHEMBL4201033	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in AKT phosphorylation at S473 at 1 uM after 2 hrs by Western blot analysis	B	CCN1CCN(C(=O)c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4202685		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558611	CHEMBL4201033	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in AKT phosphorylation at S473 at 1 uM after 2 hrs by Western blot analysis	B	Cc1cc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4cccc(C(F)(F)F)c4)ccc2C)C3)n(C)n1		CHEMBL4213673		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558612	CHEMBL4201033	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in AKT phosphorylation at S473 at 1 uM after 2 hrs by Western blot analysis	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	18558613	CHEMBL4201033	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in AKT phosphorylation at S473 at 1 uM after 2 hrs by Western blot analysis	B	Cc1ccc(Nc2ncc3c(n2)N(C)C(=O)N(c2cc(NC(=O)c4ccc(CN5CCC(N(C)C)C5)c(C(F)(F)F)c4)ccc2C)C3)cn1		CHEMBL4207036		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Dose-dependent effect	18558622	CHEMBL4201036	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in P70S6K1 phosphorylation at Thr421/Ser424 after 2 hrs by Western blot analysis	B	CC(=O)N1CCN(c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4214342		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Dose-dependent effect	18558623	CHEMBL4201036	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in P70S6K1 phosphorylation at Thr421/Ser424 after 2 hrs by Western blot analysis	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Dose-dependent effect	18558624	CHEMBL4201037	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in AKT phosphorylation at S473 after 2 hrs by Western blot analysis	B	CC(=O)N1CCN(c2ccc(Nc3ncc4c(n3)N(C)C(=O)N(c3cc(NC(=O)c5cccc(C(F)(F)F)c5)ccc3C)C4)cn2)CC1		CHEMBL4214342		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Dose-dependent effect	18558625	CHEMBL4201037	Inhibition of ACK1 in human OCI-AML3 cells harboring NRAS Q61L mutant assessed as reduction in AKT phosphorylation at S473 after 2 hrs by Western blot analysis	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
	18558646	CHEMBL4201072	Inhibition of human ACK1 at 1 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1N1Cc2cnc(N)nc2N(C)C1=O		CHEMBL459850	=	Inhibition	%	100.0	CHEMBL4599	Homo sapiens	INH	%	100.0
	18653325	CHEMBL4230243	Inhibition of TNK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc(NC(=O)c3cccc(C(F)(F)F)c3)c2)c2c(N)ncnc21		CHEMBL3736320	=	Inhibition	%	13.0	CHEMBL4599	Homo sapiens	INH	%	13.0
	18653326	CHEMBL4230243	Inhibition of TNK2 (unknown origin) at 1 uM by mobility shift microfluidics platform based assay relative to control	B	CC(C)n1nc(C#Cc2cccc3cc(-c4cccc(C(F)(F)F)c4)ncc23)c2c(N)ncnc21		CHEMBL4247506	=	Inhibition	%	3.0	CHEMBL4599	Homo sapiens	INH	%	3.0
	18655249	CHEMBL4230986	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	88.0	CHEMBL4599	Homo sapiens	Activity	%	88.0
	18737840	CHEMBL4261399	Inhibition of recombinant human ACK1 (1 to 389 residues) using EFPIYDFLPAKKK as substrate after 40 mins in presence of [gamma-33P]-ATP by scintillation counting analysis	B	CCn1cc(-c2ccc3c(c2)CCN3C(=O)Cc2cccc(OC(F)(F)F)c2)c2c(N)ncnc21		CHEMBL4281823	=	IC50	nM	995.0	CHEMBL4599	Homo sapiens	IC50	nM	995.0
	18751255	CHEMBL4263964	Inhibition of TNK2 (unknown origin) at 1 uM relative to control	B	NC1(c2ccc(-c3cnc4c(-c5ccc(S(N)(=O)=O)c6ccccc56)cnn4c3)cc2)CCC1		CHEMBL4278763	=	Inhibition	%	8.0	CHEMBL4599	Homo sapiens	INH	%	8.0
	18752238	CHEMBL4264575	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	95.0	CHEMBL4599	Homo sapiens	Activity	%	95.0
	18858238	CHEMBL4308084	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	18881256	CHEMBL4312066	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system by TR-FRET assay	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	10.0	CHEMBL4599	Homo sapiens	Ki	nM	10.0
	18892551	CHEMBL4314720	Inhibition of recombinant human ACK1 (1 to 389 residues) assessed as residual activity at 10 uM using EFPIYDFLPAKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	118.5	CHEMBL4599	Homo sapiens	Activity	%	118.5
	18919461	CHEMBL4322817	Binding affinity to recombinant N-terminal His-FLAG-GST-tagged TNK2 (unknown origin) (110 to 476 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](NCCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4465866	=	Kd	nM	36.0	CHEMBL4599	Homo sapiens	Kd	nM	36.0
	18919649	CHEMBL4322817	Binding affinity to recombinant N-terminal His-FLAG-GST-tagged TNK2 (unknown origin) (110 to 476 residues) expressed in baculovirus infected Sf9 insect cells incubated for 1 hr by TR-FRET assay	B	CO[C@@H]1[C@H](N(C)CCOCCOCCOCCNC(=O)CCC2=[N+]3C(=Cc4c(C)cc(C)n4[B-]3(F)F)C=C2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL4576489	=	Kd	nM	42.0	CHEMBL4599	Homo sapiens	Kd	nM	42.0
	18930953	CHEMBL4325611	Inhibition of recombinant human N-terminal GST-tagged ACK1 (1 to 389 residues) expressed in baculovirus infected Sf21 insect cells at 1000 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	Inhibition	%	30.9	CHEMBL4599	Homo sapiens	INH	%	30.9
	18930977	CHEMBL4325635	Inhibition of recombinant human N-terminal GST-tagged ACK1 (1 to 389 residues) expressed in baculovirus infected Sf21 insect cells at 100 nM using poly (Glu, Tyr)4:1 as substrate measured after 1 hr by ELISA relative to control	B	Cc1ccc(C(=O)Nc2ccc(Cl)cc2)cc1C#Cc1cc(-c2cnn(C)c2)cnc1N		CHEMBL4576115	=	Inhibition	%	10.3	CHEMBL4599	Homo sapiens	INH	%	10.3
	18934066	CHEMBL4326598	Inhibition of human ACK1 at 10 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	B	CC(=O)N1CCN(c2ccc(Nc3ncc(C(F)(F)F)c(N4Cc5cccc(N(C)S(C)(=O)=O)c5C4)n3)cc2)CC1		CHEMBL4476226	=	Inhibition	%	91.1	CHEMBL4599	Homo sapiens	INH	%	91.1
	18937689	CHEMBL4327574	Inhibition of human ACK1 assessed as residual activity at 1 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	90.61	CHEMBL4599	Homo sapiens	Activity	%	90.61
	18937690	CHEMBL4327574	Inhibition of human ACK1 assessed as residual activity at 1 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	99.77	CHEMBL4599	Homo sapiens	Activity	%	99.77
	18938415	CHEMBL4327935	Inhibition of human ACK1 assessed as residual activity at 100 uM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay relative to control	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	<	Activity	%	65.0	CHEMBL4599	Homo sapiens	Activity	%	65.0
	18938780	CHEMBL4328299	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	34.8	CHEMBL4599	Homo sapiens	IC50	10'-8M	3.48
	18959010	CHEMBL4333666	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	60.0	CHEMBL4599	Homo sapiens	Activity	%	60.0
	18964048	CHEMBL4334958	Inhibition of human ACK1 (1 to 389 residues) assessed as residual activity at 1 uM using EFPIYDFLPAKKK as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	93.0	CHEMBL4599	Homo sapiens	Activity	%	93.0
	18964049	CHEMBL4334958	Inhibition of human ACK1 (1 to 389 residues) assessed as residual activity at 1 uM using EFPIYDFLPAKKK as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	96.0	CHEMBL4599	Homo sapiens	Activity	%	96.0
	18971775	CHEMBL4336785	Inhibition of human ACK1 (1 to 389 residues) assessed as residual activity at 10 uM using EFPIYDFLPAKKK as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	22.0	CHEMBL4599	Homo sapiens	Activity	%	22.0
Not Active	19039907	CHEMBL4351736	Inhibition of recombinant human ACK1 (1 to 389 residues) at 10 uM using EFPIYDFLPAKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
Active	19041000	CHEMBL4352261	Inhibition of human ACK1 at 10 uM using EAIYAAPFAKKK as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL4599	Homo sapiens	INH		
	19048772	CHEMBL4354257	Inhibition of TNK2 (unknown origin) at 1 uM	B	COc1cc(N2CCNCC2)ccc1Nc1cc(N2CCC[C@H](C(=O)NCc3ccc(OC(F)(F)F)cc3)C2)ccn1		CHEMBL4523063	=	Inhibition	%	-3.0	CHEMBL4599	Homo sapiens	INH	%	-3.0
	19059863	CHEMBL4358164	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	81.0	CHEMBL4599	Homo sapiens	Activity	%	81.0
	19090427	CHEMBL4366001	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	19091803	CHEMBL4366277	Inhibition of human ACK1 at 100 nM using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	10.42	CHEMBL4599	Homo sapiens	INH	%	10.42
	19144606	CHEMBL4377622	Inhibition of recombinant human ACK1 (1 to 389 residues) at 1 uM using EFPIYDFLPAKKK as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	82.0	CHEMBL4599	Homo sapiens	INH	%	82.0
	19146816	CHEMBL4378976	Inhibition of human ACK1 (1 to 389 residues) at 10 uM using EFPIYDFLPAKKK as substrate after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	C=CS(=O)(=O)Nc1ccc(Cc2ccc3ccccc3c2)cc1		CHEMBL4459587	=	Inhibition	%	10.0	CHEMBL4599	Homo sapiens	INH	%	10.0
	19147736	CHEMBL4379132	Inhibition of human recombinant ACK1 (1 to 389 residues) using EFPIYDFLPAKKK as substrate incubated for 40 mins in presence of [gamma-33P]ATP by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	uM	10.0
	19159691	CHEMBL4382795	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	0.15	CHEMBL4599	Homo sapiens	Activity	%	0.15
	19159734	CHEMBL4382838	Inhibition of recombinant GST-tagged human TNK2 catalytic/cytoplasmic domain (110 to 476 residues) expressed in baculovirus expression system by LanthaScreen assay	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	IC50	nM	13.0	CHEMBL4599	Homo sapiens	IC50	nM	13.0
	19181158	CHEMBL4387369	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system at 0.1 uM measured after 60 mins by Lanthascreen assay	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	2.4	CHEMBL4599	Homo sapiens	INH	%	2.4
	19181383	CHEMBL4387369	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system at 0.1 uM measured after 60 mins by Lanthascreen assay	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	5.0	CHEMBL4599	Homo sapiens	INH	%	5.0
	19191316	CHEMBL4389514	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	100.0	CHEMBL4599	Homo sapiens	INH	%	100.0
	19192177	CHEMBL4389991	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	100.0	CHEMBL4599	Homo sapiens	INH	%	100.0
	19200433	CHEMBL4391617	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	19218930	CHEMBL4394545	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system by Kinomescan method	B	COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1		CHEMBL3545396	<	Kd	nM	225.0	CHEMBL4599	Homo sapiens	Kd	nM	225.0
	19266300	CHEMBL4405250	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL4599	Homo sapiens	INH	%	50.0
	19292305	CHEMBL4411556	Inhibition of N-terminal GST tagged human ACK (110 to 476 residues) catalytic domain expressed in baculovirus expression system at 1 uM in presence of ATP at its Km level relative to control	B	Cn1cc(Nc2nccc(N3C[C@H]4CC[C@H](C3)N4C(=O)[C@@H]3CC3(F)F)n2)cn1		CHEMBL4458435	=	Inhibition	%	82.0	CHEMBL4599	Homo sapiens	INH	%	82.0
	20635422	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL1672987	=	IC50	nM	44.0	CHEMBL4599	Homo sapiens	IC50	nM	44.0
	20635423	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2C		CHEMBL1673039	=	IC50	nM	959.0	CHEMBL4599	Homo sapiens	IC50	nM	959.0
	20635424	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cccc(C)c1C(=O)N2		CHEMBL4646229	=	IC50	nM	1610.0	CHEMBL4599	Homo sapiens	IC50	nM	1610.0
	20635425	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccc(C)cc1C(=O)N2		CHEMBL4644397	=	IC50	nM	363.0	CHEMBL4599	Homo sapiens	IC50	nM	363.0
	20635426	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cc(C)ccc1C(=O)N2		CHEMBL4636937	=	IC50	nM	223.0	CHEMBL4599	Homo sapiens	IC50	nM	223.0
	20635427	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1c(C)cccc1C(=O)N2		CHEMBL4649556	=	IC50	nM	73.0	CHEMBL4599	Homo sapiens	IC50	nM	73.0
	20635428	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cccc(F)c1C(=O)N2		CHEMBL4633699	=	IC50	nM	217.0	CHEMBL4599	Homo sapiens	IC50	nM	217.0
	20635429	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccc(F)cc1C(=O)N2		CHEMBL4640243	=	IC50	nM	26.0	CHEMBL4599	Homo sapiens	IC50	nM	26.0
	20635430	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cc(F)ccc1C(=O)N2		CHEMBL4645012	=	IC50	nM	308.0	CHEMBL4599	Homo sapiens	IC50	nM	308.0
	20635431	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1c(F)cccc1C(=O)N2		CHEMBL4642494	=	IC50	nM	101.0	CHEMBL4599	Homo sapiens	IC50	nM	101.0
	20635432	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccc(C#N)cc1C(=O)N2		CHEMBL4635766	=	IC50	nM	723.0	CHEMBL4599	Homo sapiens	IC50	nM	723.0
	20635433	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1cc(C#N)ccc1C(=O)N2		CHEMBL4642279	=	IC50	nM	2480.0	CHEMBL4599	Homo sapiens	IC50	nM	2480.0
	20635434	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1CCN(c2ccc(Nc3ncc4c(n3)N(C)c3ccccc3C(=O)N4)cc2)CC1		CHEMBL4640316	=	IC50	nM	16.0	CHEMBL4599	Homo sapiens	IC50	nM	16.0
	20635435	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CCOc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4637720	=	IC50	nM	88.0	CHEMBL4599	Homo sapiens	IC50	nM	88.0
	20635436	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	Cc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4634637	=	IC50	nM	97.0	CHEMBL4599	Homo sapiens	IC50	nM	97.0
	20635437	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1CCN(c2ccc(Nc3ncc4c(n3)N(C)c3ccccc3C(=O)N4)c(Cl)c2)CC1		CHEMBL4648368	=	IC50	nM	63.0	CHEMBL4599	Homo sapiens	IC50	nM	63.0
	20635438	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)ccc1N1CCN(C)CC1		CHEMBL4640664	=	IC50	nM	4.0	CHEMBL4599	Homo sapiens	IC50	nM	4.0
	20635439	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CCOc1cc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)ccc1N1CCN(C)CC1		CHEMBL4642708	=	IC50	nM	4.0	CHEMBL4599	Homo sapiens	IC50	nM	4.0
	20635440	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	Cc1cc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)ccc1N1CCN(C)CC1		CHEMBL4646285	=	IC50	nM	6.0	CHEMBL4599	Homo sapiens	IC50	nM	6.0
	20635441	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1CCN(c2ccc(Nc3ncc4c(n3)N(C)c3ccccc3C(=O)N4)cc2Cl)CC1		CHEMBL4648763	=	IC50	nM	11.0	CHEMBL4599	Homo sapiens	IC50	nM	11.0
	20635442	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCC(O)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4647423	=	IC50	nM	37.0	CHEMBL4599	Homo sapiens	IC50	nM	37.0
	20635443	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1c2ccccc2C(=O)Nc2cnc(Nc3ccc(N4CCC(O)CC4)cc3)nc21		CHEMBL4641789	=	IC50	nM	7.0	CHEMBL4599	Homo sapiens	IC50	nM	7.0
	20635444	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCOCC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4637921	=	IC50	nM	41.0	CHEMBL4599	Homo sapiens	IC50	nM	41.0
	20635445	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2CCN(CCO)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4639091	=	IC50	nM	37.0	CHEMBL4599	Homo sapiens	IC50	nM	37.0
	20635446	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(N2C[C@H](C)N[C@H](C)C2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4639490	=	IC50	nM	29.0	CHEMBL4599	Homo sapiens	IC50	nM	29.0
	20635447	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4646592	=	IC50	nM	62.0	CHEMBL4599	Homo sapiens	IC50	nM	62.0
	20635448	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(C2CCN(CCO)CC2)ccc1Nc1ncc2c(n1)N(C)c1ccccc1C(=O)N2		CHEMBL4644218	=	IC50	nM	66.0	CHEMBL4599	Homo sapiens	IC50	nM	66.0
	20635449	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)ccc1N1CCN(CCO)CC1		CHEMBL4645836	=	IC50	nM	7.0	CHEMBL4599	Homo sapiens	IC50	nM	7.0
	20635450	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)ccc1N1C[C@H](C)N[C@H](C)C1		CHEMBL4641234	=	IC50	nM	4.0	CHEMBL4599	Homo sapiens	IC50	nM	4.0
	20635451	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)ccc1C1CCN(C)CC1		CHEMBL4640785	=	IC50	nM	13.0	CHEMBL4599	Homo sapiens	IC50	nM	13.0
	20635452	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1ccc(N2CCN(C)CC2)cc1Nc1ccc(Nc2ncc3c(n2)N(C)c2ccccc2C(=O)N3)cc1		CHEMBL4644196	=	IC50	nM	254.0	CHEMBL4599	Homo sapiens	IC50	nM	254.0
	20635453	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1Cc2ccc(Nc3ccc(Nc4ncc5c(n4)N(C)c4ccccc4C(=O)N5)cc3)cc2C1		CHEMBL4644425	=	IC50	nM	26.0	CHEMBL4599	Homo sapiens	IC50	nM	26.0
	20635454	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc2c(cc1Nc1ccc(Nc3ncc4c(n3)N(C)c3ccccc3C(=O)N4)cc1)CN(C)C2		CHEMBL4633821	=	IC50	nM	91.0	CHEMBL4599	Homo sapiens	IC50	nM	91.0
	20635455	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1CCc2cc(Nc3ccc(Nc4ncc5c(n4)N(C)c4ccccc4C(=O)N5)cc3)ccc2C1		CHEMBL4635845	=	IC50	nM	18.0	CHEMBL4599	Homo sapiens	IC50	nM	18.0
	20635456	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc2c(cc1Nc1ccc(Nc3ncc4c(n3)N(C)c3ccccc3C(=O)N4)cc1)CCN(C)C2		CHEMBL4645704	=	IC50	nM	50.0	CHEMBL4599	Homo sapiens	IC50	nM	50.0
	20635457	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	CN1CCc2ccc(Nc3ccc(Nc4ncc5c(n4)N(C)c4ccccc4C(=O)N5)cc3)cc2C1		CHEMBL4647099	=	IC50	nM	28.0	CHEMBL4599	Homo sapiens	IC50	nM	28.0
	20635458	CHEMBL4611611	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 catalytic domain (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by Lanthascreen assay	B	COc1cc2c(cc1Nc1ccc(Nc3ncc4c(n3)N(C)c3ccccc3C(=O)N4)cc1)CN(C)CC2		CHEMBL4648786	=	IC50	nM	140.0	CHEMBL4599	Homo sapiens	IC50	nM	140.0
	20661619	CHEMBL4618351	Inhibition of human ACK1 using [EAIYAAPFAKKK] as substrate in presence of [gamma33P]ATP by hotspot assay	B	CC(O)(C#Cc1ccc(N2CCOCC2)c(Nc2ncnc3[nH]ccc23)c1)c1nccs1		CHEMBL4645565	=	IC50	nM	191.7	CHEMBL4599	Homo sapiens	IC50	nM	191.7
	22392179	CHEMBL4667274	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system at 10 uM incubated for 60 mins by Lanthascreen assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	1.5	CHEMBL4599	Homo sapiens	INH	%	1.5
	22423128	CHEMBL4674139	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate at 0.5 uM by [gamma-33P]-ATP assay relative to control	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Inhibition	%	80.0	CHEMBL4599	Homo sapiens	INH	%	80.0
	22423851	CHEMBL4674501	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	103.43	CHEMBL4599	Homo sapiens	Activity	%	103.43
	22423852	CHEMBL4674501	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	104.71	CHEMBL4599	Homo sapiens	Activity	%	104.71
	22757764	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccccc1NC(=O)N2		CHEMBL4793238	=	IC50	nM	738.0	CHEMBL4599	Homo sapiens	IC50	nM	738.0
	22757765	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccccc1NC(=O)N2C		CHEMBL4758523	>	IC50	nM	10000.0	CHEMBL4599	Homo sapiens	IC50	nM	10000.0
	22757766	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccccc1N(C)C(=O)N2		CHEMBL4797362	=	IC50	nM	4770.0	CHEMBL4599	Homo sapiens	IC50	nM	4770.0
	22757767	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1cccc(C)c1NC(=O)N2		CHEMBL4744309	=	IC50	nM	942.0	CHEMBL4599	Homo sapiens	IC50	nM	942.0
	22757768	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4761486	=	IC50	nM	224.0	CHEMBL4599	Homo sapiens	IC50	nM	224.0
	22757769	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1cc(C)ccc1NC(=O)N2		CHEMBL4762595	=	IC50	nM	91.0	CHEMBL4599	Homo sapiens	IC50	nM	91.0
	22757770	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1c(C)cccc1NC(=O)N2		CHEMBL4787806	=	IC50	nM	1070.0	CHEMBL4599	Homo sapiens	IC50	nM	1070.0
	22757771	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1cccc(F)c1NC(=O)N2		CHEMBL4761820	=	IC50	nM	248.0	CHEMBL4599	Homo sapiens	IC50	nM	248.0
	22757772	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccc(F)cc1NC(=O)N2		CHEMBL4740752	=	IC50	nM	683.0	CHEMBL4599	Homo sapiens	IC50	nM	683.0
	22757773	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1cc(F)ccc1NC(=O)N2		CHEMBL4744202	=	IC50	nM	204.0	CHEMBL4599	Homo sapiens	IC50	nM	204.0
	22757774	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccc(C3CC3)cc1NC(=O)N2		CHEMBL4744937	=	IC50	nM	135.0	CHEMBL4599	Homo sapiens	IC50	nM	135.0
	22757775	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1ccc2c(c1)NC(=O)Nc1cnc(Nc3ccc(N4CCN(C)CC4)cc3OC)nc1-2		CHEMBL4741829	=	IC50	nM	394.0	CHEMBL4599	Homo sapiens	IC50	nM	394.0
	22757776	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	Cc1ccc2c(c1)NC(=O)Nc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2		CHEMBL4742655	=	IC50	nM	113.0	CHEMBL4599	Homo sapiens	IC50	nM	113.0
	22757777	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(Nc2ncc3c(n2)-c2ccc(C)cc2NC(=O)N3)ccc1N1CCN(C)CC1		CHEMBL4788961	=	IC50	nM	13.0	CHEMBL4599	Homo sapiens	IC50	nM	13.0
	22757778	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(CCO)CC2)ccc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4798452	=	IC50	nM	164.0	CHEMBL4599	Homo sapiens	IC50	nM	164.0
	22757779	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2C[C@H](C)N[C@H](C)C2)ccc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4792672	=	IC50	nM	102.0	CHEMBL4599	Homo sapiens	IC50	nM	102.0
	22757780	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)cc(F)c1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4741425	=	IC50	nM	3935.0	CHEMBL4599	Homo sapiens	IC50	nM	3935.0
	22757781	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(N2CCN(C)CC2)c(F)cc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4746671	=	IC50	nM	120.0	CHEMBL4599	Homo sapiens	IC50	nM	120.0
	22757782	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(C2CCN(C)CC2)ccc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4776316	=	IC50	nM	405.0	CHEMBL4599	Homo sapiens	IC50	nM	405.0
	22757783	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(C2CCCCN2C)ccc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4749755	=	IC50	nM	3410.0	CHEMBL4599	Homo sapiens	IC50	nM	3410.0
	22757784	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc(C2CCCN(C)C2)ccc1Nc1ncc2c(n1)-c1ccc(C)cc1NC(=O)N2		CHEMBL4777299	=	IC50	nM	364.0	CHEMBL4599	Homo sapiens	IC50	nM	364.0
	22757785	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc2c(cc1Nc1ncc3c(n1)-c1ccc(C)cc1NC(=O)N3)CN(C)C2		CHEMBL4749442	=	IC50	nM	313.0	CHEMBL4599	Homo sapiens	IC50	nM	313.0
	22757786	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc2c(cc1Nc1ncc3c(n1)-c1ccc(C)cc1NC(=O)N3)CN(C)CC2		CHEMBL4796379	=	IC50	nM	279.0	CHEMBL4599	Homo sapiens	IC50	nM	279.0
	22757787	CHEMBL4701282	Inhibition of tracer 236 binding to recombinant human GST-tagged TNK2 (110 to 476 residues) expressed in baculovirus expression system incubated for 60 mins by by Lanthascreen assay	B	COc1cc2c(cc1Nc1ncc3c(n1)-c1ccc(C)cc1NC(=O)N3)CCN(C)C2		CHEMBL4743052	=	IC50	nM	131.0	CHEMBL4599	Homo sapiens	IC50	nM	131.0
	22815897	CHEMBL4714743	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system at 10 uM by Kinomescan method relative to control	B	CNC(=O)CN(Cc1ccccc1OC(F)F)C(=O)c1c[nH]c(C(=O)N2CCCC2)n1		CHEMBL4779479	>	Inhibition	%	65.0	CHEMBL4599	Homo sapiens	INH	%	65.0
	22820418	CHEMBL4716211	Inhibition of recombinant N-terminal GST-tagged human ACK1 (1 to 389 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1		CHEMBL2403108	=	Activity	%	-1.0	CHEMBL4599	Homo sapiens	Activity	%	-1.0
	22820419	CHEMBL4716211	Inhibition of recombinant N-terminal GST-tagged human ACK1 (1 to 389 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control	B	COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCNC2		CHEMBL4782674	=	Activity	%	1.0	CHEMBL4599	Homo sapiens	Activity	%	1.0
	22843852	CHEMBL4720838	Inhibition of human ACK1 using EAIYAAPFAKKK as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	24.9	CHEMBL4599	Homo sapiens	IC50	10^-8M	2.49
	22844328	CHEMBL4721191	Inhibition of human ACK1 assessed as residual activity using EAIYAAPFAKKK as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	93.33	CHEMBL4599	Homo sapiens	Activity	%	93.33
	22844610	CHEMBL4721285	Inhibition of ACK1 (unknown origin) assessed as residual activity at 1 uM relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	27.95	CHEMBL4599	Homo sapiens	Activity	%	27.95
	22950610	CHEMBL4766177	Inhibition of human recombinant ACK1 (1 to 389 residues) using EFPIYDFLPAKKK as substrate incubated for 40 mins in presence of [gamma33P-ATP] by radiometric scintillation counting analysis	B	Cc1ccc(NC(=O)c2ccc(C)c(C(F)(F)F)c2)cc1C#Cc1nn([C@H]2CC[C@H](O)CC2)c2ncnc(N)c12		CHEMBL4798527	=	IC50	nM	175.0	CHEMBL4599	Homo sapiens	IC50	uM	0.175
	22952745	CHEMBL4766682	Inhibition of human ACK1 (1 to 389 residues) assessed as residual activity at 10 uM using EFPIYDFLPAKKK as substrate incubated for 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	68.0	CHEMBL4599	Homo sapiens	Activity	%	68.0
	22979780	CHEMBL4772662	Binding affinity to wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system by Kinomescan method relative to control	B	C[C@@H](Nc1ccc2[nH]nc(/C=C/c3ccccn3)c2c1)c1cc(F)cc(F)c1		CHEMBL4792981	=	Kd	nM	21.0	CHEMBL4599	Homo sapiens	Kd	nM	21.0
	22979814	CHEMBL4772696	Inhibition of wild-type human partial length TNK2 (S159 to D474 residues) expressed in bacterial expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C[C@@H](Nc1ccc2[nH]nc(/C=C/c3ccccn3)c2c1)c1cc(F)cc(F)c1		CHEMBL4792981	>	Activity	%	90.0	CHEMBL4599	Homo sapiens	Activity	%	90.0
	23120148	CHEMBL4804337	Inhibition of ACK in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	IC50	nM	23300.0	CHEMBL4599	Homo sapiens	IC50	uM	23.3
	23120149	CHEMBL4804337	Inhibition of ACK in human NCI-H929 cells by mass spectroscopic analysis	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1	Outside typical range	CHEMBL4860979	=	IC50	nM	-18800.0	CHEMBL4599	Homo sapiens	IC50	uM	-18.8
	23120150	CHEMBL4804337	Inhibition of ACK in human NCI-H929 cells by mass spectroscopic analysis	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	IC50	nM	11300.0	CHEMBL4599	Homo sapiens	IC50	uM	11.3
	23120151	CHEMBL4804337	Inhibition of ACK in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4855730	=	IC50	nM	-39000.0	CHEMBL4599	Homo sapiens	IC50	uM	-39.0
	23120152	CHEMBL4804337	Inhibition of ACK in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	IC50	nM	30700.0	CHEMBL4599	Homo sapiens	IC50	uM	30.7
	23120153	CHEMBL4804337	Inhibition of ACK in human NCI-H929 cells by mass spectroscopic analysis	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O	Outside typical range	CHEMBL4859660	=	IC50	nM	-17300.0	CHEMBL4599	Homo sapiens	IC50	uM	-17.3
	23121193	CHEMBL4804519	Inhibition of ACK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc3ncsc23)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855542	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	23121194	CHEMBL4804519	Inhibition of ACK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	CN(C1CC1)S(=O)(=O)c1ccc(-c2cnc(N)c(-c3ccc4c(c3)CCNC4=O)c2)c(F)c1		CHEMBL4860979	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	23121195	CHEMBL4804519	Inhibition of ACK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	COc1cc(NS(=O)(=O)C2CC2)ccc1-c1cnc(N)c(-c2ccc3c(c2)CCNC3=O)c1		CHEMBL4867931	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	23121196	CHEMBL4804519	Inhibition of ACK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4855730	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	23121197	CHEMBL4804519	Inhibition of ACK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2ccc(NS(=O)(=O)C3CC3)cc2OC2CCCCC2)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4868141	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	23121198	CHEMBL4804519	Inhibition of ACK in human NCI-H929 cells at 10 uM by mass spectroscopic analysis relative to control	B	Nc1ncc(-c2cccc([N+](=O)[O-])c2F)cc1-c1ccc2c(c1)CCNC2=O		CHEMBL4859660	=	Inhibition	%	0.0	CHEMBL4599	Homo sapiens	INH	%	0.0
	23122848	CHEMBL4805199	Inhibition of human TNK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	94.0	CHEMBL4599	Homo sapiens	Activity	%	94.0
	23123543	CHEMBL4805787	Inhibition of human TNK2 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	23123995	CHEMBL4806239	Inhibition of DNA-tagged human TNK2 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	93.0	CHEMBL4599	Homo sapiens	Activity	%	93.0
	23125176	CHEMBL4806804	Inhibition of human TNK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	23125177	CHEMBL4806804	Inhibition of human TNK2 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL4599	Homo sapiens	Activity	%	100.0
	23127783	CHEMBL4807736	Inhibition of ACK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	<	Activity	%	25.0	CHEMBL4599	Homo sapiens	Activity	%	25.0
	23127784	CHEMBL4807736	Inhibition of ACK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	<	Activity	%	25.0	CHEMBL4599	Homo sapiens	Activity	%	25.0
	23127785	CHEMBL4807736	Inhibition of ACK1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Activity	%	25.0	CHEMBL4599	Homo sapiens	Activity	%	25.0
Not Active	23317684	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	85.0	CHEMBL4599	Homo sapiens	% Control	%	85.0
Not Active	23318152	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23318818	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23319302	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23319938	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23320414	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	91.6	CHEMBL4599	Homo sapiens	% Control	%	91.6
Not Active	23321092	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23321560	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23322190	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23322658	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	90.0	CHEMBL4599	Homo sapiens	% Control	%	90.0
Not Active	23323347	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23323815	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	99.0	CHEMBL4599	Homo sapiens	% Control	%	99.0
Not Active	23323947	CHEMBL4880566	ACK1 (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	2.0	CHEMBL4599	Homo sapiens	% inhibition	%	2.0
Not Active	23324669	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23325304	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23325772	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23326419	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	79.0	CHEMBL4599	Homo sapiens	% Control	%	79.0
Not Active	23326887	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	82.0	CHEMBL4599	Homo sapiens	% Control	%	82.0
Not Active	23327587	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	85.0	CHEMBL4599	Homo sapiens	% Control	%	85.0
Not Active	23328055	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	84.0	CHEMBL4599	Homo sapiens	% Control	%	84.0
Not Active	23328642	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	71.0	CHEMBL4599	Homo sapiens	% Control	%	71.0
Not Active	23329110	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23329238	CHEMBL4880945	ACK1(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	101.0	CHEMBL4599	Homo sapiens	% residual kinase activity	%	101.0
Not Active	23330056	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23330524	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23331280	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	97.0	CHEMBL4599	Homo sapiens	% Control	%	97.0
Not Active	23331748	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23332335	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	83.6	CHEMBL4599	Homo sapiens	% Control	%	83.6
Not Active	23332801	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23333519	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	78.6	CHEMBL4599	Homo sapiens	% Control	%	78.6
Not Active	23334158	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23334626	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23335605	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	95.0	CHEMBL4599	Homo sapiens	% Control	%	95.0
Not Active	23336073	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	85.0	CHEMBL4599	Homo sapiens	% Control	%	85.0
Not Active	23336700	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23337168	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23337799	CHEMBL4882170	TNK2 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	99.0	CHEMBL4599	Homo sapiens	% Ctrl	%	99.0
Not Active	23338249	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	91.0	CHEMBL4599	Homo sapiens	% Control	%	91.0
Not Active	23338717	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	96.0	CHEMBL4599	Homo sapiens	% Control	%	96.0
Not Active	23339329	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23339797	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23340434	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23340902	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23341559	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23342027	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23342643	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	84.0	CHEMBL4599	Homo sapiens	% Control	%	84.0
Not Active	23343111	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23343741	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23344209	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23344847	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	81.0	CHEMBL4599	Homo sapiens	% Control	%	81.0
Not Active	23345420	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23345888	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23346464	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23346933	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23347532	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	94.8	CHEMBL4599	Homo sapiens	% Control	%	94.8
Not Active	23348025	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23348604	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23349072	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	92.0	CHEMBL4599	Homo sapiens	% Control	%	92.0
Not Active	23349659	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	96.0	CHEMBL4599	Homo sapiens	% Control	%	96.0
Not Active	23350277	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23350745	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23351350	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23351818	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	92.0	CHEMBL4599	Homo sapiens	% Control	%	92.0
Not Active	23352250	CHEMBL4882939	TNK2 (ACK) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	22.9	CHEMBL4599	Homo sapiens	% Inhibition	%	22.8976
Not Active	23352842	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	79.0	CHEMBL4599	Homo sapiens	% Control	%	79.0
Not Active	23353310	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	96.0	CHEMBL4599	Homo sapiens	% Control	%	96.0
Not Active	23354192	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23354660	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23355392	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23355860	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	99.0	CHEMBL4599	Homo sapiens	% Control	%	99.0
Not Active	23356496	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23356964	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23357573	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23358220	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23358688	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23359274	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	89.6	CHEMBL4599	Homo sapiens	% Control	%	89.6
Not Active	23359872	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	83.0	CHEMBL4599	Homo sapiens	% Control	%	83.0
Not Active	23360340	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	95.0	CHEMBL4599	Homo sapiens	% Control	%	95.0
Not Active	23360925	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23361393	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	91.0	CHEMBL4599	Homo sapiens	% Control	%	91.0
Not Active	23361966	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	90.0	CHEMBL4599	Homo sapiens	% Control	%	90.0
Not Active	23362502	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23362970	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23364612	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	96.0	CHEMBL4599	Homo sapiens	% Control	%	96.0
Not Active	23365080	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23365819	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23366362	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	80.0	CHEMBL4599	Homo sapiens	% Control	%	80.0
Not Active	23366952	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	89.0	CHEMBL4599	Homo sapiens	% Control	%	89.0
Not Active	23367420	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23367463	CHEMBL4883816	ACK1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	108.0	CHEMBL4599	Homo sapiens	% Residual activity with Skepinone-L	%	108.0
Not Active	23368298	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	93.0	CHEMBL4599	Homo sapiens	% Control	%	93.0
Not Active	23368766	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	99.0	CHEMBL4599	Homo sapiens	% Control	%	99.0
Not Active	23369365	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23369833	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	96.0	CHEMBL4599	Homo sapiens	% Control	%	96.0
Not Active	23369963	CHEMBL4884210	ACK1(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	94.0	CHEMBL4599	Homo sapiens	% residual kinase activity	%	94.0
Not Active	23370801	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	81.0	CHEMBL4599	Homo sapiens	% Control	%	81.0
Not Active	23371269	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	86.0	CHEMBL4599	Homo sapiens	% Control	%	86.0
Not Active	23372078	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	70.0	CHEMBL4599	Homo sapiens	% Control	%	70.0
Not Active	23372546	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	91.0	CHEMBL4599	Homo sapiens	% Control	%	91.0
	23372919	CHEMBL4884884	Ack(TNK2LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL4599	Homo sapiens	pIC50		6.0
	23373328	CHEMBL4885175	Ack(TNK2LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL4599	Homo sapiens	pIC50		6.0
	23373682	CHEMBL4885459	Ack(TNK2LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL4599	Homo sapiens	pIC50		6.0
Not Active	23375116	CHEMBL4886103	TNK2 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	37.5	CHEMBL4599	Homo sapiens	% Inhibition	%	37.5
Not Active	23375401	CHEMBL4886383	tyrosine kinase, non-receptor, 2  Millipore kinase panel	B	COCCc1ccc(-c2c(C)nc3c(N4CCOCC4)ccnn23)cn1		CHEMBL2180408		Inhibition	%	0.0	CHEMBL4599	Homo sapiens	% inhibition	%	0.0
Not Active	23375973	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23376441	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	90.0	CHEMBL4599	Homo sapiens	% Control	%	90.0
Not Active	23377018	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23377486	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23378346	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	90.0	CHEMBL4599	Homo sapiens	% Control	%	90.0
Not Active	23378814	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	87.0	CHEMBL4599	Homo sapiens	% Control	%	87.0
Not Active	23379981	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	99.0	CHEMBL4599	Homo sapiens	% Control	%	99.0
Not Active	23380449	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	85.0	CHEMBL4599	Homo sapiens	% Control	%	85.0
Not Active	23381143	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23381791	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	94.0	CHEMBL4599	Homo sapiens	% Control	%	94.0
Not Active	23382259	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	86.0	CHEMBL4599	Homo sapiens	% Control	%	86.0
Not Active	23382883	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23383351	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	86.0	CHEMBL4599	Homo sapiens	% Control	%	86.0
Not Active	23384017	CHEMBL4887615	TNK2 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	97.0	CHEMBL4599	Homo sapiens	% Ctrl	%	97.0
Not Active	23384170	CHEMBL4887765	ACK1(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	10.5	CHEMBL4599	Homo sapiens	% inhibition	%	10.5
Not Active	23385265	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL4599	Homo sapiens	% Control	%	100.0
Not Active	23385733	CHEMBL4879990	KinomeScan assay: inhibition of TNK2	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	84.0	CHEMBL4599	Homo sapiens	% Control	%	84.0
